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Abstract 
A study of cross neutralising epitopes of selected HRVs and 
other picornaviruses was carried out. A panel of 17 HRV-2 
neutralising monoclonal antibodies (Mabs) was raised. Fifteen 
Mabs were studied in indirect immuno-fluorescence test (IIF 
test) for the physical presence of the epitope(s) and 14 of 
these were included in cross neutralisation studies on HRVs. 
Two Mabs could not be included due to lack of material and the 
results of one Mab were not included due to doubts of false 
positivity. Mabs cross reacted both in IIF and neutralisation 
tests extensively. Though, there was, in general, an ag rEvent 
between the results obtained with the two tests, there were 
instances when particular Mabs reacted in the IIF test but 
failed to neutralise the virus. Also other Mabs did not react 
in IIF test but did neutralise the virus. 
Three patterns of cross reactivity were observed-1) with 
all viruses, 2) with many and 3) with few viruses. One Mab (D- 
24) reacted with all HRVs in the IIF test and also neutralised 
all the viruses. Four other Mabs (D-6, D-9, D-25 and D-29) also 
neutralised all viruses, they were tested against. Three Mabs 
(D-9, D-25 and D-29) could not be tested with 3 HRVs and D-6 
failed to react with one HRV in IIF test. Three HRV cross 
neutralising Mabs (D-6, D-24 and D-36) and one not so 
extensively cross neutralising Mab (D-34) were tested for their 
ability to neutralise a few chosen picornaviruses. None of them 
neutralised EMC and coxsackie virus A-18. D-24 neutralised all 
coxsackie virus-B serotypes but not poliovirus. Mab D-6 
neutralised all but one coxsackie B serotypes and poliovirus. 
D-34 and D-36 neutralised both poliovirus and coxsackievirus 
though tested with only one coxsackie B virus serotype. The 
neutralisation of coxsackie-B virus and poliovirus byD-34, 
which did not extensively cross' neutralise the HRVs, was an 
interesting observation. 
On the observation that all Mabs produced in the study werte 
cross neutralising, the immunisation protocol was critically 
analysed and a hypothesis was proposed that the inoculation of 
the antigen in purified and concentrated form through the I/P 
route and without an adjuvant could lead to the suppression of 
the immune response against the dominant antigens and this 
could lead to the desuppression of the immune response against 
immuno-subdominant antigens and hence evoke selective 
immunisation against these immuno-subdominant epitopes. It was 
suggested that such an immunisation protocol together with the 
Mab approach might improve the chances for detection of such 
cross reactive epitopes on other micro-organisms 
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Introduction 
A. Overview - 
Human Rhinoviruses (HRV) are one of the major causes of 
the Common Cold infection. They account for 
approximately 30% of cold infections (Gwaltney Jr., 
1985). The common cold is the most familiar of all 
infections and there can be few, if any, of the general 
population who have not suffered from this condition at 
one time or other in their lives. 
The HRVs cause a mild afebrile respiratory 
disease. The most common symptoms are coryza, sore 
throat, cough and general malaise (Rosenbaum, et 
al., 1971). Although not serious for the individual, the 
widespread dissemination of the infection makes the 
total economic loss from mild ill health and short 
absences from work appreciable. 
The multiplicity of the serotypes of the HRV based 
upon the neutralisation reaction using polyclonal 
antiserum (Couch, 1985) and the susceptibility of 
individuals convalescent from one of the HRV serotype to 
be protected against a second serotype (Gwaltney, 
Jr., 1982) pose a difficult problem for the development 
of a common cold vaccine. 
Polyclonal antiserum is generally composed of many 
distinct antibody populations, which, depending upon 
their relative concentration, determine the effector 
function of and overall antigenic specificity exhibited 
by the antiserum. It has, also, been difficult to 
1 
produce antisera specific to a particular viral protein 
without causing alteration of the immunogenic and anti- 
genic properties associated with the native structure of 
that viral protein (Gerhard and Koporowski, 1984). 
However, the technique which results in the 
production of monoclonal antibody (Mab) described by 
Kohler and Milstein (1975) can overcome these problems 
and can produce antibodies specific to a single epitope 
of an antigenic site (Gerhard and Koporowski, 1984). 
As it has been observed that those antigens which 
are most active in inducing the immune response are also 
those which are the most variable (Schild, 1984; Cross 
and Ferguson, 1985; and Gotschlich and Blake, 1985) and 
hence the consequence of lack of cross protection. It is 
unlikely that a vaccine which would be protective 
against infection by HRV would be based on such 
antigenic sites. It was therefore decided to determine 
whether there were other invariant antigenic sites which 
could be used to evoke neutralising antibodies which 
would cross neutralise all the HRV serotypes. The search 
for such antigenic sites may be accomplished by the use 
of Mabs. 
The work described in this thesis was undertaken 
to develop a panel of neutralising Mabs against a single 
serotype of HRV and perform those cross neutralisation 
tests which would identify more cross reactive or 
conserved neutralising epitopes on HRV. 
2 
Historical Background 
Colds were a nuisance in early civilisations, then, as 
now, many useless remedies were proposed for their 
treatment. Hippocrates (400 B. C. ) noted that bleeding 
was a frequently used, although worthless, treatment for 
colds. Pliny, The Young recommended " Kissing the hairy 
muzzle of a mouse" as treatment for colds. The 
contagious nature of the cold was established by the 
observation that sea voyagers and the inhabitants of the 
isolated communities were free of colds and that the 
cold occured when the contact with continental 
population was re-established (Gwaltney, Jr., 1982). 
The direct evidence for the infectious nature of 
the colds was produced by Kruse (1914) when the cold 
symptoms were transmitted to volunteers by intra-nasal 
inoculation with filtrates of nasal secretidh from other 
volunteers with colds. Dochez, et al. (1930) established 
the viral etiology for the colds by showing transmission 
with bacteria free filtrates. Van-Loghem (1928) observed 
the seasonality of colds and Frost and Gover (1941) 
made the observation that the high prevalence of the 
colds from September to March, was composed of short 
epidemics of irregular sequence and magnitude, 
suggesting the involvement of a variety of agents 
responsible for the cold illness. 
In the 1940s, long term studies on the common 
cold were started at the Common Cold Research Unit in 
Salisbury, England headed by Andrewes and later by 
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Tyrrell. A great wealth of knowledge about properties 
and the spread of colds was obtained by these studies 
using human volunteers (Gwaltney, Jr., 1982). 
Pelon, et al. (1956) and Price (1956), working 
separately, reported the isolation of a new virus in 
1956 which was, later, designated as rhinovirus 1A. This 
was the start of the specific work on rhinoviruses. In 
the 1960s, Tyrrell and Parsons (1960) at Salisbury 
defined the condition for the isolation of rhinoviruses 
using monkey kidney cells. They observed that the growth 
of the rhinovirus was favoured by lowering the 
incubation temperature to 330C, lowering the pH to 
around 7.0 and gently rotating the cultures. Use of 
these "Conditions of the Nose" then led to isolation 
of the virus in many locations. Shortly afterwards, 
Ketler, et al. (1969) isolated number of different 
serological types in the highly sensitive human 
embryonic lung cell line developed by Hayflick and 
Moorehead (1961) and thus established the multiplicity 
of the rhinovirus serotypes. 
The name Rhino Virus was originally suggested by 
Andrewes (Couch, 1985). Tyrrell and Chanock (1963) 
provided the description of the group. In 1967, a 
collaborative programme was launrýed to assign numbers to 
the known rhinovirus serotypes. The first phase of the 
programme identified serotypes from IA to 55, then the 
second phase extended the numbers to 89. Later this was 
extended to 100 serotypes in the third phase which was 
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completed in 1986 (Kapikian, et al., 1967; 1971 and 
Hamparian, et al. , 1987). 
C The Common Cold Illness 
The common cold is a group of illnesses commonly 
encountered in a clinical practice (Kawana, 1978). It is 
characterised by rhinorrhoeae, nasal obstruction, 
sneezing and pharyngeal discomfort. The median length of 
the illness is 7 days with peak symptoms occurring on 
the 2nd and 3rd day (Gwaltney, Jr., et al., 1967). 
HRVs have a worldwide distribution (Taylor- 
Robinson, 1965). The disease has two seasonal peaks. One 
peak in spring and the other in fall (Fox, et al., 1985). 
Clinico - virological investigations have reported 
that a large number of the virus serotypes circulate in 
an area over a period of time and some serotypes have a 
tendency to persist. However, the ranking of the 
serotypes in order of importance is difficult on the 
basis of existing data (Monto, et al. , 1987). 
The infection is related to age. The highest 
infection rates have been found with infants (1.21 in 0 
to 1 year age group) and lowest infection rate of 0.20 
with adults (Gwaltney, Jr., 1982). In a family setting, 
the children play an important role in the spread of the 
infection. The family size (number of children) and 
their health determine the number of the episodes and 
secondary attack rates. However, equally higher attack 
rates have been reported in the non-family setting with 
little contact with children (Couch, 1985). Mogabgab 
(1968) suggested that the infection was more related to 
age than to population group. The virus is highly 
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infectious for humans (Couch, et al. , 1966). It is 
transmitted from person to person by direct, indirect 
hand to hand contact and by aerosols (Gwaltney, Jr., and 
Hendley, 1982 and Dick , et al. , 1987). In the hand to 
hand direct and indirect contact, the virus can spread 
from fingertips to fingertips by hand shaking or to door 
knobs, handles and other "environmental" surfaces. Once 
the virus has reached the hands, it may be transferred 
to nasal and conjunctival mucosa by means of auto 
inoculation (Hendley, et al. , 1973 ; Gwaltney, 
Jr., et 
al., 1978; Pancic, et al., 1980 and Gwaltney, Jr. and 
Hendley, 1982). 
The major site of the disease symptoms is the nose 
which is also the major site of the infection (Cate, et 
al., 1964). Histopathologically, nasal biopsies have 
shown marked edema of subepithelial connective tissue 
together with little infiltration of inflammatory cells. 
Hyperemia, exudation of semimucinious fluid and 
narrowing of nasal passage are known to accompany the 
histopathologic changes (Couch, 1985). 
It appears that of the humoral immune response, 
the secretory antibody (IgA), is more important for 
protection than IgG (Hendley, et al. , 1969). The 
neutralising antibodies appear simultaneously both in 
serum as well as in nasal secretion in the natural 
infection (Douglas Jr., et al. , 1967). The *elative 
importance of the nasal and the serum antibodies is not 
yet known. A decrease in the level of nasal antibodies 
and persistence of serum antibodies after the infection 
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(Holmes, et al. , 1976), possibly indicates that the 
nasal antibodies have a role in the recovery while the 
serum antibody plays an important role in conferring 
protection. Further work is necessary for a clear 
understanding of the mechanism of protection by 
antibodies. 
Interferon or some other mechanism may play an 
important role in modifying the course of illness and in 
the recovery (Couch, 1985) and final clearance of the 
virus from the body is accomplished by antibody 
particularly, the nasal antibody (Cate, et a1., 1966). 
A wide range of laboratory tests are available for 
detection of the virus and antibody. The tests are : 
macro and micro neutralisation test (Douglas Jr., et al., 
1968; Gwaltney, Jr., 1966 and Monto and Bryan, 1974), 
haemagglutination test (Stott and Killington, 1972), 
indirect immunofluorescent test (Dreizin, et al., 1971 
and Hruskova, et al., 1981) and gel immunodiffusion test 
(Smith, 1978) and recently more sophisticated, more 
sensitive and easy to perform tests like ELISA (Barclay 
and Al-Nakib, 1987 and Dearden and Al- Nakib, 1987) and 
DNA probes for antigen detection (Al - Nakib, et al., 
1986) have been described. 
C. 1 Prevention and Control - 
At present vaccine development, viral chemotherapy and 
environmental management for containing the infection 
are being actively pursued. 
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C. 1A Vaccine Development- 
The virus has been succesfully inactivated for vaccine 
development. The inactivated virus has been shown to 
elicit both a serum and a nasal antibody response 
(Knopf, et al. , 1970). Intra - nasal instillation of the 
inactivated virus invoked both serum and nasal antibody 
responses and conferred protection against the challenge 
with the homologous virus (Knopf, et al., 1970 and 
Perkins, et al., 1969). However, the parenteral route of 
the administration of the vaccine evoked only a serum 
responses. The serum antibody response failed to prevent 
the infection by intra-nasal challenge but significantly 
reduced the virus shedding and severity of the illness 
(Douglas Jr. and Couch, 1972). 
Despite the successful inactivation of the 
virus, attempts to develop an effective vaccine for HRVs 
have, as yet, been unsuccessful. Failures are largely 
due to absence of a heterologous response (Stott, et 
al., 1969). In an attempt to develop a multivalent 
vaccine, Hamory, et al. (1975) found only a scattered 
protective response with the decavalent vaccine to non- 
vaccine serotypes. 
The discovery of an ever increasing number of 
specific antigenic types has led to "pessimism" for the 
prospect of an efficient rhinovirus vaccine. However, 
there is hope that advances in immunology and the new 
approaches in vaccine development may eventually make 
such a vaccine possible. 
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Recent approaches for a vaccine have been based on 
antibodies to cellular receptors. The cell receptor 
divides the HRVs into a major and a minor group (Abraham 
and Colonno, 1984) and the anti-receptor antibody of 
the major group has been found to be able to inhibit 
the infection by all the members of this group (Colonno, 
et al., 1986) and McCray and Werner (1987) showed that 
polyclonal antisera prepared against a conserved region 
on the virus (the putative cell receptor binding site) 
neutralised 48 serotypes. These promising in vitro 
experiments are yet to be tested in vivo. 
C. 1B Anti-viral Chemotherapy 
As a result of failure to develop an effective vaccine 
for the common cold illness, research has concentrated 
on anti-viral chemotherapy. 
C. 1B. 1 Anti- viral Drugs 
A wide variety of naturally occuring and chemically 
synthesised drugs show anti-rhino virus activity in 
cell culture systems (Schleicher, et al., 1972 ; Sato and 
Muro, 1974 ; Yoshinori, et al., 1985 ; Yoshiaki, et al. 
1988 and Ash, et al. , 1979). Investigations 
into the 
mechanisms of the anti-viral activity of these drugs 
showed that the compounds specifically affected events 
of the viral growth cycle for example early events 1) 
before uncoating (Lonberg- Holm, 1975), 2) uncoating 
(Kenny, et al., 1985) and 3) viral RNA synthesis 
(Panicali and Nair, 1978). A direct interaction between 
the anti-viral agent and the virus has been demonstrated 
(Tisdale and Selway, 1983 and Ninomiya, et al., 1985). 
10 
In a crystallographic study, Badger, et al. (1988) 
showed that eight anti-viral compounds which inhibited 
the uncoating, bound in the hydrophilic pocket within 
the viral protein VP1 p barrell structure. The binding. 
caused the protein shell to become less flexible and so 
inhibited disassembly. 
In double blind placebo controlled studies on 
human volunteers, anti-viral compounds have not, so far, 
showed much benificial effects upon the rhinovirus 
infections. Waldman and Gangully (1977) and Simon and 
Glasky (1978) reported that Isoprinosine (a potent in 
vitro anti-viral drug) reduced clinical symptoms. 
However, Soto, et al. (1973) and Pachuta, et al. (1974) 
did not find any evidence that the compound had useful 
anti-viral activity in vivo. 
Zinc salts have also been reported to have anti- 
rhinoviral activity (Geist, et al., 1987). In two 
studies using zinc gluconate lozenges, contradictory 
claims were made. Al-Nakib, et al. (1987) reported that 
it had effects on the signs and symptoms, of the illness 
whilst Farr, et al. (1987) found that the zinc gluconate 
lozenges were not therapeutically useful in the common 
cold illness. Pauling (1970) proposed that large dose of 
vitamin C were therapeutically useful in the illness. 
Further evaluation of the claim showed that it was 
effective in vitro for example in terms of virucidal 
effects (Schwerdt and Schwerdt, 1975) but not in vivo 
(Anderson, et al., 1972). 
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C. lB. 2 Interferons 
The possible role of interferon (alpha type) in reducing 
the infection encouraged work on its application in 
prophylaxis and in the therapy of the illness. 
HRVs are poor inducers of the interferons. 
However, the interferon effects the virus multiplication 
in vitro ( Fiala, 1972 ; Ponomareva, et al., 1973 and 
Stoker, et al. , 1973). The problem of the 
induction was 
solved by use of interferon inducers. The interferon 
inducers were used in the volunteers but they failed to 
show any significant effect on the virus shedding 
pattern or on the neutralising antibody response (Hill, 
et al. , 
1972; Aoki, et al. 1978 and Doughlas, Jr., et'- 
al. , 1979 
). 
The role of interferons on the course of the 
illness and their anti- viral effects in vitro (Fiala, 
1972; Ponomareva, et al., 1973 and Stoker, et al., 1973) 
indicated that the interferons might have a role in the 
clinical treatment of the illness. Intra-nasal 
application of interferon showed encouraging results but 
caused minor epistaxis and hi 
sological changes like 
lymphocytic infiltration in the subepithelial and 
underlying glaýular zones (Monto, et al., 1986; Hayden, 
et al. ; 1986 and Hayden et al., 1987). Dose and 
tolerance studies showed that lower doses were well 
tolerated (Monto, et al. , 1988). 
Such low doses were 
insufficient to protect and higher doses though 
protective caused unwanted side effects (Scott, et al., 
1985). It is therefore, essential to find an interferon 
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preparation with less inflammatory activity before it 
can be considered for use as long term prophylactic 
agent in the common cold illness. 
C. 1C Environmental Control 
The use of virucidal agents in breaking the 
transmission of the infection is another approach for 
the control of the cold infection. A 2% solution of 
glutamic acid and iodine applied onto the surface of 
fingers inactivated the virus (Carter, et al., 1980 and 
Gwaltney, Jr., et al., 1980). Longini, Jr, and Monto (1988) 
conducted a randomised field trial in Tecumseh, 
Michigan (USA) to test the efficacy of virucidal nasal 
tissue. They reported that this treatment partially 
interrupted the transmission of the causative agents of 
, 
respiratlory disease. 
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D The Virus 
The HRV is a small almost spherical, non enveloped RNA 
containing virus. The virus is classified under the 
family Picornaviridae genus Rhinovirus. The family 
is currently divided into four genera : Enterovirus, 
Cardiovirus, Rhinovirus and Aphthovirus (Table-1). The 
name rhinovirus stems from the special adaptation of the 
virus to the naso-pharyngeal region (Rueckert, 1976). 
D. 1 Physical and Chemical Properties of the Virus 
The mean diameter of the virus varies from 15 to 50 nm 
depending upon the serotype and the method of the 
measurement (Dimmock and Tyrrell, 1962; 1964; Ketler, et 
al., 1962 and Johnson and Rosen, 1963). In a sedimentation 
study, McGregor and Mayor, (1971) showed that the virus 
had a sedimentation coefficient of 158S and diffusion 
coefficient of 1.71X10-7 cm2/sec. On the basis of these 
values, the hydrated diameter of the virus was 
calculated to be 25 nm. The molecular weight of the 
virus is 8.4X106 Da and for the RNA 2.6X106 Da, 
calculated from the value of the sedimentation 
coefficient. The particle mass of the picornaviruses, 
including the HRVs, is 8.4 ± 0.58 million Da using the 
best values for the sedimentation coefficient and 
partial specific volume of 156±4 S and 0.687±0.009 ml/g 
respectively. One milligram of the virion with a 
molecular weight of 8.3x106 Da corresponds to 7.2X10 
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particles. Assuming an extinction coefficient of 7.7 
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Table-1 The Picornaviridae Family 
------------------------------------------------------- 
Genus No. of Members 
serotype 
------------------------------------------------------ 
Enterovirus 3 Poliovirus 1-3 
23 Coxsackie virus A-22,24. 
A-23 = ECHO 9 
6 Coxsackievirus B1-6. 
32 Human ECHO-virus 1-9,11-27, 
29-34, ECHO-10= reovirus and 
ECHO-28=HRV-lA 
4 Human enterovirus (68-71) 
1 Human hepatitis A 
1 Vilyuisk virus 
18 Simian enterovirus 
11 Porcine enterovirus 
1 Murine poliovirus 
( Theiler's virus) 
Cardiovirus 1 EMC , Mengovirus 
Maus Elberfeld 
Columbia SK MM 
Rhinovirus 100 HRV 1- 100 
2 Bovine virus 
Aphthovirus 7 FMD 1-7 
Unassigned >3 equine Rhinovirusl, 2 
cricket paralysis virus, 
drosophila C virus and 
--------------- -------- 
tussock moth picornavirus 
--------------------------------- 
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Optical density units (OD) per centimeter light path in 
a 0.1% w/v solution of the virus in 0.3 M salt at pH 7 
to 8,9.4X1012 virions per OD 260 unit are calculated 
(Rueckert, 1971). 
The acid lability of the HRVs separates them 
from the entero viruses (Tyrrell and Parsons, 1960). 
Studying the effect of hydrogen ion concentration on the 
morphology and the infectivity of the virus, Reeves and 
Mayor, (1973) reported that considerable morphological 
degradation of the capsid occured at pH 5.5. Electron 
microscopy studies of the three dimensional structure of 
the acid treated virus showed that the viral genome was 
released in the form of an RNA strand. This was due. to 
the loss of discrete capsomere groups. However,. the 
virus tolerated alkaline pH's up to 9.8 with little or 
no loss of infectivity but there was a precipitous loss 
in infectivity at around pH 10.9 accompanied by a 
complex breakup of viral capsid morphology. 
The virus is sensitive to heat and shows a 
variable response to stabilisation by magnesium ions 
(Strizova, et al., 1970 and McGregor and Mayor, 1971). 
However, the virus remains stable indefinitely at - 700C 
(Jackson and Muldoon, 1973). 
Chemical analysis of the HRV-14 (Mc Gregor and 
Mayor, 1971) and serotype 1A (Medappa, et al., 1971) 
revealed that the virus had 31t 1% of RNA and 69% 
protein. Picornaviruses appear to consist of protein and 
RNA only. Attempts to demonstrate the presence of 
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carbohydrate, other than in the nucleotide ribose, have 
been unsuccessful (Burness, et al. , 1973). 
D. 2 The Viral Protein 
The virus is composed of five polypeptides. The four 
polypeptides (VP1 to VP4) are the structural proteins. 
The structural polypeptides are found in equimolar 
concentration (Medappa, et al. , 1971). The MrS of 
these 
polypeptides have been reported to be 32 KDa, 29 KDa, 26 
KDa, and 7 KDa respectively for VP1 to VP4 for HRV-14 
(Rossmann, et al. , 1985) and 33.8 KDa, 29.5 KDa, 
26 KDa 
and 7KDa respectively for 1A (Medappa, et al., 1971). By 
cloning and sequencing of the entire genome of the HRV- 
14, Callahan, et al., (1985) predicted that the 
structural proteins VP1, VP2, VP3 and VP4 had 289,262, 
236, and 69 amino acids. 
In addition to these structural proteins, the 
virus also contains a small protein (VPg) covalently 
linked to the genome (Hughes, et al. , 
1988). There is 
also information in the genome for enzymes such as the 
viral RNA replicase and proteases (Callahan, et al., 
1985). 
D. 3 The Ribonucleic Acid ( RNA ) 
The virion contains a single positive strand of RNA 
which is translated into a single polyprotein and then 
processed step-wise into its component proteins 
(Pallansch, et al., 1984). The genomic RNA is poly- 
adenylated at the 3-prime end and covalently attached to 
a protein (VP g) at the 
5-prime terminus. The nucleotide 
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composition is A-34.1%, C-17.4%, G-19.5% and T- 29.0% 
with the genome being somewhat A+T rich (Hughes, et 
al. , 1988). 
By molecular cloning and complete sequence 
determination of the genome of HRVs- 1B, 2,14 and 89, the 
rhinoviral genome has been found to be typical of the 
picornaviridae family (Stanway, et al., 1984; Skern, et 
al., 1985; Duechler, et al., 1987 and Hughes, et al., 
1988). It is composed of a 5- prime non-translated 
region, a long reading frame of 6537 nucleotides (90.8% 
of the genome) and a 3-prime non-coding region of 47 
nucleotides. The comparison of the nucleotide sequence 
and the predicted amino acid sequence with those of 
poliovirus reveals a striking homology of 44-65%. The 
viral genomic RNA is rich in adenosine (34.1%) and 
strongly favours adenosine or uridine in the third 
position of the codons (Stanway, et a1., 1984 and 
Callahan, et al. , 1985). 
D. 3.1 Poly -adenvlated (Poly-[ A ]) Sequence 
The viral RNA has been shown to be poly-adenylated 
(Nair and Owen, 1974 and Macnaughton and Dimmock, 1975). 
The poly-(A) content of the genomic RNA of the HRV-14 
has been reported to be nearly twice as long as that of 
genomic RNA of the poliovirus type 2 (Nair and Panicali, 
1976). In HRV, the poly-(A) tract does not appear to be 
genetically coded. Macnaughton and Dimmock (1975) 
failed to find a poly-(U) region in any of the virus 
specified RNA species in the virus infected cells. It 
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was suggested that the poly-(A) was added to the RNA 
post transcriptively (Macnaughton and Dimmock, 1976). 
The poly _(A) region performs important biological 
functions in picornaviruses. In poliovirus, the removal 
of the poly _(A) region with the enzyme ribonuclease H 
markedly reduces the infectivity (Spector and Baltimore, 
1974). In HRV-14, Nair and Owens (1974) reported that 
cordycepin (an analogue of the poly adenylic acid) 
inhibited virus growth in HeLa cells and addition of 
the poly-adenylic acid reversed the cordycepin 
inhibition of the viral induced cyto- pathology in the 
HeLa cells. Nair and Panicali (1976) reported that the 
cordycepin inhibited viral specific RNA synnthesis. 
However, their results did not indicate that this 
inhibiton was due to the preferential inhibition of the 
viral poly-(A) synthesis by the cordycepin. 
D. 3.2 5-Prime Non Translated Region 
Little information is available on the 5-prime non- 
translated region and its functional importance in HRV. 
Callahan, et al., (1985) described the 5-prime non- 
translated region of the HRV-14. The region contains 628 
nucleotides and also it contains four unused AUG 
codons. These initiation codons are capable of 
initiating peptides with amino acid lengths of 2,8,10 
and 24 amino acids. Analysis of two other reading frames 
revealed nine additional initiation sites and six of 
these would result in protein of less than 29 amino 
acids (Callahan, et al., 1985). Almost similar length 
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(about 620 nucleotide) 5-prime regions have been 
reported by others for HRV-1B, 2,14 and 89 (Stanway, 
et al. , 1984; Skern, et al. 1985 and Hughes, et al., 
1988). An analysis of the relationship between HRV-1B 
and HRV-2, HRV-14 and HRV-89 in the 5- prime non- 
translated region revealed that HRV-1B was most closely 
related to HRV-2 and HRV-89 than the HRV-14. However, 
certain conserved frequences were particularly evident 
and although the overall homology to HRV -14 was less 
(69.1% for HRV-14,83.1% and 80.5% for HRV-2 and HRV-89 
respectively), there was striking conservation of two of 
the three blocks of conserved frequences at positions 
180 and 440-560 (Hughes, et al. , 1988). The region in 
HRV is shorter than that of the enteroviruses. In 
polioviruses, the region has been reported to be 740 
nucleotides long (Toyoda, et al. , 1984). 
Rivera, et al. (1988) compared the region of 
poliovirus, coxsackie B3 virus and HRV-14 and revealed 
the conservation of certain features despite the 
divergence of the sequence. Two long stretches of the 
sequences, two pyrimidine rich regions and 22 
"hairpins" were conserved. Recently, Pilipenko, et al., 
(1989) derived the secondary structure for the central 
part (about 400 nucleotides) of the 5-prime non- 
translated region of all the so far sequenced genomes of 
the poliovirus, coxsackie virus and HRV. The secondary 
structure was derived on the basis of evolutionary and 
thermodynamic considerations. According to the model, 
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this part of the genome is comprised of three domains, 
which appear to be involved, at least in the poliovirus 
genome, in the control of neuro-virulence and in vitro 
translation. 
The conservation of certain regions and features 
among the members of the picornavirus family appears to 
indicate that the region performs a function common to 
all members of the family. The similarity of the region, 
among various serotypes, of a virus in the family, 
possibly indicates a role common to that particular 
virus genus. However, it is not clear how the length of 
the region could contribute to the characterstics of the 
genus. These observations suggest that the region has an 
important role in transcription, translation of the 
viral genome and in virulence. 
D. 3.3 Poly-Cytidylic Acid (Poly-[C]) Region 
The poly-(C) region has not, so far, been found on any 
other member of the picornavirus family. This includes 
the HRVs but not the cardioviruses and aphthoviruses 
(Brown, et al. , 1974). 
D. 3.4 Virion Protein Genome (VP, RNA) 
The 5-prime end of the RNA is not capped. A small viral 
protein termed VP g is covalently attached 
to it 
(Nomoto, et al. , 1977). The protein 
is conserved in HRVs 
(Werner, et al. , 1986). The protein 
does not appear to 
be involved in the infectivity (Wimmer, 1982). From the 
observation that the VPg is cleaved from those plus 
strands that are destined to become mRNA molecules, it 
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has been suggested that it has a role in morphogenesis. 
However, there is evidence that the protein acts as a 
primer of RNA synthesis in polioviruses (Nomoto, et al., 
1977). In HRVs, a role has not yet been found for the 
protein. 
D. 3.5 Protein Coding Region- 
The large open reading frame of the HRVs coding various 
viral proteins is approximately 6500 nucleotide long 
(Stanway, et al , 1984; Duechler, et al., 
1987 and 
Hughes, et al. , 1988). The reading frame starts at 
nucleotide 678 and ends at 47 nucleotides from the 3- 
prime end of the viral RNA. Rueckert and Wimmer (1984) 
described the systematic nomenclature of the picorna- 
viral proteins, as recommended by the L434 convention 
which held that the virion is translated into a large 
single polyprotein before it is processed, step-wise 
into its component proteins. The gene order is 
essentially the same as for the other members of the 
picornavirus family. The polyproteins of the 
picornaviruses are accommodated in to the pattern of L- 
ABCD - ABC - ABCD, in which L is a leader protein and 
ABC represent end product of a capsid piece (P1), a mid 
piece (P2) and a right piece (P3). The pattern is shown 
diagramatically below (Fig-1). The poliovirus and HRV 
poly-protein appears to lack a leader (L) protein, 
whereas that of the foot and mouth disease virus (FMDV) 
appears to lack a protein 2B in the mid piece; in 
addition FMDV encodes three VPg's, whereas other 
22 
picornaviruses appear to encode for only one VP9 
protein. 
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Leader Region 
The leader is defined as that part of the region of the 
poly-protein preceding the capsid precursor proteins. 
The Pl Region 
The P1 region is defined as that part of the poly- 
protein which generates the coat proteins VP4, VP2, VP3 
and VP1. 
The P2 Region 
The mid piece P2 is defined as the region between P1 
and P3. It is cleaved into three proteins in poliovirus 
and two in FMDV. 
The P3 Region 
The P3 region is entire right piece of the poly-protein 
begining with the protein 3A flanking the VPg on the 
left. 
Cleavage Proteins and Overlap Proteins 
Cleavage proteins are products of a tyrosine-glycine 
cleavage site located in P3 protein 2. These alternative 
cleavage products of the region 3CD are known as 3C' 
and 3D' respectively. Certain proteins overlap the 
borders defined by the L-P1-P2-P3 regions. Such 
overlapping proteins are Al and 1-2 A for the encephalo 
- myocarditis (EMC) virus and 2 BC-3 AB and 2 C-3 AB 
overlapping the P2 and P3 regions in polioviruses. 
The RNA of the HRV-14 has been reported to code 
for seven proteins (2A, 2B, 2C, 3A, 3B, 3C and 3D 
including 3B for the VPg)in addition to the structural 
proteins (lA-VP4,1B-VP2,1C-VP-3 and 1D-VP-1). 
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D. 4Structure of the Virion 
Lonberg-Holm and Butterworth (1976) investigated the 
structure of the HRV by the use of selective chemical 
reactivity. Labelling with the reagents [3H] acetic 
anhydride, [1251] and [14C] iodoacetamide showed that 
the VP1 was labelled to a greater extent than the 
smaller poly-peptides VP2 and VP3 and the VP4 was not 
labelled. This suggested that the major surface protein.. 
was VP1 and VP4 might be an internal protein as it does 
not contribute directly to the surface properties of the 
natural virion. Acidification of the virion caused major 
conformational changes (loss of VP-4) and then VP2 
showed an increased relative susceptibility to the 
labelling. Since both VP2 and VP4 are derived from the 
same precursor, it is likely that both are relatively 
hidden in the native virions. 
A clear picture of the structure of the HRV has 
emerged from the atomic resolution of the HRV-14 in a 
crystallographic study conducted by Rossman, et al. 
(1985). The atomic model of the HRV-14 at the 3.0 AO 
resolution map shows that the particle consists of an 
icosahedral protein shell surrounding an RNA core. The 
three larger capsid proteins (VP1, VP2 and VP3) are 
mainly exposed on the surface (Fig-2). The amino ends of 
the VP1 and VP3 are in contact with the internal RNA 
cavity. 
The first 64 of the 73 amino terminal residues of 
the VP1 reside under VP3 and the first 42 of the 71 
amino terminal residues of VP3 are under VP1. VP4 is 
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Fig-2: Diagram of HRV-14 showing VP1, VP2, and VP3 on the 
surface of the virion, folding and position of the 
neutralising immunogens ( Nlms) on these capsid 
proteins ( Adapted from Rossmann, et al., 1985) 
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Icosahedral Capsid 
positioned internally below but in contact with VP1 and 
VP2. 
Sequence insertions cause protrusions on the VP1, 
VP2 and VP3. These protrusions create a deep cleft or 
canyon on the viral surface. This canyon separates the 
major part of the VP1 subunits surrounding clusters 
around a pentamer axis from the surrounding VP2 and VP3, 
thus forming a moat around the VP1 protrusions on the 5 
fold axis. The overall shape of the VP1 is like a kidney 
and the depression forms a large part of the canyon. 
The canyon is 25 A0 deep and 12-30 AO wide. Its 
walls, in the south, are lined with the carboxy terminal 
end of the VP1 whilst the north canyon wall is partially 
lined with the carboxy terminus of the viral protein 
VP3. The viral protein VP2 is hardly associated with 
the canyon while the VP1 is the major contributor. The 
canyon is the putative receptor binding site (Rossmann, 
et al,. 1985). 
The 'HRV-14 and the HRV-2 are the main 
representatives of the major and the minor receptor 
classes respectively (Abraham and Colonno, 1984). Blass, 
et al. (1987) attempted to build a model for the HRV-2 
on the basis of the known structure of the HRV-14. 
Irpite of differences in the amino acid sequences in 
the VP1 protein together with insertions and deletions, 
several cases of the conservation of the functions for 
example salt bridges or the filling of restricted spaces 
were found. The large variations in the VP1 proteins 
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were found amongst the carboxy terminus amino acids of 
the residues lining the canyon. 
D. 5 Propagation of the Virus 
Lack of knowledge about the special requirements for the 
propagation of the virus in the cell culture systems 
hampered the work on the virus initially until.. Tyrrell 
and Parsons (1960) defined the conditions. They used the 
monkey kidney cell and recommended that, 1) the 
incubation temperature was 330C instead of 37 
OC 
, 
2) 
bicarbonate concentration less than 0.35 g /1 (pH 7.0 - 
7.2) and 3) slow rolling of the cultures (12 rev/hr). 
This breakthrough resulted in intensive research in the 
field of rhinovirus colds. Sensitive continious cell 
lines of a particular clone of HeLa cell known as HeLa 
(Ohio) (HeLa[O]) cell line (Conant and Hamparian, 1968) 
and semicontinuous cell lines WI-38 (Hayflick and 
Moorhead, 1961) became available. Fiala and Kenny 
(1966) reported that the magnesium ion (approximately 30 
mM magnesium chloride) favoured the plaque development 
in HeLa (Ohio) cells. The HeLa (Ohio) cells have also 
been adapted to grow in suspension culture (Thomas, et 
al., 1970). 
Comparison of the HeLa cell and the human 
embryonic fibroblasts (WI 38) for the isolation and 
propagation of the HRV, has shown the HeLa cell line to 
be more sensitive than the WI-38 cells. (Lewis and 
Kennett, 1976). The pH of the culture is not a critical 
factor during propagation of the HRV in the HeLa cells 
(Couch, 1985). 
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D. 6 Multiplication Cycle 
The multiplication cycle of the virus is divided into - 
1) attachment, 2) penetration and uncoating, 3) 
synthesis of the viral RNA, 4) Viral protein synthesis 
and morphogenesis and 5) cyto-pathic effects of the 
viral growth. 
D. 6.1. Attachment - 
The attachment of the virus to the cell is temperature 
dependent (Lonberg-Holm and Korant, 1972). Lonberg - 
Holm and Whitely (1976) showed that the initial rate of 
the attachment of HRV-2 doubled for a 10OC increase in 
temperature over the range of 20 to 390C. The rate of 
the virus attachment also depends upon cell 
concentration and divalent ions such as Mg2+ and Ca2+ 
which play an important role in the electrostatic 
interaction between the cell and the virus (Lonberg- 
Holm and Korant, 1972). 
Lonberg-Holm and Korant (1972) indicated that the 
HRV-2 and the HRV-14 used different cell receptors for 
the attachment to cells. The excess of the HRV-2 did 
not cause saturation for HRV-14. Later, Tomassini and 
Colonno (1986) isolated the receptor protein of the HeLa 
cells with the help of Mab raised against the HeLa 
cells. The Mab protected the cells against the virus 
infection. Competition studies showed that the HRVs used 
either one or the other receptor for binding with the 
cells. All HRV serotypes can now be classified into two 
groups (The major and the minor group) on the basis of 
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the receptors they attach to. The canyon on the virus 
surface is the putative receptor binding site. Rossmann 
and Palmenberg (1988) found greater conservation in the 
amino acids lining the canyon than other surface 
residues. The direct evidence of the involvement of the 
viral canyon in the binding was given by Colonno, et al. 
(1988). By using mutagenesis of an infectious cDNA 
clone, they created mutants of single amino acid 
subsitution or insertion and they found that mutation at 
various positions on the VP1 protein affected the 
binding. 
D. 6.2 Penetration and Uncoating - 
The attached virus passes from a state in which it can 
be dissociated from the cells by detergents like 
ethylenediaminetetra-acetic acid (EDTA), to a more 
tightly bound form that cannot be dissociated with EDTA. 
The tightly bound virus is either multivalently bound or 
it has undergone engulfment or penetration. The tight 
binding event is affecthd by metabolic inhibitors like 
concanavalin A, fluoride plus cyanide or by 
iodoacetamide. The tightly bound virus progresses 
towards the stage of eclipse becoming a cell associated 
virus. Specific anti-viral compounds such as 
thiopyrimidine and sodium dodecyl sulfate (SDS) block 
cell mediated eclipse by interacting with and 
stabilising picornaviruses in their native unaltered 
conformation. The mechanism of action of the metabolic 
inhibitors affecting the tight binding event is 
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different from the action of SDS and thio-pyrimidine on 
the eclipse process. The cell plays an active role in 
the progression from the stage of tightly bound virus to 
the eclipse stage. In the case of poliovirus, a certain 
amount of the virus is eluted or sloughed off from the 
infected cell in an irreversibly altered form. This form 
is called the A- particle. These A-particles lack virion 
polypeptide VP4. A-particles are the major product of 
the cell mediated eclipse of HRV-2. Addition of fluoride 
and iodoacetamide slows the formation of the A-particle. 
The A-particle have lipophilic properties and may be 
able to interact with the membrane lipid directly, and 
subsequent uncoating of the viral RNA might proceed 
while the A-particles remain associated with the 
membrane (Lonberg-Holm and Whitely, 1976). 
D. 6.3 Viral RNA Synthesis- 
The RNA synthesis of HRV appear to be a closely 
regulated process. Koliais and Dimmock (1973) found that 
the single stranded viral RNA molecules synthesized in 
the infected cells during the exponential increase of 
the virus and during the plateau of the virus production 
had no detectible variation in size. While, the FMDV 
(Brown and Martin, 1965) and bovine enteroviruses 
(Clements and Martin, 1971) synthesize larger single 
stranded RNA than the Viral RNA. 
Studies employing sedimentation velocity, 
electrophoretic mobility and treatment with ribonuclease 
showed that virus infected cells contained single 
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stranded RNA, double stranded RNA, replicative form RNA 
and a putative replicative intermediate form. The double 
stranded RNA, which is possibly the replicative 
intermediate form, is resistant to ribonuclease 
treatment and the single stranded RNA which is similar 
to the virion RNA is sensitive to ribonuclease (Sethi 
and Schwerdt, 1972 and Koliais and Dimmock, 1973). 
Studies on the kinetics of the RNA synthesis in 
the infected cells showed that the virus specified RNA 
was first detected at 4 hours post infection (p. i. ), rose 
exponentially to about 7 hours p. 1. and then its rate of 
production was linear for an additional 3 hours (Sethi 
and Schwerdt, 1972). 
Viral specific RNA dependent RNA polymerase has 
also been isolated from infected cells (Koliais and 
Dimmock, 1974; Griffith and Gauntt, 1975 and Morrow et 
al, 1985). The polymerase specifically copies the HRV 
RNA. The polymerase has also been shown to contain the 
virus specific poly-uridylic acid (Poly[U]) polymerase 
activity ( Morrow, et al. , 1985). 
The kinetics of the appearance of the polymerase 
shows a close association with the rate-of the synthesis 
of the viral RNA in vivo. Griffith and Gauntt (1975) 
found that the polymerase had its maximum activity at 6 
and 7 hours p. i. and the activity was reduced 
considerably by 8 to 9 hours p. i. 
Host protein synthesis is necessary for the RNA 
polymerase activity. Koliais and Dimmock (1974) showed 
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that the polymerase activity declined in the presence of 
cyclohexamide and Morrow, et al. (1985) reported that 
both replicase and poly-(U) activities purified together 
untill the step at which poly-(U) polymerase but not 
replicase activity was recovered. Addition of a purified 
HeLa cell protein to this poly-(U) polymerase completely 
reconstituted the HRV replicase activity. This suggested 
that the host cell protein acted at an initiation step 
of the viral RNA replication. 
The polymerase is associated with the cell 
membrane. It is, later, irreversibly released into the 
soluble phase of the cytoplasm (Griffith and Gauntt, 
1975). Yin and Knight, Jr. (1972) reported that the 
membrane bound RNA polymerase synthesized both single 
and double stranded RNA whereas the deoxycholate treated 
RNA polymerase synthesized only the double stranded 
viral RNA. The role of the cell membrane is not yet 
clear, however it is speculated that the integrity of 
the cell membrane may be necessary for the synthesis of 
the single stranded RNA by protecting it from the 
exposure to the cellular nucleases. 
The absence of the variation in the size of the 
viral RNA synthesized by the infected cell (Koliais and 
Dimmock, 1973) appears to indicate that the rolling 
circle hypothesis of Brown and Martin (1965) 
proposed for the replication of the FMDV RNA does not 
work for HRV RNA replication. The displacement 
hypothesis seems more relevant for rhinoviral RNA 
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replication. According to the displacement hypothesis, 
The positive viral strand is transcribed into a template 
negative strand with the help of an RNA dependent RNA 
polymerase enzyme and a double stranded replicative form 
is produced. The positive strand is then displaced by a 
new positive strand and more copies of the viral RNA 
are produced on this negative stranded RNA template. 
D. 6.4 Viral Protein Synthesis and Morphogenesis 
The large open reading frame of the viral RNA has only 
one initiation codon towards the 5-prime terminus. The 
whole reading frame is transcribed and then translated 
into a single large polgpeptide (Protein-A). The viral 
proteases then act upon it and the protein is cleaved in 
different structural and non-structural viral proteins. 
The steps in the processing of the poly-protein into its 
component are shown in Fig-1. 
The gene order and cleage pattern of the HRV is 
similar to that of poliovirus and cardiovirus (McLean 
and Rueckert, 1973). The genetic information of the coat 
proteins lies nearest the initiation site. The product 
of the 3C is the major protease (Palmenberg, et al., 
1979) The 3C protease does not mediate all the cleavage 
processes. Hanecak, et al. (1982) reported that the 
antiserum prepared against the 3C protease affected only 
the Gin-Gly sites and Tyr-Gly cleavage was not affected. 
Product 3B is the VPg protein (Pallansch, et al., 
1980) and product 3D is the viral polymerase 
(Lundquist, et al., 1974) which is capable of elongating 
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the nascent RNA chain from an RNA template (Flanegan, et 
al. , 1977). 
The function of the P2 proteins are less well 
defined. Indirect evidence suggests that the protein' 
2C has a role in RNA synthesis and protein 2B is a host 
range determinant. The protein 2C carries a guanidine 
resistance marker (a genetic locus in FMDV and polio- 
virus). This locus affects the action of drugs by 
blocking the initiation of RNA synthesis. HRV mutants, 
having the ability to grow in murine cells (extended 
host range) appear to be selectively altered in the 
sequence found in 2B ( Rueckert, 1985). 
The control of protein processing was studied using 
1) addition of radiolabelled amino acids and 2)the drug 
pactamycin which blocks initiation but allows the 
nascent protein on the viral polysomes to be completed. 
The results of pactamycin pulses, as short as 30 
seconds, revealed nascent chains not larger than the 
capsid protein. Ribosomes take 5 to 12 minutes to 
traverse the viral message. This suggests that the 
capsid protein is cleaved during or shortly after the 
ribosome synthesises the cleavage site (Rueckert, 1976). 
It is generally accepted that all picornaviruses 
have a single initiation site however the number of the 
termination sites is still a subject of speculation. 
Translation of the entire poliovirus RNA molecule in 
cell free extracts using membrane bound polysomes, 
Roumiantzeff, et al., (1971) produced a large poly- 
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protein. This suggests that the genome has only one 
termination site. However, Kerr, et al., (1972) reported 
that the EMC RNA was translated in a cell free extract 
into several much smaller products having capsid 
precursor chain A plus an additional length which 
terminated prematurely at a certain preferred region. 
The suggestion was that this type of translation was an 
artifact attributed to "nicks" in the m-RNA. 
At present, it is not clear as to how the 
synthesis of the viral protein is controlled. Paucha et 
al (1974) found that the structural and the non- 
structural proteins of the EMC virus were not produced 
in equimolar concentration. There was two fold increase 
in structural proteins over the non-structural proteins. 
In the absence of any practical evidence, they 
postulated that the ratio between structural and non- 
structural proteins, from energy considerations, came 
about because the capsid proteins were required in 
larger amount for the assembly of the progeny virion 
while the non-capsid polypeptides, which had only a 
catalytic function were in less demand. A weak terminal 
signal just after the structural protein was activated 
late in the infection while it remained suppressed 
during the log phase of the infection. McLean and 
Rueckert (1973) reported that a relatively large amount 
of non-structural poly-protein in HRV-lA infection was 
presumbly generated by cleavage at a non-standard site 
in the poly- protein. They suggested that the ratio 
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between the structural and non-structural proteins could 
be due to the variation in the frequency of these 
cleavages at different times in the infection cycle. 
These ambiguous cleavages (öýcurrence of cleavages at 
sites other than the "programmed" one) have been 
reported for other picornaviruses (Rueckert, 1976). 
It may be that this non-standard cleavage plays a 
role in the control of viral replication and protein 
synthesis. The non-standard cleavage occurs only in the 
non -structural protein and therefore it may cause 
malformation of the enzymes required for the viral RNA 
and the viral protein synthesis. 
The picornaviral morphogenisis can be described as 
a tandem three or four stage processes. McGregor) et al., 
(1975) identified two capsid precursor subunits in virus 
infected HeLa cells and these authors proposed that the 
Protomers (A) were assembled in to pentamers (A5). 
Protein-A was then cleaved into VPO, VP1 and VP3 and 
the procapsids formed. The cleavage also caused a shift 
in the sedimentation values from 13 S to 14 S, possibly 
due to structural changes. McGregor and Rueckert (1975) 
later showed a similar pathway for the assembly of HRV- 
1A. 
The assembly pathway is summarised as a three or 
four stage process (Fig-3) in which monomers (A-protein) 
are converted into pentamers (A5). The pentamers then 
assemble into a 12 plated capsid. The RNA is inserted in 
to the capsid either during the formation of the capsid 
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or after the formation of the empty particles. In this 
provirion (125 S) the VPO is finally cleaved in to VP2 
and VP4 and so the mature particles (155 S) are formed 
(Rueckert, 1985). The empty capsids are also called 
naturally occuring top component (NTC) or immature 
shells and have been reported for HRVs. The NTC 
particles are composed of VPO , VP-1 and 
VP3 (Korant et 
al, 1972). 
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Fig-3: Morphogenesis of HRVs ( Adapted from 
Rueckert, 1985) 
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D. 6.5 Cyto-pathic Effects of Viral Growth- 
HRV like other picornaviruses causes cytocidal infection 
of the cells they infect. However, Gauntt (1979) 
reported the persistence of the infection in HeLa 
cells. The persistence developed when the HRV infected 
cells were cultured in the presence of guanidine at 3 mM 
concentration.. The production of defective interferfing 
particles was not observed and the cells were as 
efficient as " standard " HeLa cells for other cellular 
functions, including supporting virus growth. Gercel, et 
al., (1985) initiated a persistent infection of cells 
with a temperature sensitive mutant of HRV-2. During the 
persistence of the infection, the virus was continually 
produced at a low level and the cells underwent multiple 
episodes of partial destruction (crisis) and subsequent 
recovery. Super-infection of the cells cured of the 
persistent infection indicated the selection of a cell 
population during the persistence that could no longer 
support the growth of the homologous type. However, the 
effect became less pronounced upon further passage of 
the cured cells. 
Keck and Rosenthal (1967) studied the cyto- 
pathic effects of the HRV on HEp 2 cells. The virus 
induced charactertic morphologic changes. The cells 
began to contract from their neighbours and round up. 
The nuclei became shrunken and there was a perinuclear 
cytoplasmic condensation, retraction and occasionally 
cytoplasmic projection. Shortly, afterwards, the cells 
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became completely rounded containing only remnants and 
they eventually detached from the surface. 
The picornaviruses including the HRVs cause the 
inhibition of cell functions after viral infection. This 
phenomenon is known as the shut-off phenomenon. Carrasco 
and Smith (1976) and Carrasco, (1977) explained this 
phenomenon. They proposed that the virus first attached 
to the cell membrane and caused changes which 
distorted the gradient of monovalent ions maintained by 
the cellular membrane. This led to an influx of sodium 
ions causing an increased sodium ion concentration and 
these changes in the monovalent cation concentration 
resulted in differential translation of the host and 
viral RNA. A concentration of 30 mM sodium chloride 
(NaCl) inhibited the protein synthesis by cellular RNA 
by about 80% but stimulated the synthesis of the 
picornavirus proteins, directed by viral RNA, by about 
50%. Carrasco and Smith (1976) observed that the EMC 
viral RNA was efficiently translated in vitro over a 
wide range of potassium ion concentrations with a 
maximum effect at 110 mM KC1. In contrast the 
translation of cellular RNA had a more stringent 
potassium requirement with a maximum effect at about 80 
mm potassium chloride (KC1). The KC1 at 90 mM and NaCl 
at 30 mM concentrations stopped cellular protein 
synthesis completely. The authors suggested that sodium 
ions had a direct effect on the initiation of protein 
synthesis and also on the interaction between mRNA and 
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the ribosomes, thereby increasing the affinity of the 
picornavirus RNA and decreasing the affinity for the 
cellular mRNA. 
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E Antigenic Structure of the Virus - 
The HRV serotypes are classified on the basis of their 
neutralisation antigens. The native viral particles are 
known as D-particles. The native antigenicity can be 
altered by heating at 56 
OC 
or by acidification. These 
altered particles are known as C-particles. These 
treatments yield two types of C-particles. One particle 
looses the RNA and sediments at 80 S whilst the second 
type of the C-particles are those which retain the RNA 
and sediment at 135 S. The C-particle's antigenic 
determinants are cross-reactive in immunodiffusion and 
complement fixation tests. The C-particles are non- 
infectious as they do not have the ability to attach to 
the host cells. Many or the most of the D-particle 
determinants are lost in conversion to C-antigenicity. 
The D- and C-particles are also found in Natural Top 
Component (empty capsids). Acidification destroys the D- 
antigencity (Lonberg-Holm and Yin 1973). 
The antigenic analaysis of the D-paricles shows 
massive antigenic variation in cross neutralisation 
studies. Neutralisation is generally observed in 
homologous virus and serum mixtures (Schieble, et al. 
1974). Lack of a close relationship between strains has 
been demonstrated not only at the surface of the virion 
but also at the genomic level (Yin, et al, 1973). The 
antigenic variation has even been demonstrated among 
different isolates of a single type of the virus 
(Schieble, et al. , 1970). The pattern of 
the antigenic 
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variation is not well understood. Even though there is 
massive antigenic variation, one way or both way 
relationships have been demonstrated between the virus 
types in cross neutralisation studies with potent 
antiserum (Cooney, et al. , 1973). In a particular 
study, Cooney, et al. (1982) demonstrated extensive 
relationships among the HRVs. Only 40 antisera did not 
neutralise at least one heterotypic virus and the 
remaining 50 HRVs were in 16 groups when the grouping 
was done according to an antigenic relationship. Five 
pairs of the HRVs (1A: 1B, 2: 49,12: 78,13: 41 and 29: 44) 
were shown to have reciprocal relationships without 
evidence of matching to any other serotypes and four 
pairs were shown to have reciprocal crosses in which one 
or both members of the pair showed a relationship to 
other serotypes. HRVs-9 and 32 showed reciprocal crosses 
as well as with HRV-67. HRV-36 showed a cross 
relationship with HRV-58 and one way relationships with 
HRVs-50 and 89. HRV-74 and HRV-15 showed a reciprocal 
relationship and HRV-14 showed a relationship with HRV- 
6. Halfpap and Cooney (1983) isolated the rhinovirus 
inter types. The inter types were neutralised equally by 
antisera to related HRVs (12 & 78, or 36 & 58). 
Recently, all HRVs have been grouped into only two 
groups (Major and minor groups) on the basis of the 
receptor of the cell they bind to (Abraham and 
Colonno, 1984). However, the significance of this 
grouping in terms of protection has yet to be shown. 
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Overall, the virus appears to have a complex antigenic 
structure. Despite the various relationships in vitro, 
the HRVs have not yet been shown to cross protect in 
vivo (Stott, et al. , 
1969) and it seems difficult to 
group the HRVs into types and subtypes. 
E. 1 Neutralising Epitopes of Picornaviruses " Mapping 
Mapping of neutralising antigenic sites is of particular 
importance for studies on the mechanism of 
neutralisation. First, as a foundation for understanding 
the molecular basis of sero-type specificity and 
secondly as a starting point for developing sub-unit 
vaccines. 
Five antigenic sites have been reported on polio- 
virus type 1. One site at residue 93 to 100 of VP1. has 
been identified for poliovirus type 1 and type 3. The 
other sites are located at residue 11 to 17 and 70 to 75 
on VP1. At residue 162 to 173 on VP2 and at position 71 
to 82 of VP3 (Rueckert, 1985). 
Immunity and antibody responses to an isolated 
capsid protein of FMDV (Bachrach, et al. , 1969) gave 
rise to a widely held opinion that only the trypsin 
sensitive VP1 capsid protein was the site of important 
immunogens. McCullough, et al. (1987) with the help of 
Mabs mapped the antigenic site on a FMDV type 01. Six 
major antigenic sites containing one or more epitopes 
were identified. These sites were : 1) the trypsin 
sensitive sequential site on VP1 and one antibody 
identified an epitope present on VP1, VP2 and VP3. This 
( 
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site was at or near the cell attachment site of the 
virion. 2) a trypsin resistant, conformational site on 
VP1,3) a second trypsin resistant, conformational site 
involving both VP1 and VP2,4) a third trypsin 
resistant, conformational site on VP1 and at this site, 
the monoclonal antibody dependent neutralisation of the 
virus infectivity was inefficient, 5) the expression of 
this site was impaired but not destroyed by trypsin 
treatment and was not related to the virus infectivity 
and 6) an internal site which appeared to be a 12 S 
subunit specific site. The FMD virus, therefore, has 
both trypsin sensitive and trypsin resistant 
neutralising (infectivity associated) sites. 
Studies on neutralising escape mutants have 
identified four neutralisation immunogens on the common 
cold picornavirus, HRV-14 ( Sherry, et al. , 
1986). 
These sites are named as neutralising immunogens (NIm) 
1A, 1B, II and III. The NIm 1A is present on VP1 at 
amino acid residue 91 or 95. The NIm II is located on 
VP2 at residues 158,159,161 or 162. The NIm III is on 
VP3 at residue 72,75 or 78 and NIm 1B has two sites 
either VP1 at residue 183 or 185 or residue 138 or 139. 
The sites NIm 1B, II and III are the discontinious sites 
and a distal mutation does not cause alteration in any 
of the antigenic sites (Fig-1). 
McCullough, et al. (1987) suggested that although 
it was difficult to draw a relationship between the 
antigenic sites identified on FMDV and the physical 
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structure of HRV and poliovirus, It was probable that 
the trypsin sensitive site (site 1) on FMDV was 
equivalent to NIm II (but on VP1). The partially trypsin 
sensitive site (site 5) might be related to the 
protrusion close to the HRV NImII site. The sites (sites 
1 and 3) involving more than one virion poly. peptide were 
perhaps akin to NIm II and NIm III on HRV. 
E. 2 Mechanism of the Virus Neutralisation 
Neutralising antibody is one of the main components of 
the protective immunity which usually results from 
vaccination. Secondary factors such as complement or 
cells which interact with antibodies can also cause the 
inactivation of the viruses. 
Mandel (1979) proposed that virus neutralisation 
might be classified as either an intrinsic, an extrinsic 
or a pseudophenomenon. Intrinsic neutralisation is the 
direct consequence of the union of a virion with one or 
more molecules of antibody. Extrinsic neutralisation is 
defined as "the binding of antibody to non-critical 
sites which may, under certain conditions, result in 
neutralisation. The binding of the antibody molecule 
with non-critical sites can cause steric hindrance to 
the critical areas in performing important biological 
functions for example attachment to the cell. 
Pseudoneutralisation is described as under the condition 
of equivalent concentration, the binding of the antibody 
to non-critical sites may lead to secondary interactions 
such as "aggregation". Although the individual virions 
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are not neutralised, each multimeric aggregate registers 
as one infectious unit. It is this intrinsic loss of the 
infectivity which is of greatest interest. 
Picornaviruses are neutralised by the direct 
action of the antibody as well as by formation of the 
aggregate. 
Neutralising antibodies of poliovirus change the 
isoelectric point from pH 7.0 to pH 9.0 and there is a 
correlation between stabilisation of the isoelectric 
point and the neutralisation (Mandel, 1979). 
Wetz, et al. (1986) studied the neutralisation of 
poliovirus by polyclonal serum. They used non-saturating 
antibody concentrations to allow binding of a single IgG 
molecule per virion. Various antibody virus complexes 
were produced which were isolated by sucrose density 
gradient centrifugation and then identified by electron 
microscopy. The majority of the virus particles formed 
aggregates of different sizes, which were cross linked 
by antibody. The complexes were as a monomer, dimer, 
trimer, tetramer and pentamer. A small fraction of the 
total virus concentration was associated with one IgG 
molecule and was neutralised. However, the aggregation 
of the virus particles resulting in neutralisation does 
not appear to be a non - specific interaction. Taniguchi 
and Urasawa (1987) isolated two poliovirus Mabs showing 
virus precipitating activities. The two Mabs identified 
distinct antigenic sites on the virus and differed in 
their virus precipitating activity. The strength in 
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precipitating activity of the Mabs did not correlate 
with that of their neutralising activity. 
Conformational changes due to interaction with 
antibody have also been reported in case of FMDV. 
McCullough, et al. (1987a) reported that the 
interaction of a particular Mab with homologous FMDV 
altered the conformation of the virion to permit 
penetration of a staining reagent. A consequence of this 
structural alteration was that the RNA genome became 
susceptible to disassociation from the capsid proteins. 
The virus neutralisation was irreversible and provided 
an effective in vivo defence measure against the virus 
attack. However, the virus neutralisation by Mabs does 
not always result in in vivo protection. McCullough, et 
al. (1986) did not find consistent correlation between 
the efficiency of the neutralisation by the Mabs in 
vitro and the protection of neonatal mice against virus 
challenge. 
There is, as yet, not much information available 
on the mechanism of neutralisation of the HRVs except 
for HRV-14. This virus has been shown to be unable to 
cause the viral cytopathic effects byMabs binding at 
the receptor binding site on the virus (Colonno, et al., 
1986). Similarly, antiserum raised against the putative 
receptor binding site on the virus, has shown in vitro 
neutralisation (McCray and Werner, 1987). Colonno, et 
al. (1989) reported that the eight Mabs recognising four 
neutralisation sites on HRV-14 (one pair for each site) 
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shifted the isoelectric point (PI) of the virion from 
6.7 to much a more acidic form (from PI 1.8 to 3.2). In 
addition, Mabs targetted against 3 of the 4 neutrali- 
sation sites caused significant aggregation of the 
virion. This aggregation was reversible by papain 
digestion. The non-aggregating Mabs showed a dose 
related inhibition of the virus attachment to the cell 
receptor. 
It is, therefore, evident that both the direct 
action of the antibody as well as aggregation of the 
viral pa ýicles are mechanisms of picornaviral 
neutralisation. However, their relative importance is 
not known. Wetz, et al. (1986) observed that the 
majority of the polyclonal response was towards the 
aggregation of the virus particle. It seems that the 
antibodies first control the infection by aggregation 
of the virus particles resulting in a decrease in 
infectivity and then the other antibody specifically 
neutralises the virions. However, both may be 
independent mechanisms in which the aggregation 
stimulates other mechanisms like opsonisation and 
phagocytosis. 
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F Antigenic Variation and Vaccine Development 
Antigenic drift or change in the antigenicity of the 
surface glycoprotein, is a well established mechanism 
among parasites for escaping immune elimination. It is 
the principal means of persistence of protozoans such as 
trypanosoma, plasmodia and several species of bacteria. 
It is suggested that this phenomenon may also be 
important in persistence of several viruses for example 
influenza, rabies and measles. In the case of viruses, 
the basic mechanism of this process is mutation of the 
genome with attendant alteration in surface antigens, 
permitting escape from immune control (Clement and 
Narayan, 1984). These changeable surface antigens 
control the qualitative and quantitative aspects of, the 
immune response and are often considered to be the 
immuno-dominant antigens. 
Therefore the immuno-dominant antigens are often 
studied to better understand the mechanism and 
consequences of the variation so that vaccines can be 
developed. 
The variation in the immuno-dominant region only 
occurs if it does not interfere with the stability and 
the biological functions of the virus. Wimmer, et al. 
(1986) proposed that in case of poliovirus, HRV and FMD 
viruses, the ability of the immuno-dominant region to 
alter without interfering with virion stability and its 
biological functions determined the number of serotypes 
which are observed. This may also suggest that there is 
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an evolutionary pressure on other regions to remain 
conserved. These conserved regions which are also 
antigenically active are now called immuno- subdominant 
antigens. 
These immuno-subdominant antigens could not be 
detected in earlier work due to the use of polyclonal 
antisera. The relatively higher concentration of the 
antibodies against the immuno-dominant antigens deter- 
mined the overall antigenicity of the antisera. However 
the Mabs have been used to identify conserved immuno- 
subdominant antigens on bacteria, protozoa and viruses. 
F. 1 Vaccine Development 
Vaccination or immunisation is described as a process of 
artificially inducing a state of specific immunity in an 
individual. Immunity may be produced by transferring 
preformed antibody or sensitized cells (passive 
immunity) or by providing a direct stimulus for an 
immune response by contact with antigen (active 
immunity). 
Active immunity occurs upon recovery from a 
naturally acquired infection or by the process of 
artificially inducing immunity (vaccination) by 
inoculation, ingestion of an organism so that the immune 
material retains the immunogenicity of the intact 
organism but does not have the capacity to cause disease 
(Stewart, 1972). 
The types of artificial immunogens that have been 
used include 1) low doses of a product of the organism 
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2) altered products such as chemically modified toxin 
(toxoid), 3) antibody neutralised toxin, 4) killed 
organism, 5) low doses of virulent organism given by non 
pathogenic or innocous routes, 6) living attenuated 
strain and 7) organisms altered in such a way that they 
can not complete a complex life cycle for example lung 
worm vaccine for cattle (Stewart, 1972). 
Recent approaches for vaccine development are 
based upon synthetic vaccines and anti-idiotypic 
vaccines. Synthetic vaccines are described as those 
vaccines which contain a major antigenic determinant of 
an organism as a synthetic antigen (Arnon., et al., 1983). 
The anti-idiotypic vaccines are those vaccines which 
contain antibody whose antigen combining site is a 
mirror image of the antigen (Dreesman and Kennedy, 1985). 
F. 2 Use of Immun-Dominant Antigens In Vaccines 
The immuno- dominant antigens have been exp1Oited in 
developing effective vaccines for Foot and Mouth 
disease. Biological behavior of the virus (prevalence of 
virus in a geographical area) helped in selection of the 
appropriate immunogens. The selection of the appropriate 
immunogens was based initially on isolating the virus 
causing the outbreak and then developing a vaccine from 
the isolate. As the use of tissue culture in vaccine 
production increased, the vaccine strains were 
identified which were efficient in a replicative system 
and optimally matched with field strains (Morgan, et 
al., 1984). 
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Another example is influenza virus. Extensive 
molecular biological studies on influenza viruses have 
provided information of importance to the understanding 
of the epidemiological behavior of the virus. The virus 
shows antigenic drift and shift in their neuraminidase 
(NA) and hemagglutinin antigens (HA). The amino acid 
sequence of the 1972,1975, and 1979 strains has enabled 
a detailed evaluation of how, by an accumulation of 
amino acid mutations, the antigen can change its surface 
and evade neutralisation (Wilson, et al., 1984). Massive 
change in antigenic properties (antigenic shift) 
involves complete replacement of the gene coding for 
another HA subtype. This may also be accompanied by 
replacement of the NA gene (Schild, 1984) 
Laver and Webster (1973) proposed that new viruses 
emerged as a result of genetic mixing (gene assortment). 
one such strain of the influenza virus was shown to be 
such a recombinant of duck and equine influenza viruses. 
Schild (1984) proposed that this genetic 
reassortment was one of the three possibilities. First, 
the "new" virus might have caused an epidemic in humans 
many years previously and then remained hidden and 
unchanged in some unknown place (The H1N1 virus). The 
second way for emergence of a "new" virus was if an 
animal or bird virus became infective for humans by 
mutation. 
The three dimensional structure of the 
hemagglutinin glycoprotein has now been described. Its 
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antigenic sites have also been identified (Wilson., et 
a1., 1984). 
These developments may conceivably open the way to 
using site directed mutagenesis to tailor the 
hemagglutinin molecule so as to improve its 
characteristics for use in a vaccine. 
In some micro-organisms, one type is capable of 
expressing various forms of the immuno-dominant 
antigens. Neisseria and Trypanosoma are two examples 
where switches operate to change the antigenic forms. 
The outer membrane protein antigens of N. eisseria are 
highly variable and these variations may be important in 
enabling the bacteria to evade the host's immune 
response and to adapt to a differing host environment. 
One family of proteins that show such variations is the 
surface exposed protein-II (PII). It rapidly and 
reversibly alters the expression within a single strain 
and differs antigenically among different strains. The 
expression of these pilus proteins can be turned on and 
off at a high frequency (phase variation) as detected by 
colonial morphology (Meyer, et al. 1984). The 
chromosome of the bacterium contains "several complete 
expression genes coding for the variant proteins. DNA 
sequence analysis of two genes derived from the same 
locus (opa El) of two isogenic gonococcal variants 
reveal common and variable regions in these genes 
(Stern, et al., 1986). Meyer, et al. (1984) mapped two 
chromosomal loci in the strain MS1 of gonococcus. They 
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reported that both regions underwent rearrangement 
involving deletion of the pilus sequence. A third 
sequence which was the silent loci contained a 
structural gene sequence but not the promotor sequence. 
From the observation that there were more copies of the 
variable region pilus sequence than the constant region 
sequence in the silent loci, they suggested that it was 
more analogous to the arrangement of immunoglobulin 
structural gene sequences where copies of these variable 
regions of the immunoglobulin were separated from copies 
of the constant region sequence. However, without the 
irreversible deletion of intervening sequences for 
generating an intact immunoglobulin molecule, the 
gonococcal cell expressed one pilus idiotype. In 
addition, it was capable of expressing a novel idiotype 
and subsequently switching back to express the original 
pilus idiotype. Stern, et al. (1986) reported that the 
5-prime region of the gene was composed of identical 
pentameric pyrimidine units (CTCTT). It encoded for the 
hydrophobic region of the leader peptide. This coding 
repeat was variable in a given locus with respect of the 
number of pentameric units. While all the expression 
loci in a single cell were constitutively transcribed, 
the production of the opacity protein was determined by 
the coding repeat sequence at the translational level. 
The exact nature of the gonococcal pili phase switch and 
antigenic variation remains to be determined. 
A further example can be deduced from the 
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trypanosoma which depend upon antigenic variation to 
evade the immune response. An antigenic switch 
corresponds to the activation of a variable surface 
glycoprotein gene (VSG) from a large silent repertoire. 
Most switches require the duplicative transposition of 
a VSG gene which involves both strand break in DNA and 
its subsequent repair (Cornelissen, et al., 1985). 
These studies on antigenic variation provide a 
great wealth of information. Part of this information 
suggests that some organisms show antigenic variation 
where the genetic sequence coding for the immuno- 
dominant region is replaced by another sequence. In such 
cases, it seems probable that these sequences can be 
cloned to develop recombinants. These recombinants, 
expressing all the different immuno-dominant antigens 
could then be used for vaccines. Unfortunately this 
approach would be unsuccessful in the case of those 
micro-organisms where the switches work with large 
numbers of alternative genes. However, studies on the 
operation of these switches could yield valuable 
information on the control of expression of the various 
proteins and thereby lead to the development of 
appropriate strategies to overcome the resulting 
problems. 
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F. 3 Immuno-Subdominant Epitopes 
Studies on antigenic structures of micro-organisms with 
Mabs have identified conserved regions on the 
immunogenic sites. These conserved regions are called 
immuno-subdominant epitopes. Immuno-subdominance does 
not mean that they are of less importance 
immunogenic ally. The subdominance refers to the fact 
that they are somehow masked by the dominant epitopes 
and therefore they are not subjected to immune selective 
pressure. Subdominant epitopes have been identified in 
bacteria, protozoa and viruses. 
F. 3.1 Conserved Antigens of Bacteria 
The widespread use of antibiotics has led to the 
emergence of antibiotic resistant strains of bacteria 
and so research in bacteriology is now concentrating 
on preventive strategies rather than on chemotherepy. 
Use of Mabs to identify suitable vaccine candidates has 
identified conserved antigens on many bacteria. 
F. 3. la Conserved Neisserial Antigen 
The genus Neisseria is composed of number of a different 
species, all of which share certain properties and 
biochemical activities. There are both pathogenic and 
commensal species. Neisseria gonororhoeae and Neisseria 
meningitidis are responsible for a variety of infections 
of varying severity and cost to public health. 
Prost, et al. (1970) identified a major protein 
common between N. meningitidis groups together with at 
least five other minor proteins in immuno - 
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electrophoresis. The possible role of this protein was 
first reported by Jennings, et al. (1972). They 
extracted from the cells of N. meningitidis serogroup Y 
(Slaterus) a mixture of antigens by using a 0.9 M 
calcium chloride solution. The extracts contained mainly 
proteins and an active immunity to both homologous and 
hetýrologous groups of meningococci was shown in a mouse 
model. Later investigations into the antigenic structure 
of gonococcal pili with Mabs (Virji and Heckels, 1983 
and Cannon, et al. , 1984) and 
the antisera raised 
against cyanogen bromide generated fragments (Rothbard, 
et al., 1984) showed conserved epitopes. Cannon, et al. 
(1984) named this as the H. 8 antigen. Conserved epitopes 
were shown to be present on pathogenic gonococcal and 
meningococcal bacteria and not on commensal neisseriae 
and other gram negative bacteria. 
Virji and Heckels (1983) demonstrated the presence 
of conserved epitopes in cerebro-spinal fluid collected 
from a patient with meningococcal infection. Black, et 
al. (1985) demonstrated the in vivo expression of H. 8 
antigen by the blocking of the binding between the 
antigen and its Mab by the use of convalescent serum. 
Their experiment showed that the antigen was immunogenic 
in the case of both gonococcal and meningococcal 
infections. Aoun, et al. (1986) reported that the common 
antigen was an immunogenic, peptide in nature, exposed 
on the surface and it was stable after passage 
in 
humans. Later Lavitola, et al. (1987) confirmed that 
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the neisserial common antigen was exposed at the 
surface, and it was a heat stable protein. It was found 
that there were common antigens on the gonococci strains 
isolated from different anatomic sites in both male and 
female partners. This demonstrated antigenic stability 
after in vivo transmission of gonococcal infection. 
Competitive radioimmunoassay has shown that the 
conserved epitopes are found within a variable region 
containing other epitopes which determine the antigenic 
specificity of the protein (Heckels, et al. , 
1986). 
Although there is conservation and immunogenicity 
of the common antigen, its minimum role in infection 
appears to be due to its weak expression when present on 
intact pili. Rothbard, et al. (1984) reported that less 
than 15% of the antibodies raised against the intact 
pili were directed against this site. This region was 
immunogenic only as a fragment and not as an intact 
pilus filament. 
F. 3. lb Streptococcal M Protein 
Group A streptococci are important human pathogens 
especially in developing countries where they are a 
major cause of cardiac damage in children (Hollingshead, 
et al. , 1987). Group A streptococcal strains 
have been 
divided into more than 80 different M protein serotypes 
by absorption against streptococci of several 
heterologous serotypes (Lancefield, 1962). 
The M protein of group A streptococci is 
considered to be one of the primary virulence determi- 
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nants because it prevents phagocytosis (Scott, et al. 
1985). 
Fischetti, (1977) reported that the purified strepto- 
coccal M protein induced hyperimmune serum in the rabbit 
showed a type specific response with the development of 
opsonic antibodies against the majority of the antigenic 
determinants of the molecule. The antibodies directed 
against a small percentage of these determinants were 
cross reactive between certain M types. 
Jones, et al. (1985) showed that amino terminal 
regions of the fibrillar group A streptococci M protein 
had only limited immunological cross reaction among M 
serotypes. Two Mabs isolated after immunisation against 
almost the entire M6 molecule revealed that an epitope 
responsible for cross reaction among 5 of 56 strains of 
different M serotypes was located in the amino terminal 
half of the molecule, distal to the cell surface. In 
contrast, a more common cross reactive epitope, reacting 
with 20 of the 56 strains was located near the middle of 
the M molecule. 
The possibility that all M types share a common 
determinant was suggested by Scott, et" al. (1985) in a 
DNA hybridization study. A DNA probe consisting of the 
almost entire Emm 6 gene (encoding the M protein of 
serotype 6 hybridized with DNA's from all 56 different 
strains tested and with four non-typable strains. 
These common determinants are promising for 
vaccine development. Jones, et al. (1985) reported that 
60 
the more conserved determinant, located in proximity to 
the cell surface, was accessible to the immune system, 
even on the whole organism. This led them to make a 
suggestion that the more conserved epitope might be 
useful in devising a means to protect against the 
infection by multiple group A streptococcal serotypes. 
F. 3. lc Enterobacterial Common Antigen 
Endotoxin is responsible for many or most of the 
deleterious effects of gram negative organisms. Because 
it is an endogenous part of the cell wall of gram 
negative bacteria, endotoxin comes in contact with the 
surrounding cells and body fluids of the host. Endotoxin 
or Lipopolysacciride (LPS) is composed of 3 main parts - 
1) outermost (O)- polysaccharide, 2) the core 
oligosaccharide and 3) the inner- most lipid-A. The 0- 
polysaccharide is composed of number of identical 
replicating subunits and is highly variable among gram 
negative bacteria. The core polysacchride and to a 
larger extent the lipid-A are more conserved structures 
among these bacteria. The conserved nature of these 
inner moities has been the basis for an intensive search 
for a cross reactive vaccine. These would have to depend 
on a rough mutant that lacks O-polysaccharide and 
section of the core polysaccharide (McCallus and 
Norcross , 1987). 
Ziegler, et al. (1982) reported that passive 
immunisation of patients with human antiserum, to killed 
whole cell strain J5, substantially reduced the number 
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of deaths due to gram negative enteric and pseudomonas 
bacteraemia. Siber, et al. (1985) raised antisera 
against rough gram negative mutants such as E. coli J5 
and Salmonella minnnesota Re 595 and reported a high 
antibody response to heterologous LPS. Miner, et al. 
(1986) raised a panel of 28 Mabs directed against E. coli 
J5 endotoxin. When characterised by their capacity to 
cross react with purified endotoxin preparations from 
several gram negative bacteria, 22 Mabs exhibited no 
cross reactivity and 6 Mabs elicited a limited cross 
reactivity. However, when characterised for their 
capacity to react with the intact organism instead of 
the purified endotoxin, the pattern of cross reactivity 
was different. Most of the Mabs were able to react with 
S. -Minnesota, eighteen reacted to the E. coli parent 
strain and 13 Mabs reacted weakly with Pseudomonas 
aeruginosa and 3 Mabs reacted weakly with Klebsiella 
pneumoniae. 
Lipopolysaccharide (LPS) is a potent polyclonal 
activator. Siber, et al. (1985) were uncertain that the 
heterologous response against the rough gram negative 
mutants was specific to the conserved antigens or due 
to a polyclonal antibody response. Similarly, Ziegler, 
et al. (1982) were unable to demonstrate that the 
passive protection of patients was due to non-specific 
resistance, or to the anamnestic responses to other 
antigens or to J5 specific antibodies. In addition, the 
cross reactive Mabs used by Miner, et al. (1986) were 
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unable to provide passive protection for mice challenged 
with lethal endotoxin. 
The enterobacterial common antigen known as ECA - 
Kumin (Domingue, et al. , 1970) and 
the enterobacterial 
rough core glycoprotein (Johns, et al., 1983) are now 
claimed to have the potential to elicit protective 
antibodies. Molenda, (1982) reported that the 
hemagglutinin antibodies against enterobacterial common 
antigen showed a simultaneous rise with specific anti-O 
antibodies in sera and the colostrum of sows immunised 
against colibacillosis. 
Antigenic and immunogenic analyses of a J5 mutant 
by Sakulramrung and Domingue (1985) revealed that the 
surface antigens were very complex. A heat killed E. coli 
J5 vaccine evoked antibody responses with multiple 
specificities. The response was ECA-Kumin Strain J5 
specific and also shared cross reactive antigens against 
those present in E. coli J5 and certain salmonella 
species. This suggested that any of these reactions 
might have contributed to the protective activity of J5 
antiserum to the specific immunoprotective role of the 
common antigen. Exhausitive adsorption was used to show 
that the protective factor was antibody specific for 
strain J5 lipopolysaccharide. 
F. 3. ld Common Antigens of Pseudomonas 
Pseudomonas produces two extracellular antigens : the 0 
antigen and the protein nature antigen. The immune 
response to these extracellular protein antigens induces 
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cross immunological reaction with Pseudomonas aeruginosa 
strains of heterologous serotypes. From this 
observation, it was postulated that there was a common 
protein antigen in Pseudomonas aeruginosa strains of 
different serotypes (Shchetinina, 1985). 
Sourek, (1985) reported that the pseudomonas 
common antigen, originally known as the endotoxin 
protein, in vaccine afforded substantial protection to 
mice against Vibrio para haemolyticus. The bacterial 
endotoxin (LPS) derived from some members of the family 
enterobacteriaceae conferred between 70 to 90 percent, 
in some cases, and, in others, 20 to 50 percent 
protection against pseudomonas and vibrio infections. 
Similarly, Vetkova, et al. (1985) demonstrated that P. 
aeruginosa vaccine was capable of protecting animals 
from P. aeruginosa infection as well as from some other 
representatives of the family enterobacteriaceae. 
However, a comparative study of the antigenic spectra of 
the vaccine strain and representatives of 
enterobacteriaceae did not show a direct relationship 
between the degree of this protective effect and the 
presence of the common antigenic determinants. 
F. 3. le Conserved Antigens of Haemophillus influenzae 
H. influenzae organisms are major pathogens of human 
adults and children. H. influenzae type b (Hib) is a 
common causative agent of meningitis of young children 
and non-typable H. influenzae is regularly implicated in 
sinusitis, otitis media, neonatal sepsis and bronchitis. 
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A vaccine composed of the capsule of Hib, polyribosyl 
ribitol phosphate, is currently in use. This vaccine is 
effective in children over 18 months of age but 
ineffective in younger children. Another vaccine 
comprised of saccharide protein conjugate is effective 
for all ages of children, however, it is not effective 
against non-typable H. influenzae (Green, et al. , 
1987). 
These problems have led investigators to study 
other haemophillus antigens for their vaccinal 
potential. Murphy, et al. (1986) identified an epitope 
on a 16.6 KDa outer membrane protein (OMP) using mouse 
Mabs. This epitope (P6) was present on all 115 isolates 
of H. influenzae tested, including typable and non- 
typable strains. The epitope was found to be a highly 
specific marker for the H. influenzae because the 
epitope was absent in virtually all other bacterial 
species tested. 
Murphy, et al. (1986) detected antibodies against 
the P6 antigen in human serum. These antibodies were 
shown to be bactericidal against non-typable 
H. influenzae . 
Green, et al. (1987) studied the vaccine potential 
of P6 antigen. A peptidoglycan associated lipoprotein 
(PAL) of 15 kDa was purified from the OMP of 
H. influenzae and tested for its potential as a vaccine. 
It afforded protection to infant rats from challenge 
with each of 5 clinical Hib isolates and the antiserum 
was bactericidal for H. influenzae a, b, c, d, e, f, 
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and 181 of 182 Hib clinical strains isolated from widely 
dispersed geographical areas. This protective effect 
was additive to, and did not interfere with, the 
bactericidal and protective activities of antibodies 
against the type b capsule. 
F. 3. lf Cross Reactive Determinant of Mycobacterium 
The controversial reports on the immunogenic potential 
of tuberculosis BCG vaccine and the need to develop a 
vaccine against leprosy suggest that studies on the 
antigenic nature of the bacteria would be of value. 
Investigations into the antigenic structure of 
Mycobacterium leprae with mouse Mabs have identified 
three different types of specificities (specific, 
partially specific and cross reactive). 
Ivanyi, et al. (1983) reported that the antigen 
MY1 (12 kDa) reacted with only one Mab without 
demonstrable cross reactivity for any of the other 20 
tested species of mycobacteria. Another 4 Mabs which 
identified the antigen MY2 revealed only a marginal 
degree of cross reactivity with 3 other species of 
mycobacteria. Two antigens MY3 and MY5 showed 5 protein 
bands and were shared by several other mycobacterial 
species. Young, et al. (1985) demonstrated that the 
specific and partially specific Mabs recognised a 
spatially separate epitope on the same polypeptide 
chain. Similarly, Daniel and Olds (1985) reported a 
common epitope widely shared among M. tuberculosis and 
other mycobacteria. 
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Indirect evidence for the immunogenicity of this 
conserved antigen was provided by Britton, et al. 
(1985). They identified four antigens with a panel of 
mouse Mabs . The low molecular weight 
4.5 to 6 kDa and 
30 to 40 kDa antigens showed cross reactivity with other 
mycobacterial species whilst two other 16 and 70 kDa 
antigens showed a limited distribution. Although all 
four bands reacted with some human lepromatous leprosy 
sera in immunoblots, the 4.5 to 6 kDa and 30 to 40 kDa 
antigens were the most prominent. Lepromatous leprosy 
sera also inhibited the binding of radiolabelled Mabs to 
each of the four antigens. The mean titre causing 50% 
inhibition being higher for antibodies reacting with the 
4.5 to 6 kDa and 30 to 40 kDa antigens. This work 
suggested the involvement of all four antigens in B 
cell response to M. leprae. 
F. 3. lg Common Surface Protein of Anaplasma - 
Anaplasmosis is an important haemoparasitic disease of 
livestock. Effective immunoprophylaxis could not be 
developed against the causative rickettsiae because of 
the complexity of the organism includes persistence in 
the host and presence of antigenically variant strains 
(Barbet, et al. , 
1987). 
Palmer, et al. (1986) identified a surface protein 
of 105 KDa molecular weight (AM 105) on Anaplasma 
marginale with the help of Mabs. This antigen was shown 
to be common to eight isolates with antigenic, 
morphologic and protein structural differences. Cattle 
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immunised with AM 105, purified by immunoaffinity 
chromatography, were protected against challenge with 
virulent A. marginale. Later two more panels of Mabs 
were made (Palmer, et al., 1988). One Mab in the first 
panel identified an epitope on field isolates of A. 
marginale from different geographical areas. These 
isolates were found to be antigenically distinct with a 
panel of 11, isolate restricted, Mabs. The second panel 
of seven Mabs detected epitopes common to all isolates 
of A. marginale and also A. centrale. These common 
epitopes were present on two major surface proteins of 
Mr 36 KDa and 105 KDa. 
Barbet, et al. (1987) cloned the A. marginale DNA 
in E. coli and identified a novel protein of 105 KDa 
molecular weight as a major cellular component. Further 
characterisation of the rickettsial genome revealed 
multiple and partial homologous copies of the cloned 
sequence. 
F. 3.2 Immuno-Subdominant Antigens of Protozoa 
The malarial parasite ( Plasmodium ) and trypanosomes 
are two protozoa which are under intensive research to 
develop suitable prophylactics. Trypanosoma represents a 
classical example of antigenic variation. Malarial 
parasites also show antigenic variation as there are 
many primate plasmodial species. The Mab approach is in 
current use to identify conserved immunogenic epitopes 
on these two protozoa. 
F. 3.2a Shared Epitopes of Plasmodium 
Ring infected erythrocyte surface antigens ( RESAs ) are 
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found in the membranes of erythrocytes infected with 
young asexual stages of certain plasmodium species 
(Sulzer, et al. , 1988). Antibodies against 
the RESA of 
P. falciparum (RESA-P) show inhibition of the merozoite 
invasion of the erythrocytes in vitro (Wahlin, et al. , 
1984). Their association with clinical immunity has been 
reported (Wahigren, et al. , 1986). In addition 
to 
P. falciparum, other plasmodial species have been found 
to have RESA's. These species include the rodent 
malarial parasites P. chabaudi and P. reichenowi. The 
latter is a parasite of apes which is closely related to 
P. falciparum and P. fragile , parasites that infect the 
rhesus monkey . However, RESA has not been detected in 
other human plasmodial species such as P. vivax, P. ovale 
and P. malariae (Sulzer, et al. , 1988). 
Although evidence is not available for the 
presence of RESA on P. vivax and P. malariae, Sulzer, et 
al. (1988) found that antibody to RESA-P was inducible 
by infection with another human malarial species. Serum 
samples collected from inhabitants of three isolated 
localities in Peru where P. vivax and P. malariae were 
endemic and where P. falciparum had not been reported, 
26% had anti RESA-P antibodies. These sero-epidemic 
observations were corroborated by an experiment on six 
chimpanzees infected with P. malariae. Three of these 
animals developed anti RESA-P antibodies after the 
infection. The antigen was detected only on parasite 
itself in case of P. malariae while in case of 
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P. falciparum, the antigen was detected on the parasite 
as well as on the membrane of the infected erythrocytes. 
Schofield, et al. (1986) isolated 4 Mabs against 
P. falciparum which recognised an antigen in the 
merozoites. Two of the Mabs inhibited the merozoite 
invasion of erythrocytes. One of them recognised a 
variable epitope while the other recognised a highly 
conserved epitope found on primary isolates from 
different geographical areas. 
It seems likely that searching for RESA on the 
parasite rather than on the infected erythrocytes may 
help identify the antigens on other human species. The 
nature of these antigens has yet to be investigated. 
This cross reactivity between P. malariae and 
P. falciparum is of paricular interest, because RESA-P 
appears to be promising as a vaccine candidate. 
F. 3.2b Invariant Antigens of Trypanosoma - 
Trypanosomes present a complex disease problem for 
cattle and humans due to the lack of either suitable 
therapeutic drugs or an effective vaccine. Vaccine 
production and diagnosis are hampered by massive 
antigenic variation. 
Gray (1960) detected cross reacting precipitating 
antibodies in the sera of cattle and other animals. 
Barbet and McGuire (1978) reported cross reactive 
determinants in variant species with specific surface 
antigens. A number of variant specific surface antigens 
(VSSAs) purified from T. brucei and T. congolense were 
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tested for immunological cross reactivity. The results 
confirmed the presence, in VSSAs, of variable 
determinants specific to individual VSSAs and also 
showed cross reactive determinants. 
Shapiro and Murray (1982) characterised the 
antigens recognised during the course of the infection 
in two breeds of cattle. They found that the recognition 
of certain common trypanosome protein antigens 
correlated closely with the clinical course of the 
disease. However, the sera failed to detect such 
antigens on the surface of the living trypanosomes. It 
was possibly due to the subsurface location of these 
antigens. Similarly, Holder (1983) suggested that the 
cross reactive determinants on the VSG might also be 
buried in the densively packed array of the surface 
coat, near the carboxy terminus of the VSG. 
Burgess and Jerrells (1985) prepared two Mabs 
which were cross reactive with several antigenically 
distinct variable antigen types. The two Mabs identified 
a low molecular weight doublet of approximately 22 KDa 
molecular weight antigen, by Western blotting. These 
determinants did not appear to be on the VSG molecule 
and were destroyed by trypsin digestion. These genus 
specific Mabs also reacted with determinants present in 
sera from African trypanosomiasis patients but not from 
patients with malaria or leishmaniasis. This suggested 
that certain invariant molecules of the trypanosomes 
might be present as circulating invariant antigens in 
the patients. 
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F. 3.3 Conserved Immunogenic Epitopes on Viruses 
The mapping and elucidation of neutralising sites on 
viruses with Mabs have identified conserved 
neutralising epitopes associated with RNA as well as DNA 
viruses. 
F. 3.3a Conserved Epitopes on Herpes Viruses 
Shared epitopes have been identified on herpes viruses. 
Edson, et al. (1985) reported the sharing of antigenic 
epitopes between Herpes simplex virus glycoprotein and a 
63 KDa Varicella zoster virus envelope glycoprotein and 
suggested that these two proteins had a similar 
function in the infection. 
Conraths, et al. (1987) identified an antigenically 
and functionally conserved domain on the glycoprotein B 
of Herpes simplex virus 1 and bovine herpes virus type 
2. Two cross reactive Mabs in immunofluorescence 
tests neutralised the heterologous virus. 
F. 3.3b Shared Epitopes on Human Immunodeficiency Virus 
Acquired immuno-deficiency syndrome (AIDS) in man is 
caused by human immunodeficiency virus (HIV), a retro- 
virus. Differences among isolates of HIV have been 
analysed at the nucleotide sequence level. (Hahn, et al., 
1985 and Ratner, etal., 1985). Recently the analysis has 
been done on sequential viral isolates from the same 
patient (Hahn, et al, 1986). These variations seem to be 
concentrated in the envelope protein coding region of 
the HIV. 
Schneider, et al. (1986) reported that the two 
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envelope glycopeptides of Mr 160 KDa and 120KDa were 
regularly recognised by HIV specific antisera in lysates 
of cells persistently infected with HIV. The 120 KDa 
molecular weight protein was designated as gp120. In 
addition, the gp120 was precipitated by sera from horses 
infected with equine infectious anaemia retro virus 
(EIAV) but not by sera from uninfected horses. This 
indicated a conserved epitope common to the envelopes of 
HIV and EIAV. 
Computer assisted analyisis of the envelope 
protein sequences of 7 different isolates was carried 
out (Modrow, et al. , 1987). Of these isolates, three 
represented sequential isolates from a single patient. 
It was found that the region of high sequence 
variability was interspersed with highly conserved 
regions among the independent isolates. The membrane 
associated protein (gp 41) showed 80% conservation of 
the amino acids. One hydrophilic area on the gp4l was 
identified as accessible to antibody recognition. 
Several constant and variable domains have been 
identified in gpl20. Ho, et al. (1988) reported that in 
the constant domain, sequence conservation was greater 
than 80% among different isolates of HIV. Whereas in the 
most variable domain, sequence conservation was between 
20% and 30%. Conservation of the sequence within the 
constant domains could indicate selective pressure to 
maintain these sequences. Their functional importance is 
not understood. Rabbit antisera raised against three 
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overlapping synthetic peptides with sequence homologies 
to the second conserved domain of gpl20, 
immunoprecipitated the envelope glycoprotein. In 
particular, the antibodies directed against amino acids 
254 to 274 of envelope glycoprotein were efficient in 
neutralising three different isolates of HIV in vitro. 
Dalgleish, et al. (1987) developed a polyclonal 
anti-idiotype antibodies against a Mab that inhibited 
the in vitro binding of HIV to the CD 4 molecule. The 
antibodies to anti-idiotypic antibodies specifically 
reacted with the HIV envelope glycoprotein in a solid 
phase immnuo assay. More importantly, the anti- 
idiotypic antibodies induced antibodies which 
neutralised three distinct isolates of HIV and. one 
isolate of HIV type 2 in a syncytium inhibition assay. 
F. 3.3c Conserved Epitopes on Parainfluenza Virus (PIV) 
This virus causes bronchiolitis and pneumonia in infants 
(Chanock, et al. , 1958) and is 
frequently isolated from 
the nasal secretions of cattle with shipping fever 
(Reisinger, et al. , 1959). 
Coelingh, et al. (1986) mapped the antigenic sites 
on the haemagglutinin and neuraminidase (HN) surface 
glycoprotein of human PIV-3/ WASH /47885/57 prototypes 
strain with Mabs. First, two non-overlapping sites A and 
B were identified and a third bridging site C. Later, 
three more sites (D, E and F) were identified. The 
epitopes at sites D, F and two epitopes at the site A 
were highly conserved among human clinical isolates 
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examined. These epitopes were also present in the 
bovine strain of the virus. 
F. 3.3d Conserved Epitopes of Influenza Virus 
The eight single stranded genomic segments of influenza 
virus code for 10 or more polypeptides. The RNA segment 
7' encodes for a protein of approximately 15 KDa 
molecular weight designated M2. This protein, in 
addition to the haemagglutinin (HA) and neuraminidase 
(NA), is an integral part of the membrane and is 
abundantly expressed at the infected cell surface (Lamb, 
et al. , 1985). However, unlike HA and NA, available 
evidence indicates that the M2 is not incorporated into 
the virions (Zebedee, et al. , 1985). 
The M2 protein has been found to be antigenically 
conserved among all strains of influenza virus both in 
regions exposed on the cell surface and those held 
intra-cellularly. Antisera raised against the amino 
terminal region of the M2 have identified the protein on 
the cells infected with all avian influenza subtypes 
tested (H1 to H13). It has been proposed that the amino 
terminal region of M2 has a potential role as the target 
molecule for influenza virus infected cells for cross 
reactive cytotoxic T cells (Zebedee, et al., 1985). 
F. 3.3e Common Neutralising Epitopes on Rota Virus 
Neutralising Mabs have identified cross reactive 
epitopes on rota viruses. 
Coulson, et al. (1986) isolated a clone of Mab 
that showed a partial cross reactivity. The Mab against 
75 
serotype 1 neutralised all the strains of rota viruses 1 
and 3 but did not neutralise the serotypes 2 and 4. 
Taniguchi, et al. (1987) reported a cross reactive 
neutralising epitopes on VP3. They suggested the 
existence of at least three distinct cross reactive 
neutralising epitopes on VP3 of human rota viruses. 
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G Monoclonal Antibody Technology and its Application in 
Virus Research 
Kohler and Milstein (1975) demonstrated that individual 
antibody secreting cells could be immortalised by fusion 
with myeloma cells. These hybrids are called hybridomas. 
Such a cell secretes antibody molecules with an 
identical molecular structure. This is in contra- 
distinction to polyclonal antibodies where many 
different antibody molecules coexist. 
Any two cells types can be made to fuse by the 
addition of Sendai virus or PEG-1500. However, the 
culture of the hybridoma can be overgrown by unfused 
myeloma tumour cells. The strategy devised by 
Littlefield (1964) is an accepted strategy to allow only 
the hybrids to grow. The strategy is based on the 
following considerations - 
The main bio-synthetic pathway for purines and 
pyrimidines can be blocked by the folic acid antagonist 
aminopterin. However, the cell can still synthesise 
deoxy-ribonecleic acid (DNA) via the so called salvage 
pathways. In these pathways, the nucleotides are 
recycled with the help of the enzymes thymidine kinase 
(TK) and hypoxanthine guanine phosphoribosyl transferase 
(HGPRT). Thus, the DNA synthesis can still occur, 
provided that thymidine and hypoxanthine are available 
and the enzymes TK and HGPRT are present. 
Spleen cells possess these enzymes and the myeloma 
cells lack them. The fused cells are made immortal by 
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being fused with the myeloma cells and the hybrids. 
survive and grow in a medium containing hypoxanthine, 
aminopterin and thymidine (HAT) because the spleenic 
cells provide the enzymes TK and HGPRT. 
In the method of making the hybridoma, the PEG is 
generally used to promote the fusion of myeloma cells 
with spleen cells (Goding, 1980). The hybridomas found 
positive for the desired antibody are cloned as early as 
possible to reduce the chance of their being overgrown 
by irrelevant cells. The cloning can be performed by 
limiting dilution, cloning in soft agar and by using a 
fluorescent activated cell sorter to detect and isolate 
particular cell. However, the limiting dilution method 
is the most commonly used method (Campbell, 1984). The 
established hybridomas are either grown in vitro in cell 
culture systems or in vivo in mice as an ascites tumours 
for antibody production. In the case of cell culture 
systems, the antibody is present in the cell culture 
fluid and in case of the in vivo mice system, the 
antibody is present in fluid drained from the enlarged 
peritonium (Campbell, 1984). 
G. 1 Application of Monoclonal Antibodies in Virus 
The use of Mab as a reagent has provided much new 
information about the epidemiological, structural and 
biological properties of individual proteins of many 
different viruses. 
G. 1.1 Epidemiological Studies 
Mabs are potentially the most effective source for high 
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specificity reagents to be used for identification of 
viral isolates. 
Antinucleocapsid Mabs have shown clear 
distinctions between rabies related viruses and rabies 
virus (Wiktor, 1984). 
The vaccine specific Mabs that distinguish all 
three types of Sabin vaccine strain from wild type 
poliovirus have been described (Wiktor, 1984). 
G. 1.2 Studies on Structural and Antigenic Properties 
To date, the emphasis of many Mab studies has been on 
the determination and detailed characterisation of viral 
proteins that serve as target structures for virus 
neutralising antibodies. 
Mab selected variants are used for studying 
antigenic structure. An interesting observation was 
made, originally with influenza virus, that a small 
fraction of the virus resisted neutralisation by 
individual Mab preparation. Analysis of the 
neutralisation resistant fraction revealed that it 
consisted of a variant of the parental virus in which 
the epitope recognised by the Mab used in the neutrali- 
sation test was altered (Gerhard and Koporowski, 1984). 
Comparative analysis of a large panel of variant 
viruses in the presence of the Mab used for their 
selection, enabled the delineation of major groups of 
neutralising Mabs and variant viruses. The antigenic 
changes exhibited by several mutants viruses within a 
given group reduced or prevented binding or neutralising 
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ability of the Mab within the corresponding group, but 
had no effect on binding or neutralisation of Mab in 
different groups. Thus each of these groups apparently 
defines an area of the molecule of the virus that is 
able to undergo independent antigenic alteration, 
presumably because they represent a topologically 
distinctive structure or antigenic site (Wiktor, 1984). 
Similarly, the variants have been used in other 
viruses for the mapping of antigenic sites. 
G. 1.3 Studies on Biological Properties of Viral Proteins 
Mabs are also being applied in studies of functional 
anti-viral assays. Virus adsorption to target cells, 
neutralisation and modulation or lysis of virus infected 
cells are examples of assays performed in vitro. 
Examples of the assays done in vivo are protection 
against infection, recovery from, or modulation of, 
virus induced disease (Gerhard and Koporowski, 1984). 
These studies have provided information that 
distinct antibodies directed to the same viral protein 
exhibit different anti-viral activities. Antibodies of 
different functions may act competitively with each 
other and cause reduction of a desired anti-viral 
activity or by contrast may not only act additively but 
even synergistically. It has also been observed that 
assays performed in vitro (such as virus neutralisation) 
do not always correlate with an antibody's protective 
efficacy against viral challenge in vivo (Gerhard and 
Koporowski, 1984). 
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H Towards a Human Rhinovirus Vaccine: Possible 
Approaches 
From the information presented above, it appears that 
the development of a vaccine protective against the HRV 
caused common cold disease is a possibility. 
'ft 
H. 1 Approach Via Immuno-doming Epitopes 
To date there has not been a breakthrough in the 
exploitation of immuno-dominant epitopes for the 
development of a vaccine. However, the mapping of 
neutralisation sites of HRV-14 by Sherry, et al. 
(1986) is an important step towards the goal of 
achieving a successful vaccine. With this information and 
with that of the neutralising sites on other HRVs, a 
better understanding of the molecular basis of the 
serotype specificity can emerge. This may be of use in 
overcoming the problem of antigenic variation. A 
recombinant micro-organism expressing sequences of the 
important immunogenic sites of different sero-types 
could be constructed. However, the progressive antigenic 
changes in the virus could reduce the chances of 
success. An alternative approach might be to prevent or 
to predict the variation by understanding the mechanism 
of antigenic variation. An alternative would be to base 
vaccine on those conserved antigens which evoke 
neutralising antibodies. 
H. 2 The Approach Through Conserved Antigens 
The putative cell receptor binding site on the virus is 
highly conserved. McCray and Werner (1987) showed the 
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cross neutralisation of 48 rhinovirus serotypes with a 
polyclonal antiserum raised against a conserved region 
(putative receptor binding site) and Abraham and 
Colonno (1984) reported that all the HRVs could be 
classified in to two group on the basis of the receptor 
binding site. This approach founded on the conserved 
region looks promising for a vaccine. However, the size 
of the canyon (25 AO) of the receptor binding site 
means that it is inaccessible to the antibody molecules 
as the size of the Fab portion of antibody molecule is 
35 Ao (Rossmann, et al. , 1985) 
There are indications which point towards the 
presence of immuno-subdominant neutralising epitope (s) 
on HRVs. Physico-chemically and biochemically, all HRVs 
are identical. In addition they also share many 
properties with other members of the family 
picornaviridae (McGregor and Mayor, 1971 and Stott and 
Killington, 1972a). The gene order and cleavage pattern 
of HRVs show similarities with poliovirus (McLean and 
Rueckert, 1973). This possibly indicates the 
conservation of many physical structures of the virus in 
spite of antigenic differences. 
High neutralising titre hyperimmune serum raised 
against the virus serotypes showed more cross reactivity 
(Cooney, et al., 1973). Heterotypic stimulation with the 
related virus showed an anamnestic response, whereas the 
antibody response to the secondary antigens was high 
although it resembled a primary response. With an 
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unrelated antigen, a previously unsuspected relationship 
has been revealed and a number of clusters of related 
HRVs have been demonstrated (Cooney, et al. , 1975). 
Genomic homology studies (Yin, et al. , 1973) and 
experiments on antibody response following rhinovirus 
vaccination in human volunteers have not shown such 
relationships and also an heterogenbus antibody 
response has not been detected (Stott, et al. , 1969). 
However, Fleet, et al. (1968) reported that some HRVs 
did provoke heterogenus responses but that these 
responses did not show a more or less strong reaction 
with a particular serotype but either the serotypes 
caused an intense or mild response. 
Halfpap and Cooney (1983) reported the isolation 
of inter-types which were neutralised equally by 
antisera against related serotypes. Possibly, these 
inter-types are links in the evolution of HRVs. 
Further studies on the antigenic relationship of 
the virus with potent antisera were carried out by 
Cooney, et al. (1982). They suggested that if the HRVs 
were grouped according to antigenic relationships, 50 
serotypes could be included in 16 groups. 
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I Proposed Research Project 
It has now been clearly demonstrated above that 
conserved immunogenic epitopes exist on many 
microorganisms. These epitopes have also been found on 
the microorganisms showing massive antigenic variation 
for example N. eisseria and -rrypanosoma. Studies of these 
epitopes have also pointed out that polyclonal 
antiserum failed to demonstrate such antigenic 
relationships. The epitopes were only identified via Mab 
approach. The evidence presented in the section H. 2 in 
the Introduction chapter suggests that such epitopes 
may exist on the variable HRVs. 
Based on these considerations, a research project 
was established to study the conserved neutralising 
epitopes on HRV serotypes with Mabs. The project had 
following objectives- 
1) Preparation of the Immunogen 
It was decided to use a concentrated purified prepa- 
ration of a serotype of HRV (HRV-2) for the immunisation 
of the mice. The concentrated preparation would give an 
opportunity for the weaker antigens to stimulate their B 
cells. It is mentioned in the section H. 2 of this 
chapter that more antigenic relationships were 
identified with the use of the potent HRV antisera. The 
purification would remove the unwanted antigenic 
competition due to substances other than virus in the 
preparation. 
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2) Raising a Panel of Neutralising Mabs 
The spleen cells of the mice would be used to produce 
the hybridomas secreting the HRV-2 neutralising Mabs. It 
was decided to include not only those hybridomas 
secreting strongly reacting Mabs but also those which 
gave a positve but weak reaction. 
3) Studies on Cross Reactivity of the Mabs 
The Mabs would be used in cross reactivity studies on a 
selected group of HRVs and also on other chosen members 
of the family Picornaviridae. The presence of the 
epitopes on HRVs and other picornaviruses would be 
identified in a binding assay. The conservation of the 
neutralising function of the epitopes would be 
determined in a cross neutralistion test. 
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Materials and Methods 
A Cell Culture and General Virological Methods 
The methods of cell culture and general virological 
methods such as virus propagation, titration and the 
neutralisation test with antiserum are described below - 
A. 1 Cells 
The continuous cell lines used in the study are 
described below - 
A. la HeLa Cells (Ohio strain) 
The Ohio Strain of HeLa cells is called HeLa (0). An 
anchorage dependent strain of these cells (monolayer 
cells) called HeLa (OM) was obtained from MRC Common 
Cold Unit, Harvard Hospital, Salisbury, U. K. These 
cells were used for HRVs, EMC and coxsackie virus types 
A-18 and A-21. The passage level of the cells at time of 
receipt was not known. 
A second strain of Ohio HeLa cells adapted to 
grow in suspension culture (HeLa -[OS]) was obtained 
from Dr. R. R. Rueckert, University of Wisconsin, Madison, 
USA. These cells were used to grow HRV-2 for virus 
concentration and purification work. The passage level 
of the cells was not known. The cells were received by 
post in a cryotube. 
A. lb Vero Cells 
A vero cell line was obtained from the departmental cell 
bank. They were used for poliovirus and coxsackie virus 
types B2 B3 B4 B5 and B6. The cells were obtained at 
passage level 140. 
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A. lc LLCMK2 Cells 
Rhesus monkey kidney embryonal cell line (LLCMK2 cell) 
was obtained from the departmental cell bank. They were 
used for enteric cytopathogenic human orphan virus (ECHO' 
virus). The passage level was not known. 
A. ld Human Rhabdosarcoma Cells 
Human rhabdosarcoma cell line was kindly provided by the 
Public Health Laboratory, Guildford, U. K. through 
Dr. A. Barrett of the department. The cells were used for 
coxsackie virus A-9 . The passage level was not known 
A. 2 Propagation of the Cells 
All the cells were first propagated and a sufficient 
number of aliquots were stored over liquid nitrogen for 
future use. 
All the cell lines except HeLa (OS) suspension 
were cultured in static monolayer culture. Plastic 
flasks were used for static cultures. The tissue culture 
flasks were purchased from Flow Labs. 24 well plates 
from Linbro. 
,6 well dishes and 
96 well microplates 
were purchased from Nunc. 
A. 2.1 Monolayer Cell Culture 
A. 2. la Propagation of the Cells 
Basal minimum essential medium (BMEM) was used as the 
growth medium (Appendix-1). The cells were seeded at a 
the concentration of 1-2X105 cells/ml in the growth 
medium which was added at the level of 0.6m1/cm2 culture 
flask area. The flasks were observed microscopically for 
cell growth. It was subcultured when the cell sheet 
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appeared confluent under microscope. 
A. 2. lb Subculture 
The Hela (OM) cells were removed from the surface by 
EDTA. Versene and trypsin (VT) solution was used for 
other cells. The composition of these solutions 
described in Appendix 1. 
The spent medium was decanted and the cell sheet 
was washed with warm phosphate buffered saline (PBS). 
The EDTA or VT was added to the flask. The flask with 
its contents were incubated at 370C untill the cells 
were detached from the surface of the flask. 
The EDTA or VT was removed by pelleting of the 
cells at low speed (200 g for 5 minutes). The pellet was 
resuspended in growth medium. The cells were counted and 
were appropriately diluted in growth medium for 
reseeding. 
A. 2. lc Counting the Cells 
The trypan blue dye exclusion test was used to assay the 
viability of the cells. The trypan blue dye was added to 
the appropriately diluted cell suspension. The dead 
cells were stained blue while the live cells excluded 
the dye. The live and dead cells were counted 
separatively using a haemocytometer (Modified-Fuchs 
Rosenthal haemocytometer). The formula described below 
was used for counting the cells. 
count of the cells X dilution X 103 
cell count / ml = ---------------------------------------- 
No. of fillings counted 
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A. 2. ld Preservation of the Cells 
The cells were preserved in the vapour phase over liquid 
nitrogen. The medium used for preservation is described 
in Appendix 1. 
Only the cells from a 90% or higher viability 
culture were preserved. The freshly removed cells were 
suspended in the preservation medium at the level of 
5X106/ml for the monolayer cell and 107/ml for the 
suspension cells. The suspension was aliquoted in 1.8 ml 
volumes and stored in cryotubes. The tubes were first 
kept at -700C overnight and were transferred to the 
liquid nitrogen container on the following day. The 
cells from an ampule were revived and grown to ensure 
proper preservation and freedom from contamination. 
A. 2. le Sterility Checks 
Sterility checks were routinely performed on cell 
culture reagents and spent growth medium. All cell 
culture reagents were tested for bacterial sterility 
after their preparation. The sterility checks were also 
performed on the growth medium used just before the 
subculture of the cells. The inoculum used in sterility 
checks was prepared by centrifuging 10 ml of a reagent 
or the spent medium at 200 g for 10 minutes. The 
supernatant was decanted just leaving behind about 1 ml 
in the tube. It was then throughly pipetted in and out 
and 0.5 ml of this suspension was inoculated into 
nutrient broth and remaining 0.5 ml inoculated onto 
nutrient agar plates. The nutrient broth and the plates 
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were incubated at 370C. The cultures were examined every 
day for 7 days for bacterial colonies on the nutrient 
agar and turbidity in the nutrient browth. 
A. 2.2 Suspension Culture 
The HeLa (0) cells adapted to grow in suspension (HeLa 
[OS]) culture as received did not appear to be very 
healthy when viewed under the microscope. They were, 
therefore, first grown in monolayer culture and then 
transferred to grow in suspension culture. The cells 
were cultured as stirred cultures in Duran bottles. The 
cultures were seeded at the level of 2X105/ml in 
suspension cell growth medium (Appendix 1) and stirred 
with a teflon coated magnet on a magnetic stirrer. The 
stirrer speed was kept at approximately 100-120 rpm. The 
cells were grown largely as a monodisperse suspension 
and they doubled every 24 hours. The culture was 
subcultured when the cell count reached 6-8X105/ml. 
The cultures were subcultured by dilution. The 
cells were preserved as per the method described in 
section A. 2. ld of this chapter. 
A. 3 Viruses and General Virological Techniques 
A. 3.1 Viruses 
Various members of the picornavirus family were used in 
the study. They are described below - 
A. 3. la Human Rhinoviruses (HRV) 
HRV serotypes 1A, 1B, 2,9,14 and 32 and their antisera 
were obtained from MRC Common Cold Unit, Harvard 
Hospital Salisbury, U. K. 
[Fruend'_adjuvant-was used' 
in the raising of these polyclonal antisera in rabbit 
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The serotypes HRV-19,45,72 and 85 were supplied by 
National Institute for Biological Standards and Control, 
South Mims, Potters Bar, Hertfordshire, through Dr. A. 
Barrett. 
The serotypes HRV-3,15 and 49 were made available 
via Dr. A. Barrett from the Wellcome Biotechnology, 
Beckenham. 
A. 3. lb Polio Virus 
The Poliovirus type 1 was obtained from the departmental 
virus culture collection. 
A. 3. lc Coxsackie Virus 
Coxsackie type A viruses (seotypes A-9,18 and 21) were 
obtained from the Public Health Laboratory, Guildford, 
U. K. through Dr. A. Barrett. 
Coxsackie type B viruses (serotypes B-2,3,4,5, 
and 6) were obtained from the departmental virus culture 
collection. 
A. 3. ld ECHO Virus 
The. ECHO virus was obtained from the departmental virus 
culture collection. 
A. 3. le EMC Virus 
The EMC virus was obtained from the departmental virus 
culture collection. 
All viruses were obtained as infected cell culture 
supernatant fluids. The passage history of all these 
viruses was not known. A portion of the fluid was used 
for making a working stock and remaining portion taas 
stored at -700C as the master virus seed stock. 
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A. 3.2 General Virological Techniques 
The propagation of the viruses, harvesting, titration of 
HRVs and neutralisation tests with hyperimmunised 
antisera (HRV-1A, 1B, 2,9,14 and 32) are described as 
general virological techniques. 
All viruses were propagated in static monolayer 
culture systems. The HRV-2 was propagated in the 
suspension cell culture system as well. The cells used 
for propagation of different viruses are mentioned in 
section A. 1 of this chapter. 
A. 3.2a Virus Propagation in a Static Monolayer Culture 
System 
HRVs were grown at 33-350C and all other viruses were 
grown at 370C. The spent medium was decanted from those 
flasks having a confluent cell sheet. The sheet was 
washed with warm PBS and a virus inoculum (107TCID50/ml) 
was added at the level of 0.04 ml/cm2 culture area. The 
virus was allowed to adsorb at room temperature for 30 
minutes. The maintenance medium (Appendix- 1) was then 
added to the level of 0.2ml/cm2 culture area. The flask 
was incubated at 33-350C for HRV and 370C for other 
viruses. The cultures were examined daily for viral CPE 
and the virus was harvested on the day of maximum CPE 
before the cells were completely lysed by the virus. 
A. 3.2b Virus Propagation in Suspension Culture 
HeLa (OS) suspension cells in their late logarithmic 
phase (4-6X105/ml) were used for HRV-2 propagation. The 
cells were pelleted at 200 g for 5 minutes and washed 
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once with warm PBS. The cells were suspended in the 
maintenance medium at a concentration of 4X106/ml and 
virus inoculum was added to the level of approximately 
100 TCID50/cell. The cells were stirred to just keep 
them in suspension and the virus was allowed to adsorb 
at room temperature for 30 minutes. The infected culture 
was then diluted by ten fold by adding 9 volumes of the 
maintenance medium. The culture was incubated at 33- 
350C and stirred at about 90 rpm. 
The trypan blue dye exclusion test was used to 
monitor the growth of the virus. The samples were 
collected twice daily and the cells were counted for 
viability. The conversion of the cells from dye 
excluding to dye penetrating was taken as a criterion of 
virus growth. The virus was harvested when 80% or more 
of the cells were positive for dye penetration. 
A. 3.2c Harvesting of the Virus 
In the case of monolayer cultures the flask was shaken 
vigorously to dislodge the infected cells off the 
surface while the cell suspension as such was used in 
the case of suspension cultures. The infected cell 
suspension was frozen and thawed three times to release 
the cell associated virus. it was thawed quickly in a 
waterbath and in the case of HRV the temperature of the 
suspension was kept below 370C. 
It was then centrifuged at 1400 g for 10 minutes 
to remove cell debris. The supernatant was aliquoted and 
stored at -700C. 
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A. 3.2d Virus Titration (TCID50 determination) 
HRVs were titrated in a microplate titration system. The 
96 well flat bottomed tissue culture grade microplates 
were used. 
Maintenance medium (Appendix-1) was used as 
diluent in the test. The protocol is described below- 
1) Prepare a 10 fold dilution series of the virus 
suspension. Ten fold dilutions were made by diluting 
0.1 ml of a virus dilution with 0.9 ml of the diluent. 
2) Each dilution was pipetted into 4 wells and 50 µi was 
pipetted into each well. The three wells of the cell 
control received the diluent only. 
3) Add 50 p1 of the diluent to all the wells. 
4) The plate was incubated at 350C for 1 hour in a 
gassed incubator ( 5% C02 and 95% air). 
5) HeLa ( OM) were stripped off the surface of a 
previously prepared flask culture ( section A. 2. lb of 
this chapter) while the plate with the dilutions was 
incubating. 
6) The cells were counted and diluted in the diluent to 
a concentration of 3.5X105 cells/ ml. (section A. 2. lc of 
this chapter). 
7) 100 pi of this cell suspension was added to all the 
wells. 
8) The plate was incubated at 350C under 5% C02 and 95% 
air. 
The plate was observed microscopicaly each day for 
viral CPE. The number of wells showing positive for the 
94 
256X 
128X 
64X 
32X 
16X 
8X 
4X 
2X 
Vi us 
Control 
e 1.7 
'Contro 
va 
0 
F 
0-4 
A Anti- 
erum 
1B ti 
ser m' 
2 ti 
se m 
9 Anti- 
se m' 
14 ti 
serum 
32 ti- 
serum 
Fig-4: Layout of a microplate for polyclonal antiserum 
neutralisation test on HRVs 
0 
ý4 
95 
viral CPE were recorded. 
The final reading was taken at day 5 and the virus 
titre was calculated according to the method described 
by Minor (1985). According to this method, each positive 
well represents 100.25 TCID50 unit virus titre. The 
titre is calculated as 106.5 if all wells are positive 
at the 10-6 dilution and none at the 10-7 dilution. 
A. 3.2e Micro-Neutralisation Test (Polyclonal Sera) 
The test for neutralisation of HRV-2 and a few other HRV 
serotypes by hyperimmune polyclonal antisera (homologous 
and heterologous neutralisation) is described below. The 
micro-neutralisation test performed with the monoclonal 
antibodies is described later. 
The constant virus and varying antiserum 
neutralisation test was performed in a 96 well tissue 
culture grade flat bottomed microplate. The maintenance 
medium (Appendix-1) was used as the diluent. 
The plate was marked as shown in fig-4 . The test was 
performed as follows- 
1) 50 il of the maintenance medium was added to all the 
wells. 
2) 50 pl of a HRV antiserum was then added to two wells 
of the first row. 
3) Two fold dilutions of an antiserum were.. prepared by 
taking out 50 p1 from a row and then mixing it with the 
50µl diluent of the next row. The 50 p1 of the highest 
dilution in the top row was discarded. 
4) The appropriately diluted challenge virus in a 50 p1 
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volume containing 3.00 TCID50 / 50 pl was then added to 
all the wells except the wells marked as the cell 
controls. The latter received 50 pul of the diluent in 
place of the virus . 
5) The plate was incubated at 350C for 1 hour in a 
gassed incubator ( 5% CO2 and 95% air). 
6) The freshly stripped HeLa (OM) cells were counted and 
diluted in the diluent to the concentration of 3.5 
X105/ml. 
7) 100 F'1 of this suspension was added to all wells of 
the plate after the incubation . 
8) The plate was again incubated for 5 days at 350C 
under 5% C02 and 95% air. 
9) The highest dilution of the antiserum showing an 
absence of the viral CPE microscopically was taken as 
the neutralising titre of the antiserum. 
In a single plate, one HRV serotype was tested 
against all the 6 antisera. By using six plates, each of 
the. 6 HRV serotypes could be tested against all 6 
antisera. 
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B Preparation of the Antigen for Use in Immunisation 
The HRV-2 serotype was selected for use as an immunogen 
for making the Mabs. 
A plaque purified, concentrated and sucrose 
density gradient purified live virus preparation was 
used to produce the activated B -lymphocytes. 
B. 1 Cloning of the Virus 
The virus was cloned by plaque purification. The plaques 
were isolated, amplified and a stock of the plaque 
purified virus was raised and stored for future use. The 
identity of the isolated virus was established 
serologically in a micro-neutralisation test (section 
B. 2 of the result chapter). 
B. la Plaguing of the Virus 
Tissue culture grade 6 well plates (Flow Lab. ) were used 
for this purpose. Each well was seeded with 5X105 cells 
in 3ml of growth medium. The plate was incubated 
overnight in a gassed incubator ( 5% C02 and 95% air) at 
370C. A confluent sheet was obtained on the following 
day. 
Appropriate dilutions of the virus in 100pl 
volumes was allowed to adsorb to the cell sheet after 
the spent growth medium had been decanted and the sheet 
had been washed once with warm PBS. The plate was kept 
out of the laminar air flow cabinet and held on the 
bench to prevent the cell sheet drying. The virus was 
allowed to adsorb for 30 minutes at room temperature. 
One well which received only PBS and no virus was kept 
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as a negative control. 
The virus inoculum was aspirated and 1.5 ml of the 
agar overlay (Appendix-2) was added. The agar free 
overlay medium supplemented with 0.2% glucose, 2mM 
pyruvate, 4mM glutamine and 4 mM oxalo-acetic acid was 
added after the gelation. The plate was incubated at 
330C in a 5% C02 and 95% air gassed incubator. The 
plaques were observed on day 2. 
B. lb Picking Of the Plaque 
The well isolated and smaller plaques were picked. The 
plaque containing well was screened under an inverted 
microscope and the area which appeared to be a viral 
plaque was marked. A Pasteur pipette was then directed 
towards the marked area and agar plugs were excised. The 
plugs were suspended in PBS and freeze-thawed three 
times to release the virus. 
B. lc Amplification Of the Plaques 
The released virus was inoculated on to a preformed cell 
sheet in a well of a 24 well tissue culture plate. The 
plate was incubated for 8 hours at 330C in a 5% C02 and 
95% air gassed incubator. The cells were then removed 
from the surface by freezing and thawing the plate. The 
cell debris was removed by centrifugation at 1400g for 
10 minutes. The material was further inoculated into 
wells of another 24 well plate which had a preformed 
cell sheet and incubated as described above. This time 
the virus was allowed to grow till the appearance of the 
viral CPE. 
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B. ld Preparation of the Virus Stock 
The material from the 24 well plates was then inoculated 
into 25 cm2 tissue culture flask containing a preformed 
cell sheet of HeLa (OM). The virus from this flask was 
inoculated into a similarly prepared 150 cm2 flask. The 
virus at this passage level was titrated, (section 
A. 3.2d of this chapter) tested for serological identity 
(section B. 2 of the Results chapter) and then stored for 
future use at - 700C. 
B. le Identification of the Virus 
The virus stock was tested in the micro-neutralisation 
test system for its serological identity. The test was 
carried out according to the method described in the 
section A. 3.2e of this chapter). 
B. 2 Propagation and Concentration of the Virus 
The plaque purified virus was grown in bulk for 
concentration and purification in a sucrose density 
gradient. This concentrated and purified preparation 
was used as the immunogen for activating mice spleen 
cells. 
B. 2.1 Propagation of the Virus 
The virus was propagated in a stirred glass bottle as 
per the method described in the section A. 2.2 of this 
chapter. A total of 500 ml virus suspension (grown on 
4X106 cells /ml) was used as the starting material for 
the concentration and the purification procedures. 
B. 2.2. Concentration of the Virus 
The virus suspension was first concentrated by 
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ultrafiltration and then the reduced volume was further 
concentrated by pelleting of the virus by a high speed 
centrifugation. 
B. 2.2a Concentration by Ultrafiltration 
The Millipore Minitan Ultrafiltration Unit was used. The 
filters classified as 10,000 NMWL (able to retain 
molecules above 10,000 molecular weight) were used in 
the filtration. 
The unit was set up according to instructions 
provided in the Millipore Minitan Ultrafiltration 
Catalogue No. OM 131. The unit, all bottles and tubing 
used in the unit were sterilised by autoclaving at 1200C 
for 30 minutes and all connections were made 
aseptically. 
The unit was first cleaned by circulating 0.1% 
sodium hydroxide (NaOH) solution in deionised water 
through it. The solution was circulated for 30 minutes. 
It was then chemically sanitised by circulating 250 ppm 
sodium hypochlorite solution in deionised water for 30 
minutes. Sterilised deionised water was then pumped 
through the unit to wash away the sodium hypochlorite 
solution. Care was taken to prevent the circulation of 
the sodium hypochlorite contaminated water. Finally, the 
unit was equilibrated by circulating the maintanance 
medium through it. 
The fluid circulation pathway is shown in fig-5. 
The virus containing cell culture fluid was added to the 
retentate / reservoir bottle and pumped into the unit by 
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a peristaltic pump. 
At the end of the concentration when as small a 
volume of fluid was left in the'retentate/ reservoir 
bottle as possible, the filtrate outlet was closed"and 
the concentrated fluid was, circulated to wash the 
retained material off the filters. Finally, the fluid in 
the tubing was drawn back into the retentate / reservoir 
bottle, by, tilting the bottle while allowing air to enter 
via a filter. 
The unit was again cleaned and sanitised as 
described above. The filters were stored in 50 ppm 
sodium hypochlorite solution. 
The efficiency of the unit in concentrating the 
virus was tested by performing a virus titration on the 
fluid before and after the ultrafiltration. The 
reduction in the fluid volume and the corresponding 
increase in the titre of the virus was taken as a 
criterion to determine the efficiency of the system. 
B. 2.2b Concentration by Ultracentrifugation 
The virus suspension concentrated by the ultrafiltration 
process was then further concentrated by pelleting the 
virus at high speed and resuspension in a yet smaller 
volume. Picornaviruses are frequently associated with 
membranes when released from the host cell and detergent 
is uselly added to free the virus particle 
(Minor, 1985). Sodium lauryl sulphate or sarcosyl was 
used as detergent. It was observed that the sarcosyl (1% 
w/v) precipitated serum and other protein in the 
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medium. The ultrafiltered virus used for further 
concentration by pelleting was still in the medium which 
contained new born calf serum. It was, therefore, 
considered necessary that the pelleting should be done 
twice. The pellet from the first ultracentrifugation was 
suspended in PBS and then this virus containing 
suspension was treated with sarcosyl, Using a Beckman 
SW 50 Ultracentrifuge rotor, the viral fluid was 
pelleted twice. 2-mercaptoethanol was added to the 
fluid to give 0.1% concentration. A volume of 4 ml was 
then pipetted into each tube. A 30% sucrose solution in 
buffer IV (Appendix 2) supplemented with 1% bovine serum 
albumin (BSA) was underlaid in a 0.5 ml volume. The 
virus was pelleted through this sucrose cushion by 
centrifugation at 45,000 rpm for 90 minutes. 
The pellet was resuspended in LS buffer (Appendix- 
2). The pellet from all the six tubes was pooled and 
diluted to 4 ml. To this was added, a 10% solution of 
the sariosyl to give the final concentration of 1% w/v 
sarcosyl and the virus was again pelletted. The pellet 
was resuspended in 1 ml of LS buffer. 
B. 3 Purification of the Virus 
The concentrated virus was further purified by density 
gradient centrifugation using a sucrose density 
gradient. 
B. 3a Preparation of the Gradient 
A linear sucrose gradient of 5 ml length and from 7.5% 
to 45% w/w Sucrose was used. The sucrose solutions of 
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7.5%, 15%, 25%, 35% and 45% were made W 1W in LS buffer 
(Appendix-2). The gradients were prepared manualy by the 
method of underlayering. Each fraction in a1 ml volume 
was used. The lightest solution (7.5%) was first added 
and then the second lightest concentration solution was 
carefully underlaid. They were kept overnight at 40C for 
equilibration. 
B. 3b Centrifugation 
The gradients were centrifuged in the SW-50 Beckman 
rotor. 0.2 ml of the concentrated virus suspension was 
carefully laid on the gradient. The tubes were balanced 
and centrifuged at 45,000 rpm for 75 minutes in the 
Beckman ultracentrifuge. 
B. 3c Fractionation and Screening of the Gradient 
The whole of the gradient was collected in fractions of 
0.5 ml. The fractions were collected from the top of the 
gradient using a separate pasteur pipette for each 
fraction. The equivalent fractions from all six 
gradients were pooled together and diluted two fold with 
LS buffer. 
The virus containing fraction was identified by 
observing the absorbance of each fraction in a 
U. V. Spectrophotometer at 260 nm. The higher absorbance 
values of the fractions from the top of the gradient and 
the bottom fraction were ignored. 
The fraction suspected to contain the virus was 
also examined at 280 nm. 
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B. 3d Repelletting of the Virus 
The virus containing fraction was diluted with the LS 
buffer and repelletted as described above (section 
B. 2.2b of this chapter) to remove the sucrose. The viral 
pellet was resuspended in a smaller volume of the LS 
buffer supplemented with 0.01% bovine serum albumin 
(BSA). The suspension was aliquoted and stored at -700C. 
B. 3e Estimation of the Quantity and Purity of the Virus 
The quantity of the virus was estimated by using an 
extinction coefficient of 77 for a 1% solution of virus. 
The method described by Rueckert and Pallansch (1981) 
was used to calculate the amount of the virus from the 
value of absorbance at 260 nm (A260). According to this 
method, the concentration of the virus in mg per m-l is 
A260/7.7 . The titre of the virus was also determined 
using the method described in the section A. 3.2d of this 
chapter. 
The degree of purity was assessed according to 
the method described by Rueckert and Pallansch (1981). 
The ratio of absorbance at 260 nm and 280 nm were 
calculated and compared with the ratio obtained with the 
ultrapure preparations. The ratio of absorbance at 280nm 
relative to that at 260 nm ( A260/A280 ) for an 
ultrapure preparation is 1.72 to 1.74 (Rueckert and 
Pallansch, 1981). 
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C Development of a Panel of HRV-2 Monoclonal Antibodies 
The plaque purified, concentrated and physically 
purified HRV-2 was used for immunising mice to raise a 
panel of Mabs. They were used in the search for- 
conserved neutralising epitopes. The steps in making of 
the hybridomas and Mab production are shown in Fig-6. 
C. 1 Immunisation of the mice 
Balb/c mice were used in the experiment. The mice were 
made available by the Experimental Biology Unit of the 
department of Biochemistry. The care and management of 
the mice throughout the experiment was supervised by the 
staff of the unit. 
The mice were immunised as per two schedules of 
immunisation. A total of 4 injections were given in the 
first schedule and after a gap of about 2 months, a 
second schedule of 3 injections was carried out. The 
response was boosted 3 days prior to the excision of the 
spleens. 
Each mouse received approximately 10 pg of the 
virus in 0.3 ml of PBS. For each of the immunisations, 
half of the inoculum was injected intra-peritonially 
(I/P) and the remaining half of the inoculum sub- 
cutaneously (S/C). Adjuvant was not used for the 
immunisation. 
The days of the injections were as follows - at 
day 0,15,21 and 28, then after a gap of two months, 
the second schedule was given on days 88,95,102 and 
the final booster before the fusion was given on day 
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105. The spleen was excised 3 days after the booster. 
C. 2 The Fusion 
Polyethylene glycol (PEG) mediated fusion of the 
spleenic lymphocyte and myeloma cells was performed. The 
Leibovitz L-15 ( L-15medium ) medium was used in the 
procedure of the fusion and also later for culture of 
the hybridomas. L-15 medium was used because it has the 
advantage of not requiring a CO2 incubator or HEPES 
buffer for maintaining the pH. 
C. 2.1 Myeloma Cells 
NS-1 myeloma cells were used as the fusion partner. The 
cells were obtained from the Yellow Fever Virus 
Laboratory of the department. The passage level of the 
cells was not known. 
The cells were grown in Eagle's minimum essential 
medium (EMEM) supplemented with 10% new born calf serum 
and antibiotics. 
They were grown as static cultures in plastic 
tissue culture flasks. The cells were loosely attached 
to the surface. They were taken off the surface by 
shaking and diluted with the growth medium for 
subculture. 
The cells were used in the log phase of the growth 
cycle for fusion. This was achieved by a 1: 2 split of 
the cells every day for a period of 7 days before 
fusion. 
C. 2.2 The Spleenic Lymphocytes 
The mice were killed by cervical dislocation. The spleen 
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was collected aseptically in a petri dish containing the 
L-15 cell culture medium. The connective tissue and 
other adipose tissues were removed by teasing with 
sterile scissors and forceps. 
A sterile wire mesh was placed on a universal. The 
spleenic cells were collected by throughly rubbing the 
spleen on the fine wire mesh. The cells were washed 
into the universal by passing 10 ml of the medium 
without serum through the wire mesh into the universal. 
C. 2.3 The Fusion Procedure 
The myeloma cells were pelleted at low speed (200 g for 
5 minutes). The pellet was resuspended in 5 ml of 
medium. Similarly, the spleenic cells collected were 
also pelleted and the pellet was resuspended in 5 ml of 
medium. 
The myeloma cells and the spleenic cells were 
mixed at the ratio of approximately 10: 1. The mixture 
was then pelleted'at low speed (200g, 5 minutes). The 
supernatant was decanted and the pellet was gently 
resuspended by tapping. To this pellet, 1 ml of 50% 
PEG (PEG- 1500 )in L-15 medium was added. The PEG was 
added very slowly at the rate of 1 ml over a period of 1 
minute. The universal was kept warm by keeping it in the 
hand and it was swirled during the addition of the PEG 
for even mixing. It was then quickly transferred to a 
waterbath at 370 C and kept there for 1 minute. The PEG 
was then immediately diluted by slowly adding 10 ml of 
the medium at a rate of lml per minute. The cells were 
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gently suspended and pelleted (200g ,5 minutes). The 
supernatant was decanted and the pellet was resuspended 
in the hybridoma medium (Appendix-3) to give 
approximately 105 cells/mi. The suspension was aliquoted 
into the wells of a microplate with the help of a 10 ml 
pipette. Each well received a drop from the pipette 
(approximately 70 - 80 µl). 
It is important to handle the newly formed 
hybridoma cells very gently as they are very fragile at 
the begining. 
C. 3 Post Fusion Care 
The plates were examined microscopically each day for 
the death of the unfused myeloma cells and the 
development of hybridoma colonies. 
On the day after the fusion, 100pl of the 
hybridoma medium was added to all the wells. On every 
other alternate day, half of the medium (100 pi) from 
the wells was removed and 100 F1 of fresh hybridoma 
medium was added. This post fusion feeding is important 
because the aminopterin is sensitive to light and in its 
absence myeloma cells might survive and grow. 
In the post fusion feeding, the medium was removed 
with the help of Finn pipette tips. New tips were used 
for each well to prevent contamination of the antibody 
produced by one well with the antibody from another 
well. Another important precaution taken during the 
feeding was that the medium was removed carefully so 
that the cells were not disturbed. 
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C. 4 Screening of Wells for the Antibody 
The sandwich ELISA test developed for the detection of 
the HRV-2 antibody was used (Barclay and Al-Nakib, 
1987). The principle of the test is shown- 
diagramatically in fig-7. 
C. 4.1 Reagents for ELISA 
The reagents used in the ELISA test are described below- 
C. 4. la Capture Antibody 
HRV-2 hyper-immune serum raised in rabbits was used as 
the capture antibody. This titrated serum was provided 
by MRC Common Cold Unit, Harvard Hospital, Salisbury. It 
was aliquoted and stored at -200C. 
C. 4. lb The antigen 
HRV-2 virus in cell culture fluid was used as the 
antigen. The fluid had 108.25 TCID50/50 pl virus titre. 
C. 4. lc The Conjugate 
Horse raddish peroxidase (HRP) conjugated anti-mouse 
serum raised in rabbits was procured from ICN 
Biomedicals Ltd. Bucks, U. K.. It was titrated to find 
the optimum dilution for use in the test. It was 
aliquoted and stored at -200C. 
C. 4. ld The Coating Buffer 
The lOX coating buffer was purchased from Don Whitley 
Scientific Ltd, West Yorkshire, U. K.. One volume of the 
lOX solution was diluted with 9 volumes of deionised 
water to make 1X working solution. It was stored at 40C. 
C. 4. le The Diluent 
PBS supplemented with 1% BSA and 0.05% Tween-20 was 
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used as the diluent in the test. It was prepared fresh 
each time the test was done and stored at 40C during a 
test. 
C. 4.1f The Washing Buffer 
PBS containing 0.05% Tween- 20 was used as the washing 
buffer. It was stored at 40C during the test. 
C. 4. lg The Substrate 
3,3-5,5-tetramethylbenzidine (TMB) was used as 
substrate. Its formulation is described in Appendix- 3. 
It was stored at room temperature. 
C. 4. lh Reagent to Stop the Reaction 
Sulphuric Acid (H2SO4) at 2M strength was used to stop 
the reaction. It was stored at room temperature. 
C. 4.1i ELISA Plate Reader 
Dynatech titretek MR-600 ELISA plate reader along with 
a BBC computer and a programme to print the readings of 
the plate reader was used for reading the optical 
density (OD) of the wells. 
C. 4.2 The Assay 
The procedure of the assay is described below- 
1) The coating antibody was diluted appropriately in 1X 
coating buffer. 
2) 50 µl was aliquoted to each well. The top left well 
(Al) was kept empty to be used as a blank. 
3) The plate was covered and incubated under moist 
conditions at 370C for 2 hours. 
4) It was washed three times by dipping in washing 
buffer and shaking off residual fluids. It was kept 
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immmersed for 5 minutes in the first washing and then 
washed two more times. It was then dried by forceful 
blotting. 
5) An HRV-2 infected cell culture with a titre of 108.25 
TCID50 /5011 was used as the antigen. It was diluted 
five fold in the diluent and 50 N1 was added to each 
well. 
6) The plate was again incubated for 1 hour. 
7) It was again washed three times and dried as 
described above. 
8) 100 i1 of the supernatants from each well of the 
hybridoma plate was then added to the corresponding well 
on the ELISA plate. 
9) The plate was incubated overnight at 4 OC. 
10) The plate was washed three times on the following 
day and dried as described above. 
11) 50 p1 of the conjugate appropriately diluted in the 
diluent was added to each well. 
12) The plate was incubated at 370C for 1 hour. 
13) This time the plate was washed five times to remove 
unattached conjugate and then dried. 
14) 50 p1 of the substrate was added to each well. The 
colour reaction was allowed to proceed at room 
temperature. The decision to stop the reaction was taken 
visually by comparing the colour development in negative 
control and the test wells. 
15) The reaction was stopped by adding 50 11 of 2M 
H2SO4. 
16) The OD of the wells was read in the ELISA plate 
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reader in dual filter mode. The filter for 450nm 
wavelength was the test filter and the filter of 570nm 
wavelength was used as the reference filter. 
Each plate had a blank which received nothing but 
the conjugate and substrate. The negative controls were 
treated in the same marier as for the test well except 
that they received the raw hybridoma medium in place of 
the supernatant. 
C. 5 The Schedule of Screening 
The wells were first screened when the hybridomas were 
seen microscopically. Two screenings were done. 
C. 6 Cloning of the Hybridoma 
The hybridomas were cloned as soon as they were found to 
express a supernatant positive for the antibody by the 
limiting dilution method. 
The cells in the well were resuspended. The 
resulting suspension was then diluted 12 times in two 
fold steps in the hybridoma medium in a microplate. Each 
well was diluted in one row of the microplate. This was 
achieved by adding 100 p1 of a well to the next well 
which had 100 p1 of the hybridoma medium. The cells 
remained in the wells were fed with fresh medium. 
The wells of the higher dilutions were regularly 
'examined for the presence of single growing colonies of 
hybridoma cells. 
In the event that two colonies were seen in the 
highest dilution well, all the cells in that well were 
resuspended and recloned as described above. 
In the event of the repeated absence of a single 
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colony, the cells, from a well showing two or at the 
most three colonies but well separated, were picked up 
with the help of finn tip. 
The plate was kept on the stage of an inverted 
microscope which was held in a laminar air flow hood. 
The finn tip was directed towards a colony and cells 
were picked up while viewing through the microscope. The 
cells from each colony from the well were picked up and 
cultured individually. 
C. 7 Screening of Cloned Hybridomas 
The supernatants from wells containing a single colony 
as well as from the wells containing the cells cultured 
after picking were screened again for the presence of 
the antibody. 
The supernatants were tested in the ELISA test as 
well as for the neutralising activity. The procedure for 
the ELISA test used for screening of the cloned 
hybridomas was similar to that described in the section 
C. 4 of this chapter. 
C. 8 Amplification of the Clones 
The clones which registered positive in the ELISA test 
were amplified. The cells from a well of the microplate 
were inoculated into the well of a6 well plate and then 
once they had grown, they were subcultured into tissue 
culture flasks. 
C. 9 Selection of Clones Positive for Neutralising 
Antibody 
The neutralisation test was performed on the cell 
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at 
culture superrants as soon as they were available in 
sufficient quantity. The objective was to select only 
the clones which were positive for neutralising 
antibody. 
Each superrhänt was tested in duplicate in a 
microplate. The challenge dose of the virus was 104 
TCID50/50 }il. 100 Vl of the super$nt fluids were mixed 
with the virus and the mixtures were incubated for one 
hour at 350C in a 5%CO2 and 95% air gassed incubator. 
The HeLA (OM) cells at a concentration of 5X104 in 10OF1 
were added to all the wells and the plate was incubated 
in the gassed incubator. The test was read on day 2. The 
plates were stained with crystal violet (Appendix 1) and 
the wells were read visually for the presence of 
remaining stained cells in reference to the virus 
control. 
C. 10 Preservation of the Hybridomas 
The hybridoma cells were preserved as described in 
section A. 2. ld of this chapter. 
C. 11 Adaptation of the Hybridomas to HAT free and 10% 
Foetal Calf Serum Containing Medium 
The hybridomas were first grown in HT containing medium 
with 20% serum. 
The serum concentration was slowly reduced and the 
HT was diluted two fold in every subculture. The growth 
of the hybridomas was monitored by counting the cells. 
It was monitored to ensure that the cells were not 
subjected to any kind of selective pressure. The cell 
118 
count was taken as a criterion for the condition of the 
growth. 
C. 12 The Monoclonal Antibody Production 
The Mabs were made in vitro in cell culture as well as, 
in mice in vivo as ascites fluid. 
C. 12.1 In Cell Culture 
The hybridomas adapted to grow in HAT free and 10% 
foetal calf serum containing medium were used for making 
the cell culture Mab. 
The cells were seeded at 5X104 cells/ml in a 150 
cm2 tissue culture flask. The flask was incubated in the 
static mode and observed microscopically each day for 
cell growth. 
The supernatant was collected on the day at which 
the culture was showing high cell growth and also 
microscopic degeneration in some cells. 
The cells were resuspended and pelleted at low 
speed (200g for 5 minutes). The supernatant was 
collected, aliquoted and stored frozen at -200C. 
C. 12.2 In Mice 
The hybridomas were grown as a peritoneal tumour in mice 
and ascites fluid was collected as the source of the 
antibody. 
Balb/c mice were used for this purpose. The 
hybridomas were first cultured in vitro. The cells were 
pelleted and resuspended in PBS at a concentration of 
3X107 cells/ml. 
The balb/c mice were first primed with Pristane 
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(Tetramethyl-pentadecane) by injecting 0.5 ml i/p. The 
cells were then injected i/p about a week after the 
priming. Each mouse received 0.3 ml of the inoculum 
containing 107 cells. Each hybridoma was injected into 2 
or 3 mice. 
The mice were observed for peritoneal tumour 
formation. The ascites fluid was tapped from the tumour 
by aspiration via a sterile needle. The collections were 
made as many times as possible. The fluid was clarified 
by low speed centrifugation (200 g for 5 minutes) and 
stored frozen at - 200C. 
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D Studies With the Monoclonal Antibodies in Ascites 
Fluid 
D. 1 Studies on the Monoclonal Antibodies Using the 
ELISA Method 
The Mabs were tested in an ELISA test for their viral 
specificity and also for potency. 
The ELISA plate was divided in half. The upper 
half received the virus antigen in cell culture fluid. 
The lower half received mock cell antigen in cell 
culture fluid. The mock antigen was prepared by treating 
the uninfected cells in the same manner as the infected 
cells were treated. The first well of the first column 
of the plate was kept as a blank and the remaining wells 
in the first column were kept as a coating antibody 
control. They received only PBS in place of antigen and 
ascites fluid. The wells in the upper half of the second 
column were kept as the virus antigen control and in 
lower half as cell antigen control. These wells received 
either virus cell culture or mock cell culture fluid and 
PBS was added in place of the ascites fluid (fig-8). 
The test ascites fluids were applied in duplicate 
with viral antigen as well as with cellular antigen. The 
fluids were diluted in 0.5 log steps. 
The test was effected as per the method described 
in section C. 4 of this chapter. 
D. 2 Studies with the Monoclonal Antibodies in the Search 
for Conserved Cross Neutralising Epitopes 
The Mabs were used in the search for conserved 
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neutralising epitopes on HRV and also on a few other 
members of the picornaviridae family. 
The indirect immunofluorescence (IIF) test was 
used to test for the physical presence of the cross 
reacting and therefore conserved epitopes. The 
biological activity of the epitope was studied in vitro 
in the virus neutralisation test. 
D. 2.1 Studies on Cross Reactivity of the Monoclonal 
Antibodies in the Indirect Immunofluorescence test (IIF 
Test) 
The IIF test was performed on Mabs to detect the intra- 
cellular virus in cells fixed on IIF spot slides. They 
had 12 micro wells$ 6 wells in each row and two rows on 
each spot slide (Fig-9). The wells had about 25 p1 
capacity and the surface of the wells was specially 
coated to allow the cells to stick. 
The virus infected cells were fixed on the spots 
of the slide. The fixation of the cells with acetone 
caused the cell membrane to become permeable to an 
antibody molecule. Thus Mab could enter the cell and 
bind to the virus. The bound Mab was held so bound 
during the subsequent washing steps and it was detected 
by the anti-mouse conjugated antibody (Fig-9). 
D. 2.1A Preparation of the Spot Slide 
a) The Spot Slide 
These were made available by the Yellow fever Virus 
Laboratory of the department. The slide had 6 spots in a 
row and there were two rows. 
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b) Virus Infected Cells 
Suitable cells (section A. 1 of this chapter) for each 
particular virus were grown in tissue culture flasks. 
The cells were infected with a dilution of the stock 
virus which was sufficient to give extensive CPE. 
However, the cells were collected when they were rounded 
due to the infection and were not yet lysed by the 
virus. The dilution of the virus stock which caused this 
CPE was determined empirically. The cells were taken off 
the surface (section A. 2. lb of this chapter). They were 
then pelleted at 200g for 5 minutes, resuspended in PBS, 
counted and diluted to give 4X105 cells/ml 
c) Preparation of Spots 
25 ul of the cell suspension was aliquoted on to each 
spot. The slides were air dried. The cells in the spots 
on a slide were fixed to the spots by acetone. The air 
dried slides were washed in PBS, dipped into a tray 
containing chilled acetone and left for 15 minutes in a 
second tray of chilled acetone. They were then again air 
dried and stored at -200C. 
D. 2.1B The Test 
The ascites fluids were tested at two PBS dilutions of 
1/50 and 1/100. 
1) The spot slides were thawed and 25 ul of a dilution 
of an ascites fluid was aliquoted onto a spot. Each 
slide had an ascites fluid control as well as a 
conjugate control. The ascites fluid control spots 
received an unrelated Mab (yellow fever virus Mab) 
containing ascites fluid. Similar dilutions of this 
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control ascites fluid were used. The conjugate control 
received only PBS in place of ascites fluid. In cross 
reactivity studies , The HRV-2 spot slides were made 
each time for a positive control reference. 
2) The slides were incubated for 30 minutes at 370C 
under humid conditions. 
3) They were then washed in PBS. The slides were kept in 
a slide carrier and immersed in PBS. The PBS was then 
stirred with the help of magnet and a stirrer. Two 
washings of 30 minutes were effected. 
4) The slides were air dried in a laminar air flow 
cabinet. 
5) 25 pl of the appropriately diluted conjugate was 
aliquoted to each spot. The working dilution of the 
conjugate was determined by titration. PBS was used as 
the diluent. 
6) The slides were again incubated at 370C for 30 
minutes under moist conditions. 
7) They were again washed as described above. This time 
the washing was done three times. They were then dipped 
once in deionised water to wash off the PBS. 
8) The slides were dried and mounted with a coverslip. 
The commercially prepared mounting medium procured from 
Sigma was used in the mounting. Care was taken to ensure 
that the whole of the spot was covered by the mounting 
medium but without overflowing. 
9) The spots were examined under a U. V. fluorescent 
microscope. The cells in a spot were first brought to 
focus in visible light and then the U. V. light was 
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allowed to fall on the spots. In the case of a positive 
reaction, the cells showed a green coloured fluorescence 
(Fig-9). 
D. 2.2 Neutralisation and Cross Neutralisation Studies 
of the Monoclonal Antibodies 
The Mabs were tested for neutralisation of the plaque 
purified and the parent virus of the HRV-2. They were 
tested for cross neutralisation of other HRV serotypes 
and some selected picornaviruses. 
The constant virus varying antibody neutralisation 
test was done in case of HRVs as a micro-neutralisation 
test in a microplate. The varying virus constant 
antibody test was carried out in the case of other 
picornaviruses (poliovirus, coxsackie virus of B types, 
Coxsackie virus of A type and EMC). It was done as 
plaque reduction neutralisation test (PRNT) in 6 well 
plates. 
D. 2.2A Micro-Neutralisation Test (Monoclonal Anti- 
bodies) 
The test was carried out as described in section A. 3.2e 
of this chapter. However, there were some modifications. 
A higher challenge dose of 4 log TCID50 was used. The 
dilution of the stock to give this challenge dose was 
precisely determined. The seeding density and age of the 
cells were kept constant. 
a) Determination of the Dilution of the Virus Stock for 
a Challenge Dose 
The crucial determ'_nation of the dilution of the stock 
for use as challenge in the test was determined in a two 
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step virus titration system. 
First, the ten fold dilutions of the virus stock 
were made and tested as described in section A. 3.2d of 
this chapter. However, the test was allowed to proceed 
for 48 hours and the highest dilution showing complete 
cell lysis was selected. 
This dilution was further sub-diluted in ten steps 
and again the test on the sub-dilutions was performed. 
The highest sub-dilution showing complete cell lysis was 
selected. It was also essential for other sub-dilutions 
further up in the series to show correspondingly 
increased survival of the cells. In case such a pattern 
was'not observed, the test was repeated and this time a 
higher concentration causing complete cell lysis in 24 
hours was selected and the precise sub-dilution of this 
dilution was then determined as explained above. All 
HRVs tested showed the desired pattern of cell lysis in 
either a 24 hour or 48 hour incubation period depending 
upon the particular virus strain used. 
b) The Test 
The test was performed as described in section A. 3.2e of 
this chapter. The starting dilution of the ascites fluid 
was kept as low as possible. In the case of few ascites 
fluids, the starting dilution was 1/2. The cells were 
added at a level of 5X104cells / well. However in the 
case of a few slow growing HRVs, the cell concentration 
used was 3.5X104cells/well. Each Mab was tested in 
duplicate and each plate had two wells as a virus 
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*on the basis of four independent observations in 
duplicate on the neutralisation of HRV-2 by one Mab (D- 
24), the reproducibility of the test was within one 
dilution step. 
control and two wells as a cell control. 
c) Interpretation of the Test 
The test was interpreted by taking an absorbance reading 
after the crystal violet staining of the survived cell 
sheet in an ELISA plate reader. 
The plates were stained with crystal violet 
(Appendix-i). The readings were effected in dual filter 
mode. The test filter was 570 nm and the reference 
filter was 630 nm. 
The values in the cell control, virus control and 
test wells were taken as reference values for the 
estimation of the 50% end point. Also, the challenge 
dose was titrated. The absorbance value in the wells 
showing two fold dilutions of the challenge dose was 
used for determining the 50% lysis value., * 
D. 2.2B The Plaque Reduction Neutralisation Test(PRNT ) 
The PRNT was performed in the case of poliovirus, 
coxsackie virus B types, coxsackie virus A-18 and EMC. 
Vero cells were used for plaquing of poliovirus 
and coxsackie virus B types. HeLa (OM) cells were used 
for EMC and coxsackie virus type A-18. The test was 
performed in 6 well tissue culture dishes. 
The plates were seeded with the cells at a density 
of 5X105 cells per well in 5ml of the growth medium. 
They were ready for use the next day. 
The ascites fluids were diluted 1/10 in PBS. The 
virus dilutions in the ten fold dilution series were 
made in PBS. The viral dilutions were incubated with the 
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ascites fluid dilution for 45 minutes at 370C. In the 
virus control, the virus dilutions were mixed with an 
equal volume of PBS and similarly incubated. 
The medium from the plates was decanted and the 
cell sheet was washed once with warm PBS. The virus 
ascites fluid mixture in 100 p1 volume was added to a 
well and the plate was kept at room temperature for 30 
minutes to allow the adsorption of non-neutralised 
virus. One well in each plate received only PBS and was 
kept as a cell control. The virus was also titrated 
simultanetously in a plaque assay. 
5 ml of an agar overlay (Appendix- 2) was then 
added and the plates were incubated at 370C in a 5% C02 
95% air gassed incubator . 
The plaques were stained by neutral red (Appendix- 
2) . The plaques were counted and a serum neutralisation 
Index ( SNI ) was calculated . 
titre in virus control 
SNI = Log10 i --------------------- ) 
titre in test 
D. 2.3 Studies on the Comparison of the Neutralisation 
in the Microplate System and the PRNT in 6 Well Plates 
The neutralisation titres of'the ascites fluid obtained 
in the microtitration system and the SNI calculated in 
PRNT system were compared. 
One ascites fluid which was positive in both 
systems was tested for reduction of HRV-2 plaques. 
The PRNT was performed as explained above . Unlike the 
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method explained in the section B. la of this chapter, on 
plaquing of HRV-2 second layer of the overlay without 
agar was not added and the plaques were stained with 
neutral red. 
Similarly coxsackie virus B3 was tested in a 
micro-neutralisation test. The test was performed as 
described for HRVs ( section D. 2.2A of this chapter). A 
Mab showing cross neutralisation of HRVs and plaque 
reduction of the coxsackie virus B3 was used in the 
test. 
E. Studies on Cross Neutralisation with Cell Culture 
Monoclonal Antibodies 
Neutralisation with HRV-2 and a cross neutralisation 
test with only HRV-14 was also performed with the Mabs 
made in cell culture. 
The test was performed as described for the 
ascites fluid Mabs. However, in case of cell culture 
Mabs, 100 p1 antibody was added while it was 50 Nl for 
the ascites fluid test and the cell culture supernatant 
was used as such without any dilution. 
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Results 
A Studies on Heterologous Neutralisation of HRVs with 
Polyclonal Hyperimmune Antisera 
A. 1 Introduction 
Initially 6 HRV serotypes (HRV-lA, 1B, 2,9,14 and 32) were 
obtained along with their antisera. They were studied in 
cross neutralisation tests to confirm that they were 6 
different HRV serotypes. 
A. 2 Results 
All antisera were diluted up to 1/1280 dilution and 
challenged with an HRV serotype. The challenge dose was 
300 TCID50. The data are presented in Table-2. 
HRV-2,9,14 and 32 were neutralised by up to 1/1280 
dilution of the homologous antisera. Antisera to HRV-2 
and 14 did not cross neutralise any of the other 5 
viruses. However, HRV-9 was neutralised by up to 1/80 
dilution of the antiserum to HRV-32, but the HRV-32 
virus was not neutralised even by a 1/10 dilution of 
antiserum to HRV-9. 
The HRV-lA and 1B were not neutralised by 1/10 
dilutions of their antisera. 
A. 3 Discussion 
It was clearly evident that HRV-2,14 and 32 represented 
those serotypes which showed complete absence of shared 
neutralising antigens when tested with polyclonal 
hyperimmune antisera. Antigenic relationships have been 
demonstrated between HRV-9 and 32. Schieble, et al., 
(1974) reported a one way cross neutralisation reaction 
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Table-2: Cross Neutralisation of 6 HRVs with Polyclonal 
Antisera 
- 
Neutralisation of HRV-lA 
------------ 
Antiserum 
------ -------------------- 
Dilutions of the 
-------------- 
antisera 
against 
-------- 
1/20 
----- 
1/40 
------ 
1/80 1/160 1/320 
-------------------- 
1/640 
------- 
1/1280 
------- 
HRV-lA + + +++ + + 
HRV-1B + + +++ + + 
HRV-2 + + +++ + + 
HRV-9 + + +++ + + 
HRV-14 + + +++ + + 
HRV-32 
-------- 
+ 
----- 
+ 
------ 
+++ 
-------------------- 
+ 
------- 
+ 
------- 
---- 
Neutralisation of 
-------- 
HRV-1B 
------- -------- --------- 
Antiserum 
------ ------------ 
Dilutions of the a ntisera 
against 
------- 
1/20 
------ 
1/40 
------ 
1/80 1/160 1/320 
-------------------- 
1/640 
------- 
1/1280 
-------- 
HRV-lA + + +++ + + 
HRV-1B + + +++ + + 
HRV-2 + + +++ + + 
HRV-9 + + +++ + + 
HRV-14 + + +++ + + 
HRV-32 
------- 
+ 
------ 
+ 
------ 
+++ 
-------------------- 
+ 
------- 
+ 
--------- 
------ 
Neutralisation of 
----- 
HRV-2 
------- --------- ------- 
Antiserum 
------ --------------- 
Dilutions of the ant isera 
against 
------- 
1/20 
------ 
1/40 
------ 
1/80 1/160 1/320 
-------------------- 
1/640 
------- 
1/1280 
--------- 
HRV-1A + + +++ + + 
HRV-1B + + +++ + + 
HRV-2 - - --- - - 
HRV-9 + + +++ + + 
HRV-14 + + +++ + + 
HRV-32 + + +++ + + 
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Neutralisation of HRV-9 
------------- 
Antiserum 
------ ------------- 
Dilutions of 
-------------- 
the antisera 
--------- 
against 
-------- 
1/20 
----- 
1/40 
------ 
1/80 1/160 
------------- 
1/320 
------- 
1/640 
------- 
1/1280 
--------- 
HRV-lA + + ++ + + + 
HRV-1B + + ++ + + + 
HRV-2 + + ++ + + + 
HRV-9 - - -- - - - 
HRV-14 + + ++ + + + 
HRV-32 
-------- 
- 
----- 
- 
----- 
-+ 
-------------- 
+ 
------- 
+ 
------- 
+ 
--------- 
-- 
Neutralisation of 
- 
HRV-14 
------ --------- ----------- 
Antiserum 
----- ------------- 
Dilutions of 
------- - 
the antisera 
against 
------- 
1/20 
------ 
1/40 
----- 
1/80 1/160 
------------- 
1/320 
-------- 
1/640 
------- 
1/1280 
--------- 
HRV-lA + + ++ + + + 
HRV-1B + + ++ + + + 
HRV-2 + + ++ + + + 
HRV-9 + + ++ + + + 
HRV-14 - - -- - - - 
HRV-32 
------- 
+ 
------ 
+ 
----- 
++ 
------------- 
+ 
------- 
+ 
-------- 
+ 
--------- 
----- 
Neutralisation of 
----- 
HRV-32 
-------- --------- -------- 
Antiserum 
----- ------------- 
Dilutions of 
-- 
the antisera 
against 
------- 
1/20 
------ 
1/40 
----- 
1/80 1/160 
------------- 
1/320 
------- 
1/640 
-------- 
1/1280 
--------- 
HRV-1A + + ++ + + + 
HRV-1B + + ++ + + + 
HRV-2 + + ++ + + + 
HRV-9 + + ++ + + + 
HRV-32 
------- 
- 
------ 
- 
----- 
-- 
------------- 
- 
------- 
- 
-------- 
- 
-------------- 
+= CPE, No neutralisation, 
-= No CPE, neutralisation 
134 
between HRV-9 and 32. 
The absence of neutralisation of HRV-lA and 1B by 
their homologous antiserum can not be explained simply. 
Upon enquiry with the supplier, the MRC Common Cold 
Unit, Salisbury, it was learnt that the antisera had 
been stored for a long time. Another batch of recently 
prepared antisera was not available. However, the virus 
preparations were included in the study. 
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B Studies on Preparation of the Antigen for Use in 
Immunisation 
B. 1 Introduction 
Conserved immunogenic antigens have been identified on 
many microorganisms with the use of Mabs (section F. 3 in 
the Introduction Chapter). It has also been observed in 
those studies that the conserved antigens invoke a 
weaker immune response when such antigens are present on 
the whole organism together with the dominant antigens 
(Fischetti, 1977 and Rothbard, et al., 1984). 
In the light of these observations, a two stage 
approach was adopted in the search for conserved 
immunogenic epitope(s) on HRVs. The first aspect of the 
approach was to immunise the mice with a concentrated 
and relatively pure virus preparation. It was thought 
that the concentrated antigen would give an opportunity 
for the weaker antigens to invoke their immune response 
and the pure antigen would minimise the non-specific 
immune responses. 
To achieve the first objective, the virus was 
plaque purified and then it was grown in bulk and 
concentrated (see section B. 2 in the Materials and 
Methods chapter). The concentrated virus was purified on 
a sucrose density gradient and this preparation was 
then used as the immunogen for mice. The second stage of 
the approach was to use the spleen of these mice for 
obtaining the B-cells for making the hybridomas. 
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B. 2 Cloning of the Virus 
B. 2a Introduction 
The genome of the RNA viruses diverges rapidly. The 
rapidity has been attributed, at least in part, to the 
lack of "proof-reading" activity in RNA replicase. 
Because of the high rate of mutation, any population of 
RNA viruses, even a population from a single clone, 
consists of individuals that differ from one another 
(Strauss and Strauss, 1988). 
The HRV-2 was received as an uncloned virus 
preparation. It was also indicated that it had been 
passaged extensively in cell culture. Therefore, it was 
considered necessary that the virus should be first 
cloned by plaque purification (section B. 1 in the 
Materials and Methods chapter). 
B. 2b Results 
The virus produced very small plaques which could be 
seen only under a microscope (100X) as well as larger 
plaques which were visible to the naked eye. Large as 
well as small plaques were seen on day 2. 
Initially, two small plaques were picked. Smaller 
plaques were selected to avoid picking a mixed plaque of 
larger size. The material from these two plaques was 
used for replaquing. This time 6 plaques were picked; 
three plaques from each of the replaquings were picked. 
Twice plaque purified virus in one of the latter plaques 
was amplified for making a stock of the cloned virus. 
The stock was tested in a micro-neutralisation test 
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Table-3: Serological identity of the plaque picked 
virus with parent HRV-2 virus (300 TCID50 virus dose) 
Antiserum Replicates 
Dilutions 1234 
------------------------------------------------------- 
1/20 ---- 
1/40 ---- 
1/80 ---- 
1/160 ---- 
1/320 ---- 
1/640 ---- 
1/1280 ---- 
1/2560 -+++ 
1/5120 ++++ 
Virus control ++++ 
Cell control ---- 
-------------------------------------------------------- 
+= CPE, No neutralisation 
= No CPE, neutralisation 
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for serological identity with HRV-2 (section B. le in the 
Materials and Methods chapter). 300 TCID50 of the cloned 
virus was neutralised by 1/1280 dilution of the standard 
polyclonal antiserum. The titre of the standard 
antiserum received along with the uncloned virus was 
1/1600 against 300 TCID50 challenge dose (Table-3). 
B. 2c Discussion 
The HRV-2 can be cloned by plaque picking. However, the 
virus does not produce very clear plaques unless the 
agar overlay is removed and the cells are stained with 
crystal violet. 
The virus produced both small as well as large 
sized plaques. This size variation is phenotypic rather 
than genotypic as in the replaquing the size variation 
was observed again. Stott and Killington (1972a) 
reported that with HRV-2, plaque size did not show a 
bimodal distribution. The virus picked from large 
plaques produced the same variety of plaque sizes as the 
original inoculum. 
The virus was plaque purified twice and only the 
smaller plaques were picked. Six plaques from the 
replaquing were picked to increase the possibility that 
at least one of the pickings was from the originally 
isolated plaque. 
The plaque purified virus showed a serological 
identity with the parent HRV-2 virus. The neutralisation 
titre with the plaque purified virus was similar to the 
titre of the parent virus. A slight difference in the 
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titres may be due to differences in these dilutions. 
B. 3 Propagation of the Virus 
B. 3a Introduction 
The plaque purified virus was grown in bulk and then it 
was concentrated and purified by sucrose density 
gradient centrifugation. 
Both a monolayer as well as suspension cell 
culture systems are available for the propagation of 
the HRVs. The suspension cell culture system has an 
advantage over the monolayer cell culture system in that 
it is easily scaled up. 
In this study, the virus was grown in bulk in 
suspension cell culture. 
B. 3b Results 
Two 41 suspension cultures were set up at 5X105 
cells/ml. The procedure for infecting them with the 
virus is described in section A. 3.2b in the Materials 
and Methods chapter). 
The trypan blue dye exclusion test showed 80% or 
more dead cells in 48 hours. The virus was harvested as 
described in section A. 3.2c in the Materials and Methods 
chapter. 
The virus in the suspension was titrated in a 
microtitration system. The virus titre was 107.3 
TCID50/ml. 
B. 3c Discussion 
The suspension culture was found to be a more convenient 
method especially for obtaining large amounts of the 
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virus. However, the HeLa (OS) showed clumping of the 
cells when grown in suspension culture. Rueckert and 
Pallansch (1981) reported that the clumping of the cells 
resulted in a poor yield of the virus. The clumping of 
the HeLA (OS) cells was minimised to almost negligible 
by use of a suspension culture medium. This medium is 
essentially the EMEM (Flow Lab Catalogue No. 14-170) 
however it lacks CaC12. Rueckert and Pallansch (1981) 
reported that lower calcium concentrations reduced 
clumping of the HeLa (OS) cells. 
Monitoring the virus growth in suspension culture 
was found to be more difficult than observing the extent 
of CPE in monolayer culture. Viability testing using 
trypan blue dye is a quick method to monitor the virus 
growth as the virus causes the lysis of the cells. 
Rueckert and Pallansch (1981) reported that the course 
of the infection can be monitored by testing the 
conversion of the cells from dye exclusion to dye 
uptake. However, they also found that the results varied 
widely with different virus host cell systems. Thus 
failure to observe cell killing by this assay was not 
necessarily evidence of an unsucessful infection. 
Other methods which are more sensitive and 
specific for the virus should be used for monitoring the 
virus growth in suspension culture. One such method is 
the ELISA test which has been described by Dearden and 
Al-Nakib (1987). This test is used for the detection of 
HRV antigen. An alternative physical method is to 
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quantify the amount of the virus by U. V. photometry. 
The test has been described for monitoring the growth of 
FMD (Does, et al., 1982) and poliovirus (Doel, et al., 
1984) in suspension culture. The method involves the 
centrifugation of a crude virus preparation in a sucrose 
density gradient centrifugation. Subsequently the whole 
of the gradient is fractionated and monitored through a 
continuous flow spectrophotometer. The absorbance values 
are recorded on a chart recorder so that the area of the 
virus peak can be determined. The concentration of virus 
particles in the original sample is proportional to the 
area of the absorbance peak above the absorbance 
background due to cell debris and media component (Doel, 
et al., 1984). 
The physical method of U. V. photometric estimation 
of the virus particle appears to be a superior method to 
the ELISA test. The photometric method is more sensitive 
and rapid. In the case of FMD, it has been shown that 
the amount of intact live virus (146S) and inactivated 
virus (140S) in a sample can be differentiated. The 
ELISA test can not provide this differentiation. 
None of these methodS could be used in this study 
because the ELISA test became available only in 
November, 1987 and the virus preparation work was 
effected in August, 1987. The photometric method could 
not be standardised in our laboratory due to a technical 
problem. It was observed that the flow of the higher 
sucrose concentration fluids through the "U"- 
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configuration flow path spectro-photometer cell was such 
that uneven flows were induced and such mixing occured 
that the discharge from the cell was rendered uncertain. 
This resulted in false peaks possibly due to diffraction. 
rather than absorbance of the U. V. light. The problem 
was later solved by using a flow cell with straight- 
through flow path. Both the tests are now available in 
this laboratory. 
The virus grown in suspension cell culture showed 
a lower titre in comparison to the titres normally 
achieved in monolayer cultures with HeLa (OM) cells. 
However, lower infectivity does not necessarily indicate 
less antigen. It has been reported that the time of the 
virus harvest is crucial in case of FMD and HRV. A 
virion associated ribonuclease activity degrades the 
genomic RNA and thus reduces the viral infectivity if 
the virus harvest is delayed from 8 to 12 hours (Minor, 
1985). However, the amount of the antigen keeps 
increasing with time. Whiteside and Spier (1981) 
observed that in case of FMD the infectivity decreased 
but the antigenicity kept an upward trend. 
B. 4 Concentration Of the Virus 
Methods for the concentration of HRV by pelleting at 
high speed and precipitation by the use of chemicals are 
available. Pelleting is only suitable for small volumes 
of virus suspension and precipitation by chemicals can 
precipitate other unwanted protein (Minor, 1985). In 
addition, the chemical itself may have an effect on the 
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virus. Physical method are clearly superior to the 
chemical methods. 
In the study below, the virus was concentrated in 
two steps. First the virus was concentrated by 
ultrafiltration and then it was further concentrated by 
pelleting. The ultrafiltration was effected to reduce 
the volume of the virus containing cell culture fluid. 
B. 4.1 Concentration by Ultrafiltration 
B. 4. la Introduction 
This is a physical method and large volume can be dealt 
with. 
The principle of the ultrafiltration is that the 
clarified virus suspension is pumped across filters of 
pore size smaller than the virus. Thus the water and 
other smaller molecule pass through the filter and the 
retained virus and other larger molecules are circulated 
back in the reservoir/retentate bottle. The retentate is 
recirculated till the desired concentration is achieved. 
B. 4. lb Results 
A 500 ml aliquot of the virus suspension first clarified 
at 1400g for 10 minutes and then at 10,000 rpm for 30 
minutes was used in the ultrafiltration process. This 
treatment enabled the volume to be reduced to 45m1. This 
concentrated fluid was recirculated for 30 minutes with 
the filtrate outlet closed in order to wash the retained 
virus off the filter membrane. 
A virus titration was carried out on the 
concentrated suspension, the titre was 108'3TCID50/ml. 
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The efficiency of the system was determined by 
calculating the percentage recovery of the virus. It was 
99.8% (Table-4). 
B. 4. lc Discussion 
The ultrafiltration method was found to be a convenient 
and efficient physical method for the concentration of 
larger volumes of virus suspension, although it was 
found to be essential to first clarify the virus 
suspension at relatively higher speed (10,000 rpm) as 
larger particles in the suspension may clog the filter. 
B. 4.2 Concentration by Pelletin 
B. 4.2a Introduction 
The second concentration was done to further reduce the 
volume of the virus suspension. This was effected 
because smaller volumes of more concentrated virus can 
be loaded on the sucrose density gradient for the 
purification. Further, picornavirus preparations used 
for sucrose density gradient purification must be 
treated with a detergent which releases the virus 
particles from host cell membranes, Thus improving the 
resolution of the virus in the subsequent 
centrifugation. In this study, sarcocyl was used as the 
detergent. It was observed that it precipitated the 
serum and other proteins in the cell culture medium. 
Therefore, it was essential to pellet the virus at high 
speed and resuspend the pellet in PBS. The virus in PBS 
was then treated with the detergent (section B. 2.2b in 
the Materials and methods chapter). 
146 
B. 4.2b Results 
45 ml of the virus suspension from the ultrafiltration 
procedure was loaded into the centrifuge tubes used for 
the SW 50 rotor of the Beckman ultracentrifuge. The, 
pellets from all the tubes were pooled, diluted to 4 ml 
and treated with the detergent (0.4 ml of 10% solution 
of the sarcocyl was added to give 1% of the final 
concentration of the sarcocyl). The resuspended material 
was centrifuged again and the pellet was further 
resuspended in lml of LS buffer. 
B. 5 Sucrose Density Gradient Purification of the Virus 
B. 5a Introduction 
Picornaviruses need to be purified because of their 
association with host cell components. This is achieved 
by sucrose density gradient or caesium chloride gradient 
centrifugation. The sucrose density gradient method is 
preferred to the caesium chloride method because the 
HRVs can absorb caesium ions, however, some impurities 
are likely to remain with the virus even after sucrose 
density gradient (Minor, 1985). 
B. 5b Results 
The gradient was fractionated into 12 fractions after 
, 
the centrifugation. Each fraction contained 0.5m1 of the 
gradient. It was diluted with LS buffer to lml and 
absorbance was recorded at 260 nm for each of the 
fractions. The pattern of the absorbance is shown in 
fig-10. Higher absorbance values in the fraction 
collected from upper part of the gradient were not 
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considered to be due to presence of the virus. The peak 
in absorbance recorded in the fraction no. 10 was 
considered to be due to the virus. 
B. 5c Discussion 
In case of the picornavirus, the infectious virus peak 
has been reported to be about two third down the 
gradient (Minor , 1985). The fraction no. 10 which was 
considered to contain the intact and the infectious 
virus was about two third down the experimental 
gradient. 
B. 6 Estimation of the Amount and Purity of the Virus 
B. 6a Introduction 
The amount of the purified virus was estimated so that 
the virus concentration in each injection of the 
inoculation procedure could be determined. 
B. 6b Results 
0.5m1 of the 10th fraction was diluted to iml and it 
gave an O. D. of 0.343 at 260 nm. According to the method 
described in the section B. 3e of the Materials and 
Methods chapter- 
Amount of the virus = 0.343/7.7 X1000= 44.5pg/0.5m1. 
The total volume of the suspension was 2.5ml, 
therefore, total amount of virus recovered was 222.5pg 
and the virus concentration was 89ig/ml in the 
suspension. 0.1 ml of this preparation was used in each 
injection. The titre of the virus was 105'8TCID50/100 p1 
The optical density (OD) of the fraction no. 10 was 
also recorded at 280 nm. It was 0.234. The ratio at 
149 
280nm to that at 260 nm (A260/A280nm) was 1.46. 
B. 6c Discussion 
The virus was prepared in a concentrated and purified 
form. However, the virus recovery appeared to be low. 
Rueckert and Pallansch (1981) estimated that 106 cells 
produced lpg of the virus. Therefore, the preparation 
used to produce the concentrated and purified virus 
should have contained 2 mg of the virus. Though the 
exact reason for low (11.5%) recovery could not be 
ascertained, it appeared that the virus was not lost 
during the concentration and purification steps. The 10 
fold increase in the virus titre was achieved with about 
10 fold concentration of the virus suspension after the 
concentration by ultrafiltration. Similarly, it was 
observed that the titre of a crude virus preparation 
before and after the density gradient purification was 
the same. In the study carried out on the specificity 
and sensitivity of the ELISA test (section C. 3 of this 
chapter), the virus titre in the cell culture fluid 
before ultracentifugation on a sucrose density gradient 
was 107'47 TCID50/ml and the virus titre in ELISA peaks 
of two gradients (see fig-il) was 10' 
47 
and 10 '3. It 
was therefore speculated that the virus was not produced 
optimally during the virus growth stage in the 
suspension cell culture. However, this could be improved 
by proper monotoring of the virus growth (section B. 3c 
of this chapter). 
A lower ratio of A260/A280 (1.46) for the 
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preparation in comparison to the ratio reported for an 
ultrapure preparation (1.72-1.74) was due to higher 
value at A280. A slightly higher O. D. value at 280nm 
(protein) may be due to inherent deficiency of the 
method. It has been reported that though the sucrose 
density gradient can purify the virus, some impurities 
are likely to remain in the preparation (Minor, 1985). 
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C Development of a Panel of HRV-2 Monoclonal Antibodies 
A panel of HRV-2 neutralising Mabs was prepared for use 
in the search for conserved epitope(s) on HRVs. The 
plaque purified, concentrated and sucrose density 
gradient purified HRV-2 was used for the immunisation of 
mice. The stimulated B -lymphocytes of these mice were 
then fused with the myeloma cells to produce continious 
cell lines of HRV-2 Mab secreting cell lines. 
C. 1 Immunisation 
C. la Introduction 
Immunisation of the spleen donor mice serves two main 
purposes. The first purpose is to expand the desired 
clones of the B -lymphocytes and thus to increase the 
chances of obtaining a relevant hybrid. The second 
important function of the immunisation is to cause the B- 
cells to divide and differentiate into cells which will 
fuse and form useful hybrids. It has been generally 
observed that for successful fusion, the immune response 
should be boosted 3 or 4 days prior to the excision of 
the spleen (Goding , 1980). This 
further highlights the 
importance of the immunisation and supports the concept 
that recently activated B-cells fuse preferentially. 
C. lb Results 
Two schedules of immunisation were used. The details of 
the schedules are described in the section C. 1 in the 
Materials and Methods chapter. The immunised mice were 
bled and the sera pooled before diluting to 1/20 and 
1/40 with PBS and testing by the IIF procedure (section 
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D. 2.1B in the Materials and Methods chapter). A weak 
positive reaction (2+) was observed in a 1+ ( 25%) to 4+ 
(100%) scale and so it was decided to carry out another 
schedule of immunisation. 
C. lc Discussion 
An explanation for the weak response could not be found. 
Though the mouse does not support the HRV infection, 
however Sherry and Rueckert (1985) successfuly prepared 
mouse Mabs and they used a similar amount of the virus 
for the immunisation. 
C. 2 The Fusion 
C. 2a Introduction 
PEG mediated fusion of the B-cell and the myeloma cell 
was performed. It is the more commonly used method as it 
can be effected with higher reliability. 
C. 2b Results 
One of the three mice was sacrificed and the spleen 
excised. The spleen showed spleenomegaly. The procedures 
for separation of the B-cells and their fusion with the 
myeloma cells are described in the section C. 2 in the 
Materials and Methods chapter. 
Approximately 108 B-cells were mixed with 107 
myeloma cells. The cell pellet after the fusion was 
resuspended in 25 ml of the hydridoma medium and then 
"plated" in 4 microplates (96 wells microplate). 
Supernatant fluid from 234 wells (60%) out of 384 
wells of the 4 microplates were found to be positive for 
the antibody ( see Table-5). 
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C. 2c Discussion 
The PEG method was found to be a simple and efficient 
method. It generated positive hybridoma clones much 
above in the reported range. Though the fusion 
frequencies vary from cell line to cell line and also 
from experiment to experiment, Campbell (1984) reported 
that the hybridisation frequencies were in the range of 
1-100 clones/107 lymphocytes. Therefore with 108 
lymphocytes used in the study, the expected number of 
the clones were from 10 to 1000. 
C. 3 Standardisation of the Screening Test 
C. 3a Introduction 
Screening of the wells for the presence of the desired 
antibody is the most important step. The screening test 
should be quick, easy to perform, specific and be highly 
sensitive so as to be able to detect very small amounts 
of the antibody in culture supernatant fluids. ELISA is 
a most commonly used assay. In this study, an ELISA test 
developed at MRC Common Cold Unit, Salisbury was used 
and this test was also used as a screening test in the 
monoclonal antibody work done at the unit (Barclay, 
personal communication). It was however first tested in 
our laboratory for its specificity and sensitivity. In 
another study, the crude viral preparations 
(unconcentrated virus in cell culture fluid) were 
loaded on a sucrose density gradient and 
ultracentrifuged. The gradient was fractionated and the 
ELISA test was used to detect the virus containing 
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Fig-11: ELISA test on fractions collected from sucrose 
density gradient centrifugation of crude virus 
suspension 
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-- 
fraction using a 1/1000 dilution of the polyclonal HRV-2 
antiserum as the detecting antibody. 
C. 3b Results 
The test was performed on fractions collected from two 
gradients. The O. D. values of the expected virus 
containing fraction and a fraction above and lower to 
that fraction are shown in fig-11. 
Both gradients showed peaks in the same fraction. 
The infectivity test confirmed the results of the ELISA 
test. 
C. 3c Discussion 
The ELISA test was found to be an appropriate screening 
test. Further, it has been reported to be as specific as 
the neutralisation test(Barclay and Al-Nakib, 1987). 
C. 4 Screening of the Wells Containing the Putative 
Hybridomas 
C. 4a Introduction 
The culture supernatants fluids from the wells of the 
microplates were screened for presence of the antibody. 
It is desired to screen the wells early as the hybridoma 
colonies are seen microscopically and more than one 
screening should be done to select those hybridomas 
which are slow growing. 
C. 4b Results 
The O. D. values obtained in the test were interpreted by 
determirg a ratio between O. D. of the test well over 
O. D. of the control well. The control well received the 
complete hybridoma medium in place of the cell culture 
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26.1ö 
Fig-12: Frequency distribution of the ratios obtained in 
ELISA test with the supernatant fluid during the 
screening for HRV-2 Mab in the culture fluid 
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supernatant fluid. A frequency distribution of the 
ratios thus obtained was determined (fig-12). It was 
seen that the ratio of 1.3 represented 21% of the wells. 
This was taken as the base value for the selection of 
the positive wells. 
Using 1.3 as reference value, 77 clones were 
selected in the first screening. 
In the second screening, a large number of the 
wells showed 1.3 or higher ratio. Therefore, a higher 
value of the ratio of 2.0 was selected to allow the 
selection of only that number of the clones which could 
be conveniently handled. With this ratio, 33 wells were 
found to be positive (Table-5). 
In all 110 wells were selected. The ratios in the 
first screening varied from 1.3 to 1.94 and from 2.0 to 
4.5 in the second screening. 
C. 4c Discussion 
In this study , the object was 
to select not only those 
hybridoma cells which were giving high ratio but also 
those which were positive but had low ratio values. The 
low ratio hybridomas were thought to be the more 
important for this study. This was based on the 
assumption that either the conserved epitopes were 
relatively weak in their immunogenicity or their 
antibody had lower affinity and thus they would not 
compete with the dominant epitopes. 
This method of frequency distribution was found to 
be a satisfactory method for arriving at a base value. 
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Dearden and Al-Nakib (1987) found the ratio of 1.5 as 
the base line value for detection of the HRV antigen in 
nasal washings with a polyclonal hyperimmune serum. 
However, in the case of hybridomas, antibody production 
may vary for many reasons for example the 
characteristics of the hybridoma, the culture condition, 
the frequency of feeding during post fusion care and 
volumes of medium removed and replaced during the 
feeding. It is, therefore, more appropriate to determine 
the base line value for a set of condition by frequency 
distribution. It is interesting to observe that the 
ratio (1.3) obtained with the frequency distribution is 
very close to 1.5 which was determined by testing a 
large number of control negative samples. 
C. 5 Cloning of the Hybridoma Cells 
C. 5a Introduction 
The hybridoma cells in the positive wells are cloned as 
soon as the supernatant fluid is found to be positive 
for the antibody. The cells are cloned to reduce the 
chances of their being overgrown by irrelevant cells. 
Campbell, (1984) described various situations in which 
these irrelevant cells may develop in a hybridoma 
culture. The hybridoma cells carry a tetraploid number 
of chromosomes and therefore, have to put more energy 
into DNA replication. A cell which looses unnecessary 
chromosomes might be able to replicate its DNA and 
divide faster and be able to outgrow its neighbours. 
Another explanation is that in a plasma lymphocyte as 
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much as half of the protein synthesis apparatus may be 
occupied with the synthesis of immunoglobulin. Thus the 
hybridoma diverts so much energy into antibody synthesis 
that less energy is left for their multiplication. 
consequently, they are overgrown by non-antibody 
secreting cells. 
Therefore cloning is considered an important step 
in establishing the hybridoma cell lines. 
C. 5b Results 
Cloning of the cells in all 110 positive wells was 
attempted. However, only 53 hybridomas could be cloned. 
The remaining 57 clones (52%) were lost during the 
cloning. Of the cloned hybridomas, 62% were those which 
showed 1.5 and above ratio in the screening and the 
remaining 38% were those showing ratios between 1.3 to 
1.5. Of all the 53 cloned hybridomas, 31 (49%) clones 
were those which were selected in the first screening 
(ratio 1.3 to 1.99) and the remaining 22 (41%) were 
those selected in the second screening (ratio 2.0 and 
above). The cells from a well which gave the highest 
ratio value of 4.5 was also successfuly cloned. 
The neutralisation test against the HRV-2 was 
performed on supernatant fluids from all these cloned 
hybridomas growing in the wells of a6 well dish. Of 
these, 17 clones were found to produce neutralising 
antibody. These 17 clones were finally selected. Of 
these 17 clones, 8 clones had the ratio of 2.6 to 2.8 
and other 8 had the ratio of 1.3 to 1.4. The remaining 
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hybridoma had a ratio of 4.5. 
C. 5c Discussion 
A loss of 52% of the initial positive clones during 
cloning is not uncommon. It has been reported that about 
50% of the initially positive clones may be lost during 
the early cloning period (Campbell, 1984). 
Of the clones lost, a major difference was not 
observed between fast growing clones which were positive 
in the first screening and comparatively slow growing 
clones which were selected in the second screening. 
Similarly, the clones showing the minimum positive value 
of 1.3 and also the maximum value of 4.5 were cloned. 
C. 6 Adaptation of the Hybridoma to HAT Free and 10$ 
Foetal Calf Serum medium 
C. 6a Introduction 
The established hybridomas are adapted to grow in normal 
cell culture medium which does not contain HAT. In 
addition the serum concentration is also normally 10%. 
The general practice is that the aminopterin is removed 
first and HT allows the cells to use both main as well 
as alternate pathways of DNA synthesis and then finally, 
the HT is removed. 
C. 6b Results 
Initially, one hybridoma was adapted to grow in HAT free 
and 10% serum containing medium. The HT concentration in 
the medium was diluted by a factor of 2 at every passage 
and the cells were split every 48 hours. The HT was 
diluted first by a factor of 2 followed by factor of 4 
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and then it was completely removed. The cell counts were 
6.85X105,7.1X105 and 6.4X105 per ml respectively in 
1/2,1/4 and without HT containing medium. 
To adapt the cells to grow in medium containing 
10% serum, a 1: 2 split was made with medium containing 
10% serum. The cells were given three such passages 
before a stock of the hybridomas was raised in HAT free 
and 10% foetal calf serum. Then the cells were preserved 
and held in the vapour phase of liquid nitrogen. Cell 
counts were 5.8-6.0X105/ml in the serially diluted serum 
containing medium and 6.2-6.5X105/ml in the control 
where the cells were grown in medium containing 20% 
serum. 
The other 16 hybridomas were cultured in HT and 
20% serum containing medium. Then they were grown in 
medium without HT but 20% serum medium. The serum 
concentration was reduced as described above. The cell 
concentration for all hybridomas remained close to the 
controls during the adaptation. 
C. 6c Discussion 
All the hybridomas were successfully adapted to grow in 
normal tissue culture medium. The removal of HT was not 
found to have any adverse effect on the growth of the 
cells even when it was abruptly removed. However, the 
serum should be gradually removed. The 1: 2 split of the 
cells with medium containing 10% serum accomplishes 
this efficiently and conveniently. 
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D Studies on the HRV-2 Monoclonal Antibodies 
Studies were conducted on the Mabs in cell culture 
supernatant fluid and in ascites fluid. The cell culture 
Mabs were used in only preliminary studies and the Mabs 
in ascites fluid were used for detailed studies. This 
was because the concentration of the Mabs was higher in 
the ascites fluid preparations. 
1 Studies on the Monoclonal Antibodies in Cell Culture 
Supernatant Fluids 
la Introduction 
The cell culture Mabs were tested in the ELISA test and 
also for neutralisation. The cell culture supernatant 
fluids of the hybridomas were tested after they were 
preserved and then revived. The aim of the experiment 
was to ensure that the hybridomas retained their ability 
during the propagation. The ELISA test was performed 
with both viral and cell culture antigens. 
lb Results 
The Mabs were detected in all 17 fluids. The ratios for 
all the Mabs were above 1.3. However, control wells with 
uninfected cell antigens as opposed to virus infected 
cell also showed higher ratios. The neutralisation of 
HRV-2 was observed with all Mabs (Table-6). 
lc Discussion 
It appeared that the Mabs reacted with epitope(s) 
present in the control uninfected cell culture fluid. 
Campbell (1984) reported that a complete cross 
reactivity might be a possibility when two proteins had 
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Table-6: Studies on Cell Culture Mabs: ELISA test with 
Virus and Cell Antigen and HRV-2 Neutralisation 
----- 
Mab 
--------------- 
Ratio with 
-------------- 
Ratio with 
-------------------- 
Neutralisation 
virus antigen cell antigen 
--- ---------- ----- 
D-3 
--------------- 
1.8 
--------- -- 
2.0 
---------- 
+ 
D-6 1.5 1.4 + 
D-9 1.6 1.6 + 
D-15 1.6 1.4 + 
D-21 1.3 1.4 + 
D-23 1.4 1.4 + 
D-24 1.4 1.3 + 
D-25 1.7 1.7 + 
D-26 1.3 1.1 + 
D-28 1.3 1.2 + 
D-29 1.5 1.6 + 
D-34 1.3 1.2 + 
D-36 1.4 1.3 + 
D-54 1.6 1.7 + 
D-60 1.3 1.3 + 
D-65 1.4 1.2 + 
D-86 1.3 1.3 + 
+= cells survived , Neutralisation 
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the same prosthetic group. Though all Mabs showed the 
neutralisation of HRV-2, however Colonno, et. al. (1986) 
have shown that the Mab directed against the HeLa cells 
prevented the viral CPE. The cross reactivity of all the 
Mabs however raised a doubt about the specificity of the 
test. It was therefore necessary to further examine the 
test system and to. use Mabs in higher concentrations 
derived from ascites fluids as opposed to using lower 
concentration cell culture fluids. 
2 Studies on Potency and Specificity of the Mabs 
2a Introduction 
The Mabs in ascites fluid were first tested in the ELISA 
test for their relative potency as well as specificity. 
During the making of the hybri4omas the Mabs were not 
tested with virus containing cell culture fluids as well 
as control uninfected cell culture fluid without virus 
and studies with cell culture Mabs showed positive 
reactions with both viral and cellular antigens 
The Mabs were serially diluted and tested in dupli- 
cate with both virus and uninfected cell culture fluids. 
2b Results 
Five Mabs were tested first and the absorbance value in 
both sets of the antigens are shown in table-7. 
The values decreased as the Mabs were diluted. 
However, the values in both the sets of observations 
were identical. 
2c Discussion 
Failure to detect any difference between both the sets 
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Table-7: ELISA Test for Monoclonal Antibodies in Ascites 
Fluid 
------------------------------------------------------- 
With Virus as Antigen 
Control Control Mabi Mab2 Mab3 Mab4 Mab5 
-------------------------------------------------------- 
Blank 0.015 0.53 0.34 0.47 0.51 0.42 
0.013 0.013 0.32 0.17 0.27 0.33 0.25 
0.013 0.015 0.16 0.09 0.12 0.15 0.13 
0.013 0.018 0.09 0.03 0.05 0.07 0.06 
Wi th Cell Culture Antige n 
0.018 0.012 0.52 0.34 0.50 0.53 0.43 
0.018 0.019 0.32 0.16 0.26 0.28 0.23 
0.019 0.016 0.17 0.07 0.10 0.14 0.12 
0.018 0.019 0.09 0.04 0.05 0.07 0.066 
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of observations was not considered to indicate that the 
Mabs were not virus specific. This was based on the 
observation that all five Mabs tested showed a similar 
pattern while a purified viral preparation was used for 
the immunisation. Therefore, if there was the presence 
of cell antigens in the preparation, they should have 
been in a minor proportion. 
It was therefore inferred that the non-specific 
positive values were due to other causes. 
2.1 Further Studies on the ELISA Test 
2.1a Introduction 
The cause of non-specificity of the test using mouse 
antibody as second antibody system was investigated. The 
ascites fluid of a Mab was given various treatments. It 
was incubated with cell culture antigen, with BSA, with 
normal rabbit serum and then tested. In another set of 
experiments, the wells of the plate were coated with 
normal rabbit serum in place of the coating antibody and 
PBS, virus containing and mock cell culture antigen 
containing cell culture fluids were used as antigens. 
2.1b Results 
The preincubation of the ascites f1Uid with normal 
rabbit serum and with mock cell culture antigen showed a 
decrease in the O. D. values. However, the values still 
remained high (Table-8). 
A positive reaction was also recorded when the 
wells were coated with normal rabbit serum and PBS, 
virus and Cell antigens were used as antigens. The 
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Table-8: Further studies on ELISA: Effect of various 
treatments on the cross reactivity of the 
ascites fluid Mab 
-------------------------------------------------------- 
Normal Treated with Treated with Treated with 
untreated 1% BSA cell antigen NRS 
ascites 
fluid 
--------- 
0.61 
--------------- 
0.47 
------------------ 
0.18 
--------------- 
0.24 
0.38 0.30 0.14 0.19 
0.19 0.18 0.07 0.11 
0.09 
------ 
0.09 0.05 
------ 
0.07 
- --- --- -------------- ------------ 
NRS = Normal 
- - --------- 
rabbit serum 
Table-9: Further studies in ELISA: Effect of normal 
rabbit serum coating of the plate 
-------------------------------------------------------- 
PBS as Cell antigen Virus antigen 
antigen as antigen as antigen 
-------------------------------------------------------- 
0.70 0.73 0.74 
0.36 0.36 0.39 
0.16 0.15 0.20 
0.09 0.09 0.11 
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intensity of the reaction in all three cases was similar 
(Table-9). 
2.1c Discussion 
The positive reaction in the wells coated with normal 
rabbit serum clearly indicated that the mouse antibodies 
were cross reacting with the rabbit serum. The test was, 
though, shown to be specific and sensitive in the case 
when the capture antibody derived from rabbit serum and 
the second antibody from guinea pig serum, whereas it 
was not found suitable when the second antibody was a 
mouse antibody. It could not be tested with first 
antibody in guinea pig serum due to insufficient amount 
of the antiserum. The test was therefore discarded. 
3 Studies with the Monoclonal Antibodies for the Search 
of Conserved Immunogenic Epitopes 
IIF test and in vitro neutralisation tests were 
performed on a number of HRVs and other picornaviruses. 
The IIF test was standardised because the ELISA 
test failed to show only virus specific binding 
(sections 2 and 2.1 of this chapter). The IIF test was 
used to show the presence of the epitope by binding with 
the Mab. Neutralisation was taken as the criterion of 
the immunogenicity because the HRV serotype 
classification is based upon in vitro virus 
neutralisation. 
3.1 Studies on the monoclonal Antibodies in IIF Test 
The test was standardised for use in cross reactivity 
studies. It has been described for the detection of the 
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antigen in the HRV infected HeLa and human embryonic 
fibroblast cells (Dreizin, et al., 1971; Ponomareva, et 
al., 1972). It has also been used for the detection of 
the HRV antibodies (Hruskova, et al., 1981). 
Ponomareva, et al. (1972) demonstrated that the 
HRV serotypes were differentiated in the IIF test. 
Hruskova, et al. (1981) reported that the antibody 
titres obtained with the IIF test were comparable with 
the titres obtained with the neutralisation test. 
In the light of these observations on the applica- 
bility and specificity of the test, it was decided to 
use it for. determining the HRV-2 specificity of the 
Mabs. The test was also most suitable for cross 
reactivity studies. Since it involves the Mabs and the 
virus infected cells only and not antiserum, it was 
easier to include a large number of the viruses in the 
study but the virus propagation conditions for optimal 
CPE needed to be determined for each virus used in the 
study. 
3.1.1 Studies on Determination of the Virus Infective 
Dose to Obtain Infected Cells 
3.1. la Introduction 
The test involves the binding of the intra-cellular 
virus with the Mab. Since the picornaviruses cause a 
lytic infection of the cells, it is important in this 
test that the cell monolayer is exposed to that amount 
of the virus which infects a large number of cells 
which can be harvested before they are lysed by the 
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virus. Therefore, the challenge dose needs to be both 
defined and carefully controlled. 
3.1.1b Results 
The HRV serotypes showed an extensive variation in terms 
of amount of the virus required to produce CPE. The 
HRVs could be divided in to two groups on the basis of 
virus growth. One group comprising of serotypes 1A, 1B, 
19,42,72, and 85 showed faster growth and challenge 
with as little as 10 TCID50/ml caused the CPE after 
overnight incubation. The serotypes belonging to the 
second group showed comparatively slow virus growth and 
the challenge dose varied from one serotype to another 
serotype. The challenge doses were 7,6.5,8, and 9 
log10 for HRVs 2,9,14 and 32 respectively. It was 6, 
6.5 and 5.5 log10 for the HRVs 3,15 and 49. 
The challenge dose for other picornaviruses 
included in the study did not show such variation. The 
challenge dose for all coxsackie virus type B and 
poliovirus was 51og10 and was 41og10 for EMC virus. 
Stocks of the coxsackie viruses of type A and ECHO were 
not titrated as 10-1 dilution of their stock produced 
the CPE. 
3.1.1c Discussion 
The variation observed in terms of the amount of the 
virus required for CPE suggested that the HRVs differed 
in their ability to grow in the cell culture system. 
Lonberg-Holm and Korant (1972) studied the early 
interaction of HRV with host cells. It was reported that 
172 
the rate of attachment of HRV-2 virion was much faster 
than that of HRV-14 inspite of the fact that the number 
of the receptor sites per cell was similar for both the 
serotypes. The ability to attach with the host cell may 
have a direct effect on the extent of CPE. 
There is not yet any infcXmation available in the 
technical literature on the ability of these fast 
growing serotypes to attach to the host cells. 
3.1.2 Studies on Cross Reactivity of the Monoclonal 
Antibodies with HRVs in IIF Test 
3.1.2a Introduction 
The Mabs were used to test for the physical presence of 
epitopes on HRVs with which they react in the IIF test. 
3.1.2b Results 
15 of the 17 Mabs were tested. Two Mabs were not 
included in the study due to non-availability of their 
ascites fluids. The data are shown in table-10. 
All Mabs showed a positive reaction with the cells 
infected with HRV-2 and control non-infected cells did 
not show the fluorescence. Mabs D-6 and D-24 were also 
tested with Vero cells infected with a non-related 
Yellow Fever Virus and a negative result was recorded. 
Extensive cross reactivity was observed when the 
Mabs were tested with other HRVS. All 15 Mabs reacted 
with the cells infected with HRV- 3 and 14. 
Mabs D-9, D-15, D-21, D-24, D-26, D-29, D-34 and 
D-36 showed a positive reaction with all HRVs tested. 
Mabs D-3, D-6 and D-25 showed the positive 
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reaction with cells infected with all HRV serotypes 
tested except in case of HRV-15, when a negative result 
was recorded. 
Mabs D-28, D-60, D-65 and D-86 showed that the 
epitopes with which they react were comparatively less 
conserved. 
The Mab D-60 reacted with all HRVs except HRVs 45 
and 72. 
Mab D-28 reacted with HRVs 1A, 1B, 72 and a weak 
positive reaction was recorded in case of HRVs 15,32 
and 45. HRVS 9,19,49 and 85 gave negative reaction. 
Mabs D-65 and D-86 reacted with HRVs 9,15 and 49. 
Mab D-65 also reacted with HRV 19 and 32. 
HRV 1A and 1B are subtypes. Mabs positive for one 
were also positve for the other serotype. Similarly, 
those Mabs which were negative for one were negative for 
the other. 
3.1.2c Discussion 
The IIF test was found to be the most suitable test in 
this study for the detection of the physical presence of 
the epitope(s) which would react with the Mabs in the 
ascites fluids. This is because a large number of 
viruses can be studied readily with this test. 
The test is read visually. Therefore, it is 
recommended that each slide should have a negative 
control for the ascites fluid. Similarly, positive 
controls should also be included for reference. 
The important observation was made that an 
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epitope(s) equivalent to HRV-2 neutralising epitope(s) 
was found to be conserved on all HRVs tested with Mabs 
D-9,15,21,24,26,29,34 and 36. It is also important 
to mention that all Mabs reacted with HRV-14. Therefore, 
a relationship between HRV-2 and HRV-14 was established. 
HRV-2 and HRV-14 have so far, been shown by other 
worker (Colonno, et al., 1986 and Hughes, et al., 1988) to 
be dissimilar antigenically. 
3.1.3 Studies on Cross Reactivity of the Monoclonal 
Antibodies with Other Picornaviruses in the IIF Test 
3.1.3a Introduction 
The Mabs were also tested with other members of the 
enterovirus and cardiovirus groups of the family 
picornaviridae. One serotype of poliovirus 1 and ECHO 
virus, 5 serotypes of coxsackie virus type B, 3 
serotypes of coxsackie virus type A and EMC were tested 
to study the further conservation of the epitope in the 
family. 
3.1.3b Results 
The data are shown in table-11. Mabs D-9, D-24, D-34 and 
D-36 reacted with all the picornaviruses tested. The 
epitope(s) with which the Mabs reacted was also found to 
be present on all HRVs tested (see Table-10). 
Four Mabs (D-15, D-21, D-26 and D-29) reacting 
with all HRVs failed to show this effect when tested 
with these picornaviruses. However, only one virus 
coxsackie virus B6 was negative in case of D-21 and D- 
29. 
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Mab D-6 was negative with only coxsackie A9. It 
was negative with only HRV-15 when tested with HRVs. 
Mabs D-3, D-15, D-25 and D-26 showed a lesser 
range of cross reactivity with these picornaviruses, 
while these Mabs were broadly cross reactive with HRVs. 
The Mab D-3 did not react with Coxsackie virus type A9 
and B4. The Mab D-15 did not react with coxsackie virus 
types B5, B6 and EMC. The Mab D-25 was negative with 
cosackievirus B5, B6 and EMC. The Mab D-26 failed to 
react with coxsackie virus types B3, B6 and EMC. 
Similarly, the Mabs D-28 and D-60 showed a 
restricted cross reactivity. The Mab D-28 reacted with 
all three serotypes of coxsackie virus type A, ECHO, 
poliovirus and 3 of the 5 coxsackie virus type B virus. 
However, the reaction with one coxsackie virus type A 
and 2 of the B type coxsackie virus was only weakly 
positive. The Mab D-60 reacted with 2 of 3 type A and 2 
of 5 type B of coxsackie virus. It was also positive 
with ECHO. 
Mabs D-65 and D-86 failed to react with any of the 
picornavirus tested. 
Coxsackie type A21, B2, ECHO were positive with 
most of the Mabs ( negative with 2 Mabs), followed by 
coxsackie virus A18, B4, and poliovirus (negative with 3 
Mabs) and coxsackie virus type A9, B3 ( negative with 4 
Mabs). 
The viruses coxsackie virus type B5, B6 and EMC 
reacted with only a small numbers of Mabs . The Mabs D- 
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3, D-6, D-9, D-24, D-34 and D-36 reacted with all three of 
them while D-21 and D-29 did not react with 
coxsackievirus B6. The Mab D-26 reacted with only 
coxsackie virus B5 of these three picornaviruses 
3.1.3c Discussion 
It is an important observation that the neutralising 
epitope of a HRV serotype is conserved on other members 
of the family picornaviridae and the range of the 
conservation extends to the enteroviruses as well as 
the cardioviruses. However, the physical presence of the 
epitope does not necessarily mean that the biological 
activity of the epitope is also conserved. Grubman and 
Morgan (1986) reported that the binding and 
neutralisation assays done on FMD virus Mabs revealed 
that the presence and function of an epitope were not 
necessarily correlated. Similarly in the case of 
poliovirus, Crainic, et al., (1983) reported that a 
poliovirus isolate recovered from a vaccine fed infant 
showed a different kind of antigenic variation. One 
epitope lost its function in virus neutralisation but 
kept its antigenic conformation unaltered. 
Above all, the identification of epitope(s) 
equivalent to HRV-2 neutralising epitope(s) on HRVs and 
picornaviruses is highly significant finding. The 
importance of this new relationship should be further 
investigated by determining the ability of the Mabs 
reacting with these epitopes to neutralise the 
infectivity of the virus. 
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3.2 Neutralisation and Cross Neutralisation Studies 
With the Monoclonal Antibodies 
Neutralisations studies on HRV-2 plaque purified virus, 
parent stock as well as cross neutralisation of the 
other HRVs and selected picornaviruses were performed. 
This study was carried out to assess the conservation of 
the epitope which mediates neutralisation of these 
cross reactive Mabs across a range of picornaviruses. 
3.2A Neutralisation and Cross Neutralisation of HRVs 
A. constant virus and varying antibody micro- 
neutralisation test was developed. It is important to 
recognise that the neutralisation reaction effected by 
the Mab is different from the neutralisation caused by 
polyclonal antiserum. The polyclonal antiserum probably 
contains antibodies against number of neutralising 
sites and therefore either by additive or enhancement 
effects, the virus is neutralised efficiently. In the 
case of Nab, the virus can only be neutralised through 
one mediating epitope. The Mab can neutralise the virus 
by one of the two mechanisms. It may neutralise the 
virus by causing irreversible changes in the virion or 
it may cause a decrease in the infectivity by effecting 
the aggregation of the virions. The test with a low 
challenge dose can be performed efficiently in the first 
situation while in the second situation the effect of 
the decrease in the infectivity may be nullified due to 
the longer test duration because the low dose of the 
virus will take a longer time to cause the CPE. A test 
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performed with a high challenge dose can be expected to 
be reliable in both cases. Decreases in the infectivity 
either due to the damage to the virion or due to 
aggregation will be clearly demonstrable because the 
test duration will be short and the test will be read 
before the residual non-neutralised virus can over grow 
and nullify the effect. However, this test should be 
performed with precisely defined conditions otherwise 
the test may result in expressing false negatives. 
HRVs posed yet another problem. It was observed 
that with a low virus dose, the virus growth was 
erratic. Few wells showed massive CPE while other did 
not show CPE. This effect was probably due to cell- 
virus interactions. In the neutralisation test for 
polyclonal antiserum, the cells were added to the wells 
which already contained the virus-antibody suspensions. 
The cells and the virus then grew together and the cells 
died in antibody free virus control wells due to viral 
CPE. In the case of virus-antibody mixtures, the cells 
which survived formed a cell sheet. Therefore, it was 
speculated that the actively growing cells could cause 
an interference in the development of the viral CPE. 
This problem demanded the careful standardisation 
of the micro-neutralisation test for studying the Mabs 
in general and cross reactive Mabs in particular. The 
cross reactive Mabs were not expected to show a stronger 
neutralisation than that observed with Mabs reacting 
with dominant epitopes. 
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3.2A. 1 Standardisation of the Microneutralisation Test 
3.2A. la Introduction 
The test was standardised for the challenge dose of the 
virus, number and age of the HeLa (OM) cells and for the 
duration of the test. 
3.2A. lb Results 
Three growth patterns of HRVs were observed. In the 
first pattern, the optimum dilution of the virus stock 
gave 100% CPE in 48 hours and the cells were added at a 
concentration of 5XlO4cells/100 pl. In the second 
pattern, the 100% CPE was observed in 24 hours and the 
cell number was 5X104cells/100 pl. The third pattern 
showed 100% CPE in 48 hours but the cell number was 
lowered to 3.5X104cells/100 kul. 
HRVs 2,9 and 15 belonged to the first pattern. 
HRVs 1A, 1B, 19,45,72 and 85 represented the second 
pattern and HRVs 3,14,32 and 49 were classified in the 
third group. 
The amount of the virus used as the challenge 
dose in this test was 104 TCID50/ 50 pl for all HRVs. 
Reproducible results were obtained when the cells 
from a2 days old seeded flask were used. The cells from 
a3 days or more old seeded flasks showed variation in 
susceptibility to the HRVs. 
3.2A. lc Discussion 
It was apparent that the HRVs differed in their growth 
in cell culture. Some HRV serotypes showed a higher 
infectivity. It is important to realise here that HRVs 
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1A, 1B, 19,45,72, and 85 showed a higher infectivity 
in comparison to HRVs 2,3,9,14,15,32 and 49 in 
infecting the HeLa (OM) cells for generating the 
infected cells for IIF test (section 3.1.1 of this- 
chapter). HRVs 2,9 and 15 were differentiated from HRVs 
3,14,32 and 49 on the basis of the number of cells 
seeded. It suggests that virus cell interactions differ 
in these three group of the HRVs. Differences in 
adsorption have already been demonstrated for HRV-2 and 
HRV-14. HRV-2 adsorbs faster than HRV-14. 
3.2A. 2 Studies on Neutralisation of HRV-2 and Cross 
Neutralisation of HRVs with Monoclonal Antibodies 
3.2A. 2a Introduction 
The Mabs in ascites fluid were tested for neutralisation 
of plaque purified and parent stock HRV-2. They were 
also tested for their ability to neutralise 12 other HRV 
serotypes. In the study, those HRVs which were found to 
represent the major and minor groups of the cell 
receptor binding, one or two way related and unrelated 
serotypes in the polyclonal antiserum neutralisation 
test were included. HRV 1A and 1B are subtypes and HRV-9 
and 32 showed a one way relationship in the 
neutralisation test with polyclonal antiserum (section A 
of this chapter). HRVs 3,9,14,15,32,45,72 and 85 
belong to the major group and HRVs lA, 1B, 2 and 49 
belong to the minor group of the cell receptor (Colonno, 
et. al., 1986). Polyclonal antibody containing serum 
which neutralised the HRV-2 did not cross neutralise 
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any of the 5 HRVs tested in polyclonal antiserum cross 
neutralisation studies (section A of this chapter) 
3.2A. 2b Results 
The data are shown in table-12. All 14 Mabs showed 
neutralisation of the plaque purified and parent HRV-2 
virus (Figs-14 and 15). 
The neutralising titres for the plaque purified 
HRV-2 varied from from 1/8 in case of D-60 and D-86 Mabs 
to 1/128 for Mab D-24. 
Mabs D-3, D-6, D-29 showed 1/20 titres and Mabs D- 
15, D-26, D-28, and D-36 showed 1/16 titre. These two 
values of the titres are probably the same. Variation in 
the titres are due to different starting dilutions of 
the Mabs. 
Mabs D-9, D-25, and D-34 showed higher titres. 
Mab D-9 showed 1/40 and Mabs D-25 and D-34 showed 1/32. 
Again, variation is due to different starting dilutions. 
Mab D-21 showed 1/64 titre and the highest titre 
was recorded with D-24,1/128. 
In neutralisation of the parent HRV-2 virus, the 
Mabs D-3, D-15, D-25, D-26, D-28 and D-36 showed a two 
fold decrease in the titres and Mab D-24 showed a four 
fold less titre. The titres for Mabs D-6, D-9, D-21, D- 
34, and D-86 remained unchanged. Mabs D-29 and D-60 
showed a two fold increase in their titres which may not 
be significant. 
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All Mabs were tested with 10 of the 13 HRVs used 
in the study. Only Mabs D-3, D-6, D-24, D-28, D-36 and 
D-60 were also tested with the remaining three HRVs 
(HRV-3,15 and 49) which arrived in the laboratory in 
the final stages of the investigation. 
Mabs D-6, D-9, D-24, D-25 and D-29 showed the 
cross neutralisation with all HRVs. However, Mab D-9, D- 
25 and D-29 were not tested with HRVs 3,15 and 49. 
Mabs D-3, D-28 and D-36 neutralised all other HRVs 
except HRV-15. Mab D-15 failed to neutralise only HRV- 
1A. Similarly, Mab D-86 was negative with only HRV-9 and 
Mab D-26 failed to neutralise HRV-32. 
Mabs D-21, D-34 and D-60 showed the least cross 
reactivity. Mabs D-21 and D-60 neutralised HRV-2 and 
HRV-14 and also HRVs-3,32 and 49 by D-60. The Mab D-34 
neutralised three more HRVs ( HRV 1A, 19 and 32) in 
addition to HRV-2 and 14. 
The absorbance values obtained with the Mab D-65 
were not used for calculating the titre. Its ascites 
fluid contained a browni*sh pigment which could have 
given rise to false values. 
All Mabs neutralised HRV-2 as well as HRV-14 but 
HRV-14 was neutralised more strongly. Similarly, HRV-3 
was neutralised to an even greater extent than HRV-14. 
Mabs differed in their capability to neutralise 
different HRVs. A wide variation was observed in the 
titres obtained with a single Mab tested with different 
HRVs. 
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Mab D-3 showed a lower potency. The titres ranged 
from 1/2 for HRV-72 to as high as 1/256 for HRV-3. In 
general, the titres were between 1/4 and 1/16. However, 
It neutralised all HRVs except HRV-15. 
Mab D-6 was the cross neutralising antibody. 
Though. 
. slightly lower 
titres were obtained with HRV- 
15 (1/4), 9 and 72 (1/8), it showed a higher reactivity. 
In general, the titres were 1/32. 
Mab D-9 also neutralised all HRVs. Although, it 
was not tested with HRV-3,15 and 49, +he titres were 
1/10 or above in all cases. 
Mab D-15 failed to neutralise only HRV-lA and it 
was not tested against HRV-3,15 and 49. The titres were 
generally low ( from 1/8 to 1/16). 
Mab D-21 showed the least cross reactivity. It 
neutralised only HRV-2 and 14, though the titres were 
1/64 and 1/32 for HRV-2 and 14 respectively. 
Mab D-24 neutralised all serotypes used in the 
study. The titres were also fairly high (1/16 and 1/32). 
The range of the titres varied from 1/8 in case of HRV- 
1A and 15 to 1/128 for HRV-2. 
Mab D-25 was tested with 10 of the 13 HRVs and it 
neutralised all of them. The titres were generally 1/16 
though they ranged from 1/8 to 1/128. 
Mab D-26 was tested with 10 of 13 HRVs and it 
failed to neutralise only HRV-32. It showed a slightly 
higher titres ( 1/16 and above). 
Mab D-28 failed to neutralise HRV-15 but it 
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neutralised all other 12 HRVs. It showed either a weak 
neutralisation of 1/8 titre or a stronger neutralisation 
with titres 1/32 and 1/1012. 
Mab D-29 was tested against 10 of 13 HRVs. It 
neutralised all of them with a high titre. The titres 
were generally 1/40 and the minimum titre of 1/10 was 
recorded only in case of two HRVs (9 and 85). 
Mab D-34 showed a limited cross neutralisation of 
HRVs. It neutralised two HRVs weakly (1/4) and HRV1A and 
14 with titres 1/16 and 1/32 respectively. 
Mab D-36 was tested with all 13 HRVs and it failed 
to neutralise only HRV-15. It showed a weak as well as 
strong neutralisation. Four serotypes were neutralised 
weakly (1/4 for 3 HRVs and 1/8 for one HRV) while all 
other showed a titre of 1/16 and above. 
Mab D-60 showed a limited cross reactivity. It 
neutralised 5 of 13 HRVs. The titres were low at 1/4 and 
1/8 except in case of HRV-3 where 1/128 neutralisation 
titre was recorded. 
The OD values obtained with Mab D-65 were not 
taken in account for calculating the titres. It was 
found that the ascites fluid contained a brownish 
pigment which might have given higher values falsely or 
interfered with virus growth. 
Mab D-86 was tested with 10 of 13 HRVs and it 
neutralised all except HRV-9. However the Mab showed a 
weaker neutralisation. The titres were generally 1/8. 
3.2A. 2c Discussion 
The Mabs showed three patterns in cross neutralisation 
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of HRVs. A complete cross neutralisation, neutralisation 
of many HRVs and very limited cross reactivity were 
observed. 
Five Mabs (D-6, D-9, D-24, D-25 and D-29) showed 
complete cross reactivity though three of them( D-9, D- 
25 and D-29) were not tested with three of the HRVs due 
to insufficient amount of their ascites fluid. It was 
observed that HRV-15 behaved differently. Three of these 
highly cross reactive Mabs (D-3, D-28 and D-36) failed 
to neutralise only HRV-15. 
Mab D-29 showed the strongest reaction though the 
Mabs D-6, D-9 and D-24 also showed strong reactions. 
It is suggested that the differences in the titres 
obtained with different HRVs tested with a Mab are not 
due to the ability of the epitope to mediate the 
neutralisation. These may be due to the less precisely 
defined test condition for that particular HRV. 
The test was found to be sensitive for detecting 
the cross neutralisation of HRVs. The criterion used in 
this test for interpretation of the results has also 
been used by McCray and Werner (1987) in the cross 
neutralisation studies on HRVs with polyclonal antisera 
raised against peptides representing the receptor 
binding region of the virus. 
3.2B Studies on Cross Neutralisation of Picornaviruses 
with Monoclonal Antibodies 
3.2B. 1 Introduction 
Two Mabs showing complete cross neutralisation (D-6 and 
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D-24), one Mab showing negative reaction with only one 
HRV and one Mab which showed limited neutralisation of 
HRVs but showed complete cross reactivity in IIF were 
selected to study the neutralisation of a selection of 
picornaviruses. The viruses selected were to represent 
the enterovirus (human pathogen) and cardiovirus (non- 
human pathogen) groups. 
3.2B. 2 Results 
The Mabs neutralised some of the non-HRV picornaviruses 
(Table-13). 
EMC and coxsackie A-18 viruses were not 
neutralised by any of the Mabs tested. The highest SNI 
was obtained with poliovirus. The cross neutralisation 
of the serotypes was tested with two Mabs in the case of 
coxsackie B virus only. 5 of the 6 serotypes were tested 
and cross neutralisation was observed (Table-14). 
Mab D-6 neutralised poliovirus as well as 4 of the 
5 coxsackie B virus serotypes. In the cross 
neutralisation of coxsackie B virus, the titre did not 
differ widely among the serotypes. 
Mab D-24 neutralised all coxsackievirus B 
serotypes but it failed to neutralise poliovirus. 
However, a weaker reaction was recorded with 
coxsackievirus B6. 
Mab D-34 neutralised both coxsackie B as well as 
poliovirus. Though it was tested with only one of the 
coxsackie B virus serotypes. It was interesting to note 
that it neutralised the HRVs less efficiently. 
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Mab D-36 was an important cross neutralising 
antibody which neutralised both poliovirus"and coxsackie 
B virus. In the case of the HRVs , it failed to 
neutralise only HRV-15. However, it was tested with only 
one coxsackie B serotype. 
3.2B. 3 Discussion 
All these picornaviruses plaqued efficiently. Therefore, 
the test of choice was PRNT. The test is more precise 
than the micro-neutralisation test. 
Neutralisation of the picornaviruses specially the 
cross neutralisation of coxsackie B virus serotypes 
shows that picornaviruses have common ancestors. 
However, the absence of the neutralisation of EMC may 
indicate that human picornaviruses are different from 
non- human picornaviruses. 
Cross neutralisation of poliovirus and coxsackie B 
viruses may suggest that HRVs and some human 
enteroviruses are quite close to each other in their 
evolution. 
3.2C Studies on the Comparison of the Neutralisation 
Titre Derived from the PRNT and Micro-neutralisation 
Test 
3.2C. 1 Introduction 
PRNT is a more precise test as the number of virus 
particles neutralised can be estimated in PRNT. 
Unfortunately the HRV does not form plaques readily and 
although many attempts were made to achieve such effect 
with HRVs, they were not sucessful. Therefore the only 
assay available at the time of experimentation for all 
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the HRVs was based on micro-neutralisation- a form of 
TCID50 assay (section 3.2A. 2 of this chapter). With the 
titre obtained from the micro-neutralisation test used 
in this study, it was not possible to estimate the 
number of virus particle neutralised. 
This information was particularly important 
because the PRNT was used for other picornaviruses and 
the micro-neutralisation test was used for all HRVs. In 
the absence of a relationship between the two tests, it 
was difficult to determine the degree of neutralisation 
of HRVs in relation to the other picornaviruses. This 
became more important because Mab D-34 neutralised the 
HRVs poorly but picornaviruses more efficiently. 
To compare both tests, a Mab was used to 
neutralise HRV-2 in PRNT and a coxsackie B virus 
serotype (B3) in micro-neutralisation system. 
3.2C. 2 Results 
Unlike other picornaviruses for example poliovirus, 
coxsackievirus A and B types and EMC, the HRV-2 plaques 
were not clearly evident after staining with neutral red 
(section 3.2B of this chapter). Therefore, the micro- 
neutralisation titre of HRV-2 could not be compared with 
the PRNT. 
In case of coxsackie B3, the Mab D-6 gave 1.17 SNI 
titre in PRNT and the titre in micro-neutralisation test 
was 1/16. 
3.2C. 3 Discussign 
PRNT is a more direct method of estimation of the 
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neutralisation than the micro-neutralisation test. In 
the case of coxsackie B3 virus, the PRNT was compared 
with the micro-neutralisation test. Though the results 
obtained with coxsackie B3 virus can not be generalised 
to determine the relationship between both the tests, 
however it may be taken as an indicator of the degree of 
neutralisation. The comparison also shows that the 
results obtained in the micro-neutralisation test are 
due to the virus neutralisation and not to an artefact. 
4 Studies on Neutralisation of HRV-2 and 14 with Cell 
Culture Monoclonal Antibodies 
4.1 Introduction 
In order to act as a check on those results obtained 
with the Mabs present in ascites fluids, it was decided 
to determine the neutralisation characteristics of 
selected cell culture supernants Mabs. 
This study was conducted on the supernatant fluids 
of the hybridomas after they were adapted to grow in the 
medium free of HAT and supplemented with 10% foetal calf 
serum. Another aim of the experiment was to ensure that 
the hybridomas retained their ability to secrete the 
Mabs when in a non-selective culture medium. 
The cross neutralisation was performed with only 
HRV-14 for two reasons. Firstly, the HRV-14 is 
antigenically widely different from HRV-2. Secondly, 
more efficient neutralisation of the HRV-14 by all the 
Mabs suggested that it was possible to demonstrate the 
neutralisation under less stringent conditions. The 
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neutralisation and cross neutralisation conditions for 
each HRV were determined for Mabs in ascites fluid. 
These conditions might have not been applicable in the 
case of a lower concentration of Mabs in cell culture 
supernatant fluids. This study was conducted after the 
cross neutralisation studies with the Mabs in ascites 
fluid. 
4.2 Results 
The neutralisation of HRV-2 and cross neutralisation of 
HRV-14 was performed with 12 Mabs. Undiluted cell 
culture fluids from all 12 hybridomas neutralised and 
cross neutralised HRV-2 and 14 viruses respectively 
(Fig-16). 
Comparison of the absorbance values obtained with 
HRV-2 and HRV-14, showed that all Mabs cross neutralised 
the HRV-14 virus more efficiently than the 
neutralisation of HRV-2. Only in the case of one Mab was 
the OD for HRV-2 higher than the OD for HRV-14. However, 
the HeLa (OM) cells at the concentrations of 
5X104cells/1001i1 and 3X104cells/100}11 were used for HRV- 
2 and 14 test systems respectively (Table-14). 
4.3 Discussion 
Demonstration of the neutralisation of HRV-2 and cross 
neutralisation of HRV-14 by Mabs derived from cell 
culture supernatants further strengthened the results 
obtained with Mabs from ascites fluid. It showed that 
the neutralisation and cross neutralisation results were 
specifically due the Mabs and not due to any other 
contaminant in the ascites fluid. It was once again 
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Fig-16: Neutralisation of HRV-2 and cross 
neutralisation of HRV-14 by cell culture Mabs 
(Layout of the plate is shown in fig-15, survival 
of the cells shows the neutralisation, virus 
control received virus and cells and the cell 
control received only cells. 
199 
Table-14: Neutralisation of HRV-2 and cross 
neutralisation of HRV-14 by cell culture Mabs 
Layout of the Microtitre Plate 
-------------------------------------------------------- 
HRV-14 
Mab-11 Mab-12 virus C. Cell C. 
Mab-6 Mab-7 Mab-8 Mab-9 Mab-10 
Mab-1 Mab-2 Mab-3 Mab-4 Mab-5 
HRV-2 
Mab-il Mab-12 Virus C. Cell C. 
Mab-6 Mab-7 Mab-8 Mab-9 Mab-10 
Mab-1 Mab-2 Mab-3 Mab-4 Mab-5 
------- ---------------- 
Virus C= Virus 
-------------------------------- 
control (Virus+Diluent+Cell) 
Cell C= Cell control (Diluent+Cell) 
------------------------------------------------------- 
Absorbance Values after Staining the Survived cell sheet 
HRV-14 
0.135 0.151 0.000 0.237 
0.167 0.073 0.172 0.152 0.08 
0.137 0.188 0.101 0.160 0.053 
HRV-2 
0.025 0.097 0.000 0.305 
0.171 0.038 0.098 0.118 0.121 
0.093 0.080 0.083 0.055 0.020 
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established that the Mabs cross neutralised HRV-14 more 
efficiently. 
The results also suggest that the methodology used 
for the adaptation of the hybridomas in HAT free and 10%. 
serum containing medium does not adversely effect the 
Mab production by the hybridomas. 
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Discussion 
A Introduction 
HRVs are one of the major causative agent of the common 
cold, a disease of considerable economic importance and 
one of the most frequent virus infection of man (Fox, et 
al., 1985). Major factors in the incidence of the disease 
are the existence of about 100 immunologically distinct 
HRV serotypes and the fact that several of these can co- 
circulate within a community (Stott and Killington, 
1972a). The serotype diversity probably precludes an 
effective vaccination strategy based on conventional 
methods. 
Studies on the antigenic relationships among HRV 
serotypes using polyclonal antiserum portray a complex 
picture of the antigenic structure of the HRVs (see 
section E of the Introduction chapter). It has been 
observed that some HRVs show a one way relationship and 
some serotypes show a two way relationship in the 
neutralisation test. It has also been shown that the 50 
serotypes can be classified into 16 groups on the basis 
of their antigenicity. However, immunologically, it has 
been shown that the serotypes do not cross protect. 
Recently, the major neutralising immunogens (NIm) 
of the HRV-14 have been mapped (Rossmann, et a1., 1985 
and Sherry, et al., 1986). HRV 1B (Hughes, et al., 
1988), 2 (Skern, et al., 1985) , 
14 (Stanway, et al., 
1984 and Callahan, et al., 1985) and 89 (Duechler, et 
al., 1987) have been studied at molecular level and their 
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complete nucleotide sequence have been determined. 
However, the molecular basis of the serotype specificity 
is not yet fully known. 
A continkous increase in the number of HRV 
serotypes has been reported in all three phases of 
numbering of HRVs. It probably indicates progressive 
antigenic changes. Therefore, it seems unlikely that a 
successful vaccine for the common cold will be developed 
using the major neutralising epitopes. 
In such a situation, the immuno-subdominant 
epitopes which remain conserved offer a practical 
solution to the problem of the antigenic variation of 
the dominant antigens. 5uch epitopes have been 
identified on other microorganisms (see section F. 3 of 
the Introduction chapter) and their use as vaccine 
candidates is being actively pursued. Generally, these 
epitopes have been identified with Mabs after 
polyclonal antisera have failed to detect their 
presence. 
In this study, the HRV-2 neutralising Mabs were 
raised and tested for their ability to cross neutralise 
a selection of HRVs. Some of them were also tested for 
their ability in neutralising other picornaviruses. 
A panel of 17 HRV-2 neutralising Mabs was raised. 
However, only 15 of them were included in the study. Two 
Mabs could not be included due to the lack of their 
ascites fluids. The Mabs were tested in the IIF test for 
epitopes which could be shown to be common to a number 
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of viruses. A cross neutralisation test was carried out 
for the biological significance of the cross reactivity 
of the Mabs. 
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B Neutralisation of HRV-2 
A total of 14 Mabs were tested for neutralisation of 
HRV-2 plaque purified as well as the parent stock of the 
virus. Three Mabs were not included in the study because 
for two of them (D-23 and D-54) there was not sufficient 
ascites fluid and in case of the other Mab (D-65), 
contamination with a brownish pigment raised doubt 
about false positive results. 
Neutralising sites of HRV-2 are not yet well 
defined. Information on the mechanism of neutralisation 
of HRV-2 is also lacking. Skern, et al., (1987) identified 
a neutralising site between amino acid residues 153 to 
164 on VP2. Francis, et al., (1987) predicted six 
immunogenic sites on HRV-2 by reference to a computer 
graphic model of HRV-14 and sequence alignment of HRV-14 
with HRV-2. These sites were three on VP1, one on VP2 
and two on VP3. The peptide representing four of the six 
sites showed immunoreactivity in an indirect ELISA. 
Antisera raised against only one of the four sites could 
neutralise the homologous virus. Further, the undiluted 
antiserum achieved 2.4 log10 reduction in titre of the 
homologous virus and it was 1.9 Log10 when the 
antiserum was tested in 1/4 dilution. This site was 
present on VP2 and it was same site reported earlier by 
Skern, et al., (1987). A weak neutralisation of 0.1 
Logl0 was observed with the undiluted antiserum prepared 
against a site present on VP1. Information on other 
neutralising antigenic sites and their efficiency is not 
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available. However stronger and weaker neutralisation 
showed by the antisera raised against two sites may 
indicate that not all the sites are equally efficient in 
neutralisation reactions. 
Neutralisation sites of HRV-14 have been mapped 
and the mechanism of neutralisation has also been 
studied. Colonno, et al. (1989) reported that the Mabs 
neutralised by shifting the isoelectric point of the 
virion as well as causing a reversible aggregation of 
the virion. Antibodies targetted against three of the 
four neutralisation sites caused aggregation and thus 
these neutralising Mabs interfered with the attachment 
of the virus to the cellular receptors. It was also 
reported that all four neutralising sites were equally 
efficacious. The antibodies binding to one site were not 
more efficient in neutralisation than those that bound 
to the other sites. 
The neutralisation titres obtained in this study 
varied from 1/8 to 1/128. This suggests that the Mabs 
identified different epitopes and these epitopes 
differed in their ability to effect neutralisation. 
However, the titres were not related to the amount of 
the specific antibody in the ascites fluid. 
Yet in this study, the neutralisation was 
demonstrated with a high challenge dose(104 TCID50) and 
under a standardised set of conditions. It indicates 
that the neutralisation was not antibody dose dependent. 
It appeared more likely that the Mabs caused the 
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aggregation of the viruses which resulted in the 
decrease in infectivity because a fall in titre can be 
clearly demonstrated with high challenge doses. A low 
challenge dose may take a longer time to show CPE. The 
effect of a fall in titre due to aggregation may be 
nullified by a further an increase in the amount of the 
virus due to the subsequent growth of the virus in the 
test system. 
The HRV-2 virus from the uncloned parent stock was 
also neutralised by the Mabs. It suggests that the 
epitopes, which stimulated the B-cells for making the 
cross reactive antibody during the immunisation of the 
mice, are distributed on general population of the HRV-2 
and not specifically present on the plaque picked virus. 
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C Comparison of Cross Reactivity of Monoclonal 
Antibodies in the IIF Test and Neutralisation test 
All 15 Mabs showed extensive cross reactivity in IIF 
test. Many of the Mabs not only identified conserved 
epitopes but they also showed cross neutralisation. From 
the observation of the test, the Mab would react with 
epitopes on each of the HRVs and that the same Mab would 
also neutralise those HRVs, it may be inferred that some 
of the antigenic sites identified in the IIF test would 
also be involved in the Mab effected neutralisation 
reaction. 
In general, there was aggrement between the 
results obtained with the IIF and neutralisation tests. 
The neutralisation was recorded in cases where the 
presence of the epitope was identified by the IIF test. 
However, the results obtained with the IIF and 
neutralisation tests differed in case of Mabs D-6, D-15, 
D-21, D-26 D-28, D-34, D-36, D-60 and D-86. 
A minor difference involving only one HRV was 
detected with the Mabs D-15, D-26 and D-36. The Mabs D- 
15, D-26 and D-36 reacted with HRV-1A, 32 and 15 
respectively in IIF test but failed to neutralise 
(Tables- 10 and 12). The Mab D-21 reacted with all HRVs 
in IIF test but it cross neutralised only HRV-14. 
Similarly, Mab D-34 reacted with all HRVs in IIF Test 
but it cross neutralised only HRVs 1A, 14,19 and 32. 
The Mab D-60 did not react with HRVs 45 and 72 only in 
IIF test but it cross neutralised only HRV-3,14,32 and 
49 (Table-10 and 12). 
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Grubman and Morgan (1986) made a similar 
observation. Capsid structures of the 7 serotypes of the 
FMD virus were compared using a series of neutralising 
Mabs. A radioimmuno binding assay and in vitro 
neutralisation test revealed that the presence of a 
Mab epitope was not necessarily correlated with the 
ability to achieve neutralisation. 
An interesting observation was made with Mabs D-6, 
28, and D-86. The Mabs D-6 did not react with HRV-15 in 
IIF test but neutralised the virus. The Mab D-28 did not 
react with HRVs 9,19,49 and 85 in the IIF test and 
only a weak positive reaction with other two HRVs 32 and 
45. Similarly, the Mab D-86 reacted with only HRVs 
3,9,14,15 and 49 in addition to HRV-2. However, in 
neutralisation test, Mab D-28 cross neutralised all HRVs 
except HRV-15. Mab D-86 neutralised all HRVs except HRV- 
9. The Mab D-86 could not be tested with HRVS 3,15 and 
49. It is also important to mention that the Mab D-86 
showed a positive reaction with HRV-9 in IIF test but 
it failed to neutralise only this serotype. 
Brioen et al., (1985) described a "Hit and Run" 
mechanism of neutralisation for poliovirus 
neutralisation mediated through a Mab (351f4). A low 
ionic strength neutralisation by this Mab was 
accompanied by disruption of the virion to empty 
capsids. These empty capsids were antigenically and 
physically identical to those obtained by heating. As 
the resulting particles no longer expressed the epitopes 
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recognised by the neutralising antibody, the Mab was 
released. This type of neutralisation, where antibody 
neutralised the virus and then it was no longer bound, 
was described as "Hit and Run" type of neutralisation. 
Mab of this type may fail to identify its epitope when a 
serological test other than a neutralisation test is 
used. 
The positivity of Mabs D-6 D-28 and D-86 in 
neutralisation test but negative in IIF test may be due 
to the "Hit and Run" type of neutralisation. As in the 
case of poliovirus, the D and C particles are found in 
case of HRVs and neutralising epitopes are believed to 
be present only on D type particles. 
Mabs D-28 and D-86 also showed positive reaction 
in both the tests for some HRVs. HRV-2 and 14 were 
positive in IIF as well as in the neutralisation test 
with both Mabs. It may suggest that these Mabs 
neutralised the different HRVS by two different 
mechanisms. In one mechanism of neutralisation, the 
structure of the virus is changed and the Mab is 
released. While in the second mechanism, the antibody 
remains attached. 
Brioen, et al. (1985) also reported that with the 
Mab, the "Hit and Run" mechanism was applicable only in 
non-physiological low ionic strength conditions. At 
physiological conditions, the same Mab caused the 
neutralisation of the virus by non-destructive 
aggregation and therefore remained bound with the virus. 
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It was also suggested that this phenomenon was not 
restricted to only non-physiological conditions. 
However, for other Mabs, it may be valid at 
physiological ionic strengths. 
It is evident that the same epitope on poliovirus 
achieves neutralisation by two different mechanisms. 
Therefore, it may be possible that the same epitope 
present on different HRVs may be mediating the 
neutralisation by two different mechanisms. The epitopes 
of Mabs D-28 and D-86 mediate the neutralisation of HRV- 
2 and 14 by a mechanism where the antibody remains bound 
while other HRVs are neutralised by a Hit and Run 
mechanism. 
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D Conserved Neutralising Epitopes Identified by the 
Monoclonal Antibodies 
Many antigenic relationships have been demonstrated 
among the HRVs with the in vitro neutralisation tests. 
Cooney, et al. (1975) have even demonstrated that the 
heterotypic stimulation with the related HRV resulted in 
an anamnestic response to the primary immunogen (the 
other related virus) and the response to the secondary 
immunogen resembled a primary response. This observation 
confirmed the in vivo significance of a relationship 
identified in the in vitro neutralisation test. 
Recently more relationships between HRV serotypes 
have been identified with the monoclonal antibody and 
synthetic peptide approaches. Tomassini and Colonno 
(1986) isolated a receptor protein from HeLa cells. This 
protein was reported to be involved in virus 
attachment. All HRVs were classified into two groups : 
the major group and the minor group. The serotypes in 
major group are HRV-3 through -28, -32 through -43, -45, 
-46, -48, -50 through -52, -54 through -61, -63 through 
-81, -88 and -89. All the remaining serotypes are in the 
minor group. HRV-14, HRV-2 are regarded as the 
representatives of the major and minor groups 
respectively. The protection of the cells was shown with 
the Mab raised against this receptor protein against the 
challenge by 78 HRVs from the major group (Colonno, et 
al., 1986). McCray and Werner (1987) showed the cross 
neutralisation of 48 HRVs with a polyclonal antiserum 
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raised against the peptide representing the putative 
receptor binding site on HRV-14. 
Inspite of some cross reactivity demonstrated with 
a few HRVs in a polyclonal antiserum neutralisation 
test, there is as yet no record in the technical 
literature of cross neutralisation of HRVs by Mabs. This 
study therefore is the first report on cross reactivity 
of HRV serotype neutralising Mabs in both a binding as 
well as a neutralisation test. In this study those HRV 
serotypes were included which have been shown to have a 
relationship with polyclonal antiserum ( HRV 1A and 1B, 
HRV-9 and 32), those belonging to major receptor binding 
group (HRVs-3,9,14,15,19,32,45,72 and 85) and 
minor group (HRVs-1A, 1B, 2 and 49). 
In this report on cross neutralisation of the HRVs 
by Mabs, three patterns of the distribution of the 
epitopes were found. The epitopes recognised by the Mabs 
were found to be present on few HRVs , on many HRVs and 
on all HRVs tested. The epitopes recognised by Mabs D-6 
and D-24 are particularly important because they were 
found to be present on all HRVs tested. All HRV-2 
neutralising Mabs also neutralised the HRV-14 although 
these two serotypes have been reported to use different 
cell receptors. Therefore, this cross neutralisation 
appeared to be not mediated through the receptor binding 
site and thus different from the cross neutralisation 
demonstrated by Colonno, et al., (1986) and McCray and 
Werner (1987). 
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It is important to mention that all 14 Mabs showed 
some cross reactivity and an HRV-2 serotype specific 
Mabs was not obtained. In addition to HRV-2, all Mabs at 
least neutralised HRV-14. Interestingly, the HRV-14 was 
neutralised with higher dilutions of all Mabs than HRV- 
2. The other serotype which was readily neutralised was 
HRV-3, though it was not tested with all Mabs. 
To explain the difference in the degree of 
neutralisation of HRV-2 and 14, Lonberg-Holm and Korant 
(1972) reported that they differ in their ability to 
attach to cells. The rate of attachment of HRV-2 has 
been reported to be greater than the attachment rate of 
HRV-14. At 34.50C, the irreversible eclipse of cell 
associated HRV-2 required only a few minute whereas the 
rate of eclipse of cell associated HRV-14 was conside- 
rably slower. The slower rate of HRV-14 may allow it to 
remain in contact with the antibody longer. Further, the 
HRV-14 was observed to be slow growing and therefore did 
not require very precisely defined test conditions. 
For a more effective neutralisation of both HRV-14 
and HRV-3, a relationship has been reported with the 
polyclonal antiserum. McCray and Werner (1987) reported 
that the HRV-3 was neutralised to 1/20 titre by a HRV-14 
induced polyclonal antiserum. However, the titre of the 
antiserum for HRV-14 was 1/80,000. Information about the 
rate of attachment and growth of the HRV-3 virus is not 
yet available. However, HRV-3 was also found to be a 
slow growing HRV. 
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There appears to be further scope for improvement 
of the neutralisation test used in this study. The test 
can be refined and made more sensitive by taking in to 
account the growth kinetics of HRVs. However, it may be 
a long and difficult study because each HRVs has been 
found to differ greatly in its growth in cell culture 
system. There is also need to work out PRNT for each of 
the virus. 
I 
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E Conserved Neutralising Antigens: Evidence at the 
Molecular Level 
Inspite of a massive antigenic variation demonstrated in 
the HRV genus, new relationships have been identified 
with more sophisticated techniques. Recently, the HRVs 
1B, 2,14, and 89 have been studied in detail at the 
molecular level. These studies has given a new insight 
into the relationships within rhinovirus serotypes at 
the molecular level. 
The percentage identity of derived amino acid 
sequences of the mature virus proteins of HRVs 1B, 2,14 
and 89 are described in Table-15. It is clearly evident 
that some of the HRVs share more extensive homology than 
previously thought. 
The genome of HRV 1B when compared with HRVs 2,14 
and 89, showed considerable homology with those of other 
HRVs. However, the relationship to HRVs 2 and 89 is much 
more marked than that to HRV-14. The greatest degree of 
similarity is to HRV-2 where the homology with the 
individual protein does not fall below 74% . In many of 
the proteins there is higher degree of conservation. The 
relationship to HRV-89 is somewhat less throughout much 
of the genome except that in VP4, VP2 and VP3. In these 
structural proteins, there is mariginally greater 
homology than to HRV-2 (Table-15). 
For HRV-14,4 neutralising sites have been 
identified (Sherry, et al., 1986). When these 
corresponding regions of HRV-lB were compared with the 
216 
Table-15: Protein Homologies ($) Between HRVs 
(Structural Proteins) 
(Skern, et al., 1985 and Hughes, et al, 1988) 
Protein HRV1B/ HRV1B/ HRV1B/ HRV2/ HRV2/ HRV14/ 
HRV2 HRV89 HRV14 HRV89 HRV14 HRV89 
------- 
VP-4 
-------- 
94 
--------- 
100 
-------- 
52 
-------- 
94 
------- 
51 
--------- 
54 
VP-2 77 78 61 73 60 57 
VP-3 74 75 52 66 49 51 
VP-1 74 67 36 62 32 38 
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HRV-2 and 89, they were highly diverse in spite of an 
otherwise high degree of homology. These regions are 
regarded as immunogenic sites (Fig-17). 
HRV-14 and 89 are members of the major group and 
HRV-1B and 2 belong to the minor group. When homologies 
in structural proteins are compared, less homology is 
seen between HRV-14 and HRV-89. A higher degree of 
homology has been demonstrated on all structural 
proteins between HRV-1B and 89 as well as between HRV-2 
and 89. This varies from 62% in case of VP1 to 94% for 
VP4 (Table-15). 
HRV-14 showed a poor relationship with all of the 
other viruses it was compared with. The homologies were 
from 36% to 61% in the case of HRV-1B and they were from 
32% to 60% and from 38% to 57% with HRV-2 and 89 
respectively (Table-15). 
These studies on protein homologies indicated a 
relationship in the rhinovirus group at the molecular 
level. Such relationships were not earlier demonstrated 
with the polyclonal antiserum approach. The Mab approach 
on recent regrouping of the HRV serotypes on the basis 
of cellular receptor can not account for the overall 
genetic homologies. Therefore, it may be speculated that 
many more relationships are likely to be revealed when 
other HRVs will be studied at the molecular level and 
data on their structural proteins become available. 
The data available on the structural proteins of 
HRV-1B, 2,14 and 89 indicates the presence of a 
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conserved neutralising antigen on the HRV serotypes. 
Skern, et al. (1985) made an interesting 
observation that the coat protein VP2 was more conserved 
between HRV-2 and 14. The homology was 60%. This higher 
degree of the homologies could not be explained. The 
only plausible explanation provided was that VP2 had 
an important role in determining the structure of the 
virus and it did not contribute greatly towards the 
antigenicity. 
The VP2 protein showed a greater degree of 
conservation not only between HRV-2 and 14 but also with 
other serotypes as well . The VP2 homologies were 57%, 
60% and 61% for HRV-14/89, HRV-2/14 and HRV-1B/14 
(Table-15). 
Information available on the neutralising 
immunogenic sites (NIm) has demonstrated that the 
protein VP1 is regarded as contributing to all of the 
four NIms (Rossmann, et al., 1985). However Sherry, et 
al. (1986) reported that the site NIm II was composed 
mainly of VP2 sequences but a role for VP1 became 
evident with the discovery of a Mab resistant mutant of 
HRV-14 showing the subsitution at VP1 residue 210. 
In case of other HRVs, limited information on 
NIms is available for HRV-2 only. Only one site has so 
far been identified. Both Skern, et al. (1987) and 
Francis, et al. (1987) identified a dominant 
neutralising site on the VP2 protein. This site was 
reported to include the amino acid residues 153 to 164. 
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Interestingly, the NIm II mutants of the HRV-14 show 
subsitutions at VP2 residues 158,159,161 or 162. 
Therefore, it may be deduced that the neutralising 
site identified on the HRV-2 is NIm II of HRV-14. 
Further, the demonstration of a neutralising site on VP2 
makes the protein homologies in VP2 more important(Fig- 
17). Therefore, it may be believed that the greater 
conservation of the VP2 protein indicates the presence 
of the conserved neutralising antigens. 
E. 1 Conserved Neutralising Epitopes of HRVs on Other 
Picornaviruses 
Another highlight of this study is that the conserved 
neutralising epitopes of the HRVs were not found to be 
limited to the rhinovirus group only but were also found 
to be present on some other members of the human 
pathogens of the enterovirus genus of the picornaviridae 
family. 
The IIF test showed the existence of epitopes on 
all the picornaviruses tested which would react with 
some of the Mabs. However, the neutralisation test 
showed that the despite the physical presence of the 
epitope, the biological function was not conserved as 
universally. Some of the highly cross reactive Mabs 
reacted with epitopes on coxsackievirus A-18 and EMC but 
none were able to neutralise them. However, the 
coxsackie B virus and poliovirus were neutralised by HRV 
cross neutralising Mabs. In case of a Mab (D-34), the 
coxsackie B virus and poliovirus were neutralised but 
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Table-16: Protein Homologies ($) among Coxsackievirus, 
Poliovirus and HRV (Structural Protein) 
(Jenkins, et a1., 1987 and Lindberg, et al., 1987) 
-------------------------------------------------------- 
Protein CB4/ CB4/ CB4/ CB3/ CB3 HRV2 HRV14 
CB3 PV1 HRV14 HRV14 PV1 PV1 PV1 
VP-4 94 69 60 59 65 58 58 
VP-2 80 56 54 54 56 45 49 
VP-3 78 55 46 46 55 49 41 
VP-1 71 47 35 34 41 17 39 
CB= Cosxackievirus B type, PV= Poliovirus 
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HRVs were not neutralised and in the case of another HRV 
cross neutralising Mab, it failed to neutralise only 
poliovirus. This observation may indicate that the some 
weakly neutralising epitopes of the HRVs are capable of 
mediating the neutralisation of the some of the other 
enteroviruses more efficiently and some stronger 
neutralising epitopes of HRVs have lost their 
neutralising potential for enteroviruses. 
Protein sequence data of the structural proteins 
of poliovirus, coxsackie virus B3 (CB3) and B4(CB4) are 
available (Table-16). Amino acid sequence homologies 
have been reported for HRV-2/poliovirus, HRV- 
14/poliovirus, CB3/HRV-14, CB3/poliovius, CB4/CB3, 
CB4/poliovirus and CB4/HRV-14 ( Skern, et al. 1.985; 
Lindberg, et al., 1987 and Jenkins et al., 1987). 
In the case of VP1, HRV-2 and HRV-14 show a poor 
relationship with poliovirus. However, the homologies 
for VP2 protein are 45% and 49% for HRV-2 and HRV-14 
respectively. CB3 and CB4 viruses have been shown to be 
very close to each other. The protein homologies for all 
structural proteins have been reported to be above 70%. 
It is interesting to note that in the case of VP2 
protein, the protein sequence homologies between 
CB3/poliovirus, CB4/poliovirus are similar to the 
protein sequence homologies between CB3/HRV-14 and 
CB4/HRV-14. Also, all the three structural proteins 
(VP1, VP2 and VP3) of CB4 when compared with poliovirus 
and HRV-14 showed regions that were highly conserved, 
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interspersed with regions of substantial divergence 
(Jenkins et al., 1987). 
From neutralising immunogenic sites, the VP2 
protein is also important in enteroviruses . Lindberg, 
et al. (1987) reported that the neutralising epitopes 
of the CB3 virus have been found to be present on VP2. 
Greater conservation of the protein VP2 within 
rhinovirus serotypes and also between rhinovirus and 
enteroviruses together with the presence of the 
neutralising epitopes on it, confirm the validity of the 
cross neutralisations observed in this study. 
Strong evidence supporting the presence of the 
conserved neutralising antigens on the VP2 protein of 
the picornaviruses has been provided by Sherry, et al., 
(1986). It is reported that the poliovirus synthetic 
peptide of the VP2 sequence corresponding to HRV-14 NIm 
II induces a low level neutralising response. However, 
the site on the poliovirus is poorly immunogenic. In 
HRV-14, the site is an immuno-dominant antigen. Thus the 
dominance of the site in the neutralisation of HRV-14 
may contrast markedly with its role in poliovirus 
neutralisation. It suggests that during the evolution of 
the picornaviridae family, some neutralising sites 
became immuno-subdominant. Therefore these sites were 
not subjected to the immune selection pressure and hence 
remained conserved. 
This observation on the potential of the NIm II 
site in neutralisation of HRV-14 and poliovirus also 
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explains the most intriguing observatiolt made in this 
study. It was observed the the HRV-14 was neutralised 
more efficiently than the homologous HRV-2 virus. 
Similarly, the HRV-3 virus was also neutralised by 
highly diluted Mabs. In the absence of such information 
on HRV-3, it may be presumed that like HRV-14, the site 
is immuno-dominant in HRV-3. 
The dominance of a neutralising site in one 
serotype and subdominance of that site on another 
serotype may explain the cross reactivity observed in 
investigations carried out on HRVs with polyclonal 
antisera. It very aptly explains the one way cross 
reactivity observed in HRVs. 
It should be mentioned here that the subdominance 
of the conserved neutralising epitope does not undermine 
its importance in vaccine development. The dominant 
epitopes may be more efficient in inducing neutralising 
antibodies but the conserved epitopes have also shown 
their capability to react with antibody molecules which 
effect the neutralisation of the HRVs as well as other 
selected picornaviruses. 
225 
F Immunogenicity and Immun-dominance 
Despite the presence of the conserved neutralising 
epitopes and the suggestion that they have retained 
their potential for neutralisation, cross neutralisation 
is not observed with polyclonal antisera (see section A 
of the Result chapter). This raises the questions 1) 
What makes an antigen immuno-dominant? 2) How does the 
presence or dominance of the immuno-dominant antigens 
affect the immune response and biological function 
(cross neutralisation) of the conserved neutralising 
epitopes? 
F. 1 Characteristics of the Immuno-dominant Antigen 
The capacity of a protein to stimulate antibody 
production is defined as its immunogenicity (Crumpton, 
1974). The factors involved in the determination of the 
immunogenicty will now be described. 
F. 1.1 Accessibility 
Exposure to the aqueous environment is a cardinal factor 
in the determination of the immunogenicity (Goodman, 
1975). The conformation of macromolecules is a primary 
factor in determining the accessibility to the immune 
apparatus. It has been demonstrated with HRV-14 that 
those areas which form the loops and thus protrude are 
the sites of dominant neutralising antigens (see Fig-2). 
F. 1.2 Charge 
Electrical charge has long been considered a dominant 
factor in specificity. However, completely uncharged 
molecules can also be immunogenic. Salt concentration 
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and pH strongly influence the stability of the antigen 
and antibody bond. The binding between a charged 
polypeptide and its antibody molecule is primarily 
electrostatic. Variation in pH can alter the 
immunochemical interactions without involving the 
antibody combining sites. Charged groups contribute to 
the stabilisation of the antigen antibody complexes. It 
has also been observed that the net charge of the 
antibody is dictated by the net charge of the antigen 
and it is independent of the specificity of the antibody 
(Goodman, 1975). 
It therefore appears that the charged groups both 
at the combining site and distal from it, play an 
important role in determining immunogenicity. However, 
the charge and accessibility are interdependent. In 
general, it is expected that the charged residues are 
hydrophilic and therefore they remain in closer contact 
with the environment than the nonpolar group 
(Goodman, 1975). 
F. 1.3 Mobility 
Segemental mobility of the polypeptide backbone in 
portions of the protein molecule may contribute to the 
immunogenicity. Structural flexibility of both the 
protein antigen and the antibody may be valuable to 
achieve the optimum complementarity. 
Berzofsky (1985) proposed that in the clonal 
selection theory of antibody production, it is unlikely 
that there will be preformed antibodies on B-cells that 
227 
can bind every possible conformation of every 
polypeptide sequence. If the protein antigens are 
flexible, they are more likely to find some antibody for 
which they can achieve a satisfactory (induced) fit. 
Further, flexible antigens may stimulate more types of B 
cells and this may result in more antibody production. 
F. 2 DomiA ýce of the Antigens in the Immune Response 
: Immunodominance 
The intrinsic factors explained above determine the 
potential antigenic sites in a protein antigen, however 
only a subset of these sites will elicit antibodies when 
any given person or animal is immunised. These sites 
are called immuno-dominant or immuno-potent sites. 
Immuno-dominance or immuno-potency, then, is a 
quantitative expression of the strength of an antigenic 
determinant. The factors in the host determining the 
immune response to an epitope are distinct from the 
inherent structural features of that epitope. The host 
factors which control the immune response are: 1) Immune 
response genes (Ir genes), 2) Helper and suppressor T 
lymphocytes specificity and T-B reciprocity and 3) 
Idiotypic networks (Berzofsky, 1985). 
F. 2.1 Immune Response Genes (Ir genes) 
Ir genes are genes that regulate the ability of an 
individual to make an immune response to a specific 
antigen. Most of the immunoregulatory genes that have 
been proven to be antigenic specific are part of the 
major histocompatability complex (MHC). 
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In the case of the antibody response, Ir genes act 
indirectly by influencing the level and specificity of 
helper T-lymphocytes. The T-cells are required for B- 
cell to be activated to produce antibodies. 
F. 2.2 Helper and Suppressor T Lymphocyte Specificity and 
T-B Reciprocity 
B-cells specific for antigens generally require help 
from a T-cell specific for the same antigen molecule in 
order to be activated to secrete the antibodies. Ir 
genes act on the magnitude and specificity of the T-cell 
help. Specificities of the T-cells influence the 
specificity of the antibodies. Because Ir gene products 
that influence specific expression of B-cells and the 
resulting T-cell specificity apear to lead to selective 
activation of a subset of B-cells. This reciprocal 
effect of T- and B- cells on each other has been termed, 
T-B reciprocity. 
It has been observed that the Ir genetic low 
responsiveness to an antigen is accompanied by active 
suppression of the response by suppressor T-lymphocytes. 
F. 2.3 Idiotype Networks 
The idiotope of an antibody is that part of the molecule 
which is antigenically unique, as determined by a second 
set of the antibodies made against the first one. 
Idiotopes are therefore, in the variable region mostly 
in or near the antigen combining sites. As the same 
combining site structure may determine both the 
antigenic specificity and the idiotype of an antibody, 
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there should be some correlation between specificity and 
idiotype. According to Jerne's network theory, a system 
of antibodies and other antibodies against them (anti- 
idiotype) can act as a self contained homeostatic 
network. The role of the antigen is to perturb this 
internal network. The network may involves idiotype 
specific helper T-cells as well as antibody specific 
helper T-cells. 
In a study, newborn mice were injected with a Mab 
to levan with a rare idiotype not normally found in 
antilevan antisera. When these mice were immunised with 
the bacterial Levan 4 weeks later, the antibody response 
was dominated by the normally rare idiotype. This 
predominance was transferrable to other mice with the 
helper T-cells. Thus, the prevalence of this idiotype at 
birth induced complementary idiotype specific helper T- 
cells which altered the spectrum of the idiotypes 
produced on immunisation later in life. 
This explains how some antigenic sites are immuno- 
do11nant and some are immuno-subdominant. Immuno- 
dominance results in the production of an antiserum 
which is chiefly composed of antibodies against these 
dominant sites. Therefore, the polyclonal antiserum in 
many instances failed, while the Mab approach succeled, 
in detecting the presence of the conserved immunogenic 
epitopes (section F. 3 of the Introduction chapter). The 
monospecificity of the Mabs probably played the 
important role in detection of the conserved immunogenic 
epitopes. 
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The host immune pressure can be strongly involved 
in driving the evolution of the virus. This is clearly 
documented with influenza virus. Antigenic variants are 
regularly selected, so that previously immune hosts are 
no longer protected against the newly circulating 
strains (Steinhauer and Holland, 1987). Thus, the 
immuno-dominant regions are more prone to changes and 
the subdominant regions remain unchanged. 
Although this explains how the immunodominant 
epitopes determine the quality of the immune response 
it does not explain what happens in the immune 
response to the immuno-subdominant epitopes. Is the 
immune response against the subdominant epitope 
controied by the dominant epitopes? 
F. 3 The Immuno-dominant Epitopes and Their Effect on 
Immune Response against the Immuno-Subdominant Epitopes 
It is evident from the studies conducted on conserved 
immuno-subdominant epitopes that the presence of the 
dominant epitopes interferred with the immune response 
against the subdominant epitopes. The conserved 
immunogenic epitope of the Neisseria gonorrhoeae is 
active only as a fragment and weakly active on an intact 
pilus (Rothbard, et al., 1984). Similarly, in case of 
Streptococcal M protein, only a small percentage of the 
antibodies are directed against the cross reactive 
antigens (Fischetti, 1977). These observations may 
suggest that the immuno-dominant antigens not only 
dominate the immune response but also their presence 
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inhibits the immune response against the immuno- 
subdominant epitopes. 
It has been reported that the immune response to 
one antigen or antigenic determinant is inhibited by the 
administration of another antigen or determinant. This 
phenomenon is called Antigenic Competition (Taussig, 
1977). 
The terms dominant and suppressed have been 
introduced to describe antigens involved in competition. 
Dominant antigens are those antigens whose presence is 
inhibitory to another antigen and suppressed antigens 
are referred to these second antigens. When an animal is 
injected with a multideterminant immunogen, it is 
frequently found that a response is made to only some of 
the determinants available. In many cases, it appears 
that a response to these dominant determinants takes 
place at the expense of the response to the other 
antigens (suppressed antigens) present on the same 
molecule. This phenomenon is termed intramolecular 
competition. This type of competition has been found to 
occur between different regions of protein molecules or 
synthetic peptides, between different haptens on the 
same carrier molecule or between a hapten and the 
carrier itself (Taussig, 1977). 
F. 3.1 Mechanismsof Antigenic Competition 
The mechanism of the antigenic competition has been 
described as both T-cell and B-cell dependent. 
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F. 3. lA T-Cell Dependent Competition 
It involves the activity of the T-cells with 
particularly suppressive properties (suppressor T- 
cells). 
There is evidence that, parallel with effector and 
helper T-cells, there exists population of T-Suppressor 
(Ts) cells. Apart from antigenic competition, these are 
involved in infectious tolerance, allotype suppression 
and also in prevention of the auto-immune response 
(Taussig, 1977). 
Taussig (1977) suggested that the antigenic 
competition falls into the category of non-specific 
suppression. Inhibitors have been obtained from normal 
or immune sera and culture supernatants of T-cells. It 
is envisaged that these inhibitors serve the function of 
regulating the effect of the immune response by their 
effect on cell proliferation. Although, secreted 
specifically by T-cells, the inhibitors can act on both 
T- and B-cells. Normally, during an immune response, the 
level of the Ts-cells activity will be in proportion to 
the activity of other T- and B-cells involved in the 
response. Thus more Ts-cells may be available for active 
antigens than for the weak antigens. Since the 
inhibitors produced by Ts cells may be non-specific in 
their effect, an active response to one antigen is 
likely to inhibit the initiation of the responses to 
other weak antigens. The effect will be expected to be 
of a general type, involving many unrelated antigens. 
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The antigens may not necessarily compete when 
administered together. However, the effect is more 
pronounced during secondary contact with the antigens. 
Herzenberg (1983) reported that the dominant 
epitopes played an important role in the specific 
regulation of the immune response against the immuno- 
subdominant epitopes. Immunisation of the carrier primed 
animals with a "new" epitope (hapten) coupled to the 
priming carrier severely compromises subsequent 
antihapten antibody responses. The diminished 
responsiveness was found to be highly selective and it 
specifically affected the IgG antibody production to the 
new hapten introduced on the carrier molecule in the 
immunisation sequence. It showed no discern 4ble 
influence on the antibody production to the carrier 
borne epitopes. 
This concept may have little effect on an ordinary 
antibody response. The epitope-specific regulated 
response is derived from carrier/hapten-carrier 
immunisation conditions. It intentionally distorts the 
time at which a carrier borne epitope is presented 
relative to the time at which carrier priming is 
completed. However, the clear separation between carrier 
priming and epitope presentation possible in that 
investigation allows the exploration of a similar time 
dependent process that, in principle occurs whenever an 
animal is primed with a complex antigen. It is likely 
that the immuno-dominant antigens will induce antibody 
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production more rapidly than others. It is then quite 
possible that the immuno-subdominant antigens will be 
treated as if they were "new" epitopes on the carrier 
protein because they fail to make their presence known 
(by initiating the antibody production) before the 
carrier specific suppressor population has matured to 
the full function. 
F. 3.1B B-Cell Dependent Competition 
The B-cell dependent competition describes more aptly 
the intramolecular antigenic competition. An antigen 
containing several determinants of different 
specificities is recognised by an equivalent number of 
different populations of the specific antigen sensitive 
B-cells. Whenever, an antigen is limiting in amount, a 
competition will be set up between the B-cell 
populations of different specificity for the antigen. If 
some of these populations are of higher cell number than 
others, or if they have a higher average affinity for 
the antigen, they will capture the antigen 
preferentially. The result will be that the antibody 
production against certain 'determinants on a complex 
antigen will dominate, at the expense of antibody 
production against other determinants (Taussig, 1977). 
The dominance of certain determinants in the 
intramolecular competition is, therefore, the result of 
the greater number of the cells bearing receptors for 
those determinants, or their greater affinity, compared 
with the number and affinity of the cells bearing the 
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receptors for other determinants on the same molecules. 
The reason for this may be that the immuno-dominant 
regions are antigenically more complex than other 
antigens and the genetic control of the ability to 
respond will specifically limit the number of precursors 
available for certain determinants. 
This hypothesis predicts that the intramolecular 
competition should be a function of antigen dose and be 
more pronounced at low antigen concentration than at 
high antigen concentration. Exposure of dominant 
antigens at the surface and protuding from the surface, 
in addition to flexibility answers the question that 
the dominant antigens interfere with the immune response 
against the conserved immuno-subdominant antigens. 
Therefore, they remain biologically silent in spite of 
their presence. 
It also suggests that if the immune response 
against immuno-subdominant antigens is specifically 
boosted, they may effectively compete with the dominant 
antigens. If a host is immunised with a vaccine based on 
these conserved immuno-subdominant antigens, post 
immunisation contact with the dominant antigens 
(exposure to the whole micro-organism) may not cause the 
suppression again rather contact with the immuno- 
subdominat antigen along with the dominant antigens may 
result in a switching of the majority of the response to 
the immuno-subdominant antigens. 
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The role of immuno-dominant epitopes in 
suppression of the immune response against the conserved 
immuno-subdominant epitopes highlights the importance of 
the manipulation of the immune response before fusing 
the stimulated B-cells with myeloma cells to make the 
hybridomas for Mab production. In a general immunisation 
schedule, either the B-cells for the immuno-subdominant 
epitopes will not be stimulated or their number will be 
so low that the probability of the fusion and selection 
of their hybridomas will be small. 
The answer to the question as to how the immune 
system should be manipulated so that the suppression of 
the immuno-subdominant antigens is desuppressed probably 
lies in the immunisation done in this study. A total of 
14 Mabs were made. All the Mabs were cross reactive and 
none of them was specifically reactive to only HRV-2. It 
clearly indicates that during the immunisation, the 
immune response to the dominant antigens was suppressed 
and this suppression caused the desuppression of the 
immune response against the immuno-subdominant antigens. 
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G Desuppression of the Immune Response Against the 
Immuno-Subdominant Antigen 
Analysis of the immunisation schedule adopted in this 
study focusses attention on three points-1) First, a 
concentrated purified preparation of antigen was used, 
2) secondly, adjuvant was not used with any of the 
injections and 3) thirdly, two major sets of 
immunisation schedules each comprising multiple 
injection were carried out. 
G. 1 Effect of the Concentrated Purified Preparation on 
Desuppression 
It may be argued that the presentation of the antigen in 
concentrated and purified form reduced the competition 
because the purification removed contaminating antigens 
and the concentration of the antigen provided an 
opportunity to the B-cells of the immuno- subdominant 
antigen to become stimulated. However, this explanation 
is rejected. In this situation, the stimulation of B- 
cells for both immuno-dominant and sub-dominant antigens 
would be expected. It may explain the desuppression of 
the immune response against the sub-dominant antigens 
but it does not explain the suppression of the immune 
response against the dominant antigens. Further, Sherry 
and Rueckert (1985) and Sherry, et al. (1986) also used 
purified and concentrated virus almost in the same 
amount but cross neutralising Mabs were not reported to 
have been found. 
238 
G. 2 Effect of Adjuvant On the Desuppression 
Adjuvants are known to non-specifically enhance the 
immune response. Therefore, it may be suggested that the 
absence of the adjuvant lessened the antigenic 
competition and the immuno-subdominant epitopes were 
favoured more because the preparation used for the 
immunisation was simply the purified and concentrated 
virus. It may explain why the cross reactive Mabs were 
not reported earlier in the studies where similar types 
of preparation were used in the immunisation. However, 
it does not explain the suppression of the immune 
response against the dominant antigens 
G. 3 Effect of Multiple Injection on Desuppression 
Multiple immunisation of the mice might have played an 
important role in causing the desuppression. It is now 
well established that an antigen can cause not only 
immunisation, but, under suitable circumstances, an 
opposite event namely immunological tolerance. 
Immunological tolerance represents a condition in which 
the capacity of an individual to react to a normally 
effective antigenic stimulus has been specifically 
diminished or abolished by prior administration of that 
particular, or related antigen (Nossal and Ada, 1971). 
G. 4 Immunological Tolerance 
G. 4.1 Immunological Tolerance by Antibody 
Antibody, even in minute amounts can inhibit various 
types of immune responses. In order that the specific 
inhibition of an immune response by the antibody may 
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occur, the antibody must be capable of binding to the 
antigen; the stronger the binding the stronger the 
inhibition. Both the antigen binding portion of the 
antibody molecules as well as the antigen non-specific 
Fc portion are required for the immunosuppression by the 
antibody. The inhibitory influence of the intact 
antibody may be due to one of two general mechanisms 
First, the antigen may be eliminated more rapidly 
through an Fc dependent mechanism. In this case, the 
antibody probably induces a phagocytosis and thus the 
destruction of the antigen which would normally have 
been displayed on the macrophage surface for the 
induction of an immune response. 
The second antibody mediated immuno-suppression is 
the inactivation of the immunocompetent cells. In this 
case, the antigen with attached antibody would bind to 
the immunocompetent cells through the antigen and 
antigen receptor interaction and then the Fc portion of 
the attached antibody would bind to an Fc receptor on 
immunocompetent or other cells. There may be only one 
immunocompetent cell in this interaction so that a 
single cell binds to both antigen and the Fc portion of 
the antibody attached to the antigen. This is the 
tripartite inactivation model. The model was proposed to 
explain the Fc requirement for immuno-suppression by the 
antibody. Alternatively, a second cell could bind the Fc 
portion of the antibody alone or both the Fc portion and 
antigen. In this case, a cell mediated, antigen 
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specific, Fc dependent regulation of the immunocompetent 
cell could occur. The immunocompetent cell coated with 
antigen antibody complex may be destroyed by 
opsonisation by cells of the reticuloendothelial system. 
The possibility of suppressor cells triggered by the 
antigen-antibody complex is another mechanism for the 
destruction of the immunocompetent cells. The Fc 
mediated inhibition of the immunocompetent cell may 
involve either a temporary suppression in cellular 
activity or a long lasting inhibition of the 
responsiveness to a particular antigen. 
It has been suggested that the helper T-cells 
block the immunosuppressive Fc signal by altering Fc 
receptors on the B cells. B cells may respond to -many 
antigens, be they self or foreign, but will not reach 
the stage of massive production of antibody unless they 
are helped to overcome the inhibition when the first 
antibody molecules are secreted in the continued 
presence of the antigen. 
This observation of the immunosuppression by the 
antibodies against the dominant epitopes highlights the 
importance of the multiple injections during the 
immunisation. It may be suggested that the immune 
response against the dominant epitopes was suppressed 
due to multiple injections resulting in the continued 
presence of the antigens and then the mice were 
specifically immunised with the immuno-subdominat 
epitopes of the virus. 
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G. 4.2 Antigenic Specific Suppressor T-Cells (Ts Cell 
It is now well documented that specific or non-specific 
stimulation of the immune system generates a population 
of T-lymphocytes with suppressive activities. Such Ts- 
cells have been demonstrated following priming, 
tolerance induction, mitogen stimulation, in MHC linked 
low responsiveness and in allotype and idiotype 
suppression. Those Ts-cells activated by mitogens non- 
specifically suppress both cell mediated and humoral 
immune responses. In most other cases, Ts-cells are 
specific and inhibit the immune response only to the 
antigen which activates them. Ts-cells play a crucial 
role in regulating a variety of the immune responses, in 
antigenic competition, in induction and maintenance of 
the immunological tolerance and in the prevention of 
allergic and autoimmune phenomena (Miller, 1980). 
Ts-cells may be distinguished from other cells by 
their distinct surface phenotype (Ly123 qal+, la-, 
absence of an MHC region imposing restriction). They are 
also highly radio sensitive. and easily inactivated by 
low doses of anti-lymphocyte serum. In contrast to other 
T-cells subsets, Ts-cell. activities do not generally 
appear to be H-2 restricted. Thus, they can function in 
allogenic hosts (Miller, 1980). 
The exact mechanism of the action of the Ts-cells 
or of the suppressive factors extractable from them is 
not yet clear. However, conditions leading to the 
generation of the Ts-cells are now known. Macrophages 
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play an important role in the antigen processing and the 
presentation thereby they elicit helper T-cell response. 
The interaction of the antigen with the T-cells in the 
absence of the macrophages results in the generation of 
the Ts-cells. It has been reported that the depletion of 
the macrophages from high responder spleen cells led to 
the preferential induction of the Tscells with a normaly 
immunogenic concentration of an antigen ( Tada and 
Okumura, 1979). 
Ts-cells are able to bind the native antigens. It 
has been suggested that the antigen which bypasses the 
macrophage system activates the Ts-cells selectively. 
These types of antigens are excess antigen, highly 
deaggregated forms of the antigen and those antigens 
which fail to associates with Ir region gene product on 
macrophages in low responder strains (Miller, 1980). 
Tada and Okumura (1979) reported that the 
injection of relatively large doses of the protein 
antigens without adjuvant frequently induces the antigen 
specific Ts-cells. In some cases hyperimmunisation with 
adjuvant has also been found to be quite effective in 
generation of TS-cells. The authours described their 
expermental design for generation of the Ts-cells 
suppressing the IgE antibody response in rats and the 
IgG antibody response in mice. 
In the experiment performed for the suppression 
of the IgE antibody response in rats, hyperimmunisation 
with carrier antigens in complete Freund's adjuvant was 
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routinely used to obtain the suppressor T-cells and the 
suppressive factor from them. This method was based on 
the observation that the immunisation of the rats with 
antigen in Freund's complete adjuvant was ineffective in 
producing the IgE antibody but rather suppressed the 
response induced by subsequent immunisation with the 
immunogenic form of the antigen with a potent adjuvant 
for IgE antibody production for example Bordetella 
p! M ertus s vaccine. 
In suppression of the IgG antibody response in 
mice against haptenated KLH, it was observed that the 
adjuvant was not necessary, but rather inadequate to 
obtain consistently high levels of Ts-cells to KLH. It 
was also noted that the higher doses of an antigen were 
required for the induction of immunosuppression. If the 
same amount of the antigen is coupled to an immunogenic 
carrier, such as methylated bovine serum albumin, 
strains of the suppressor genotype do not generate the 
cells producing antigen specific suppressor factor. 
In light of the above discussion, the most likely 
sequence of the events resulting in the suppression of 
the immune response against the dominant epitopes, 
desuppression and stimulation of the immune response 
against the immuno-subdominant epitopes of the HRv-2 are 
as follow- (Fig18) 
The concentrated and purified antigen was 
inoculated without adjuvant through the i/p route and 
multiple injection were given. Higher amount of the 
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Attracted) r ach to lymphocytes) 
Processed by Not Processed by Processed by 
Macrophages Macro ha es Macrophages 
T-Helper (Alone or together) T-Helper 
Cells Cells IT-Suppressor Cells 
Immune Immuno-suppression Immune 
Response of Response to Dominant Response 
to Dominant Antigen to Dominant 
Epitopes Epitopes 
Fig-18: Schematic representation of the hypothesis for 
the immuno-suppression (Fate of the antigen 
following - S/C route, with adjuvant, without 
adjuvant and or through I/P route) 
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antigen together with the absence of the adjuvant and 
inoculation through i/p route resulted in the induction 
of dominant epitope specific suppressor Ts-cells. 
Suppression of the immune response against the dominant 
epitopes prevented the suppression of the immuno- 
subdominant epitope. Thus, the inoculations caused the 
immune system to expand to the sub-dominant epif'o. pes. 
It is difficult to specify that all these factors 
together or the absence of the Freund's adjuvant alone 
caused the immunosuppression of the dominant"epitopes. 
It seems unlikely that the number of the inoculations 
played an important role. It has been stressed above 
that even in the first contact with the antigen, the 
immune response to the sub-dominant epitopes is 
suppressed by the dominant epitopes. Therefore, the 
subsequent multiple inoculations may cause the 
suppression of the immune response against the dominant 
epitopes but they may not be able to invoke the immune 
response against the sub-dominant epitopes also. 
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H Conclusion 
This study reports on the presence of conserved 
neutralising epitopes present on a number of HRV 
serotypes. The range of the conservation extends into 
other members of the genus enterovirus. These epitopes 
remained conserved possibly because they were not 
subjected to the immune selection pressure. The immune 
response against the dominant neutralising epitopes 
probably specifically suppressed the immune response 
against those neutralising epitopes where the mutation 
would have been a lethal mutation. 
These immuno-subdominant epitopes may be the key 
candidates for developing an effective vaccine against 
the common cold. This would not only provide protection 
against the existing HRV serotypes but may also ensure 
the protection against new serotypes. It is speculated 
that progressive antigenic changes are responsible for 
the emergence of new serotypes. The virus may not be 
able to mutate in the area of the immuno-subdominant 
epitopes if they are important for carrying out the 
biological function or maintaining the structure of the 
virus. 
The presence of the conserved neutralising 
epitopes on HRVs encourages similar studies on other 
microorganisms where antigenic variation is the major 
obstacle in the path of vaccine development. It would be 
important to use the Mabs in such studies. However the 
probability of making and selecting a cross reactive Mab 
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is increased if the immuno-subdominant epitopes are 
selectively allowed to invoke the immune response. It is 
another important finding of this study that the 
inoculation with a purified and concentrated form of the 
preparation without adjuvant through intra-peritoneal 
route may lead to the specific suppression of the immune 
response against the dominant epitopes. This suppression 
would then cause the desuppression of the immune 
response against the immuno-subdominant epitopes. 
Further inoculations would then stimulate the B-cells 
for the conserved immuno-subdominant epitopes. B-cells 
obtained from such immunised mice would increase the 
chances for the fusion of these B-cells with the myeloma 
cells resulting in the development of hybridomas 
secreting the Mabs against these conserved epitopes(Fig- 
18). 
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I Further Direction for Research 
The finding of this project that conserved neutralising 
epitopes exist on HRVs is an important step in the 
direction of developing an effective vaccine for the 
common cold. However, it is important to first establish 
that the cross neutralising epitopes are immunogenic in 
humans and that when they are presented to the human 
immune system, they remain immunogenic. 
I. 1 Studies on Immunogenicity of the Conserved Epitopes 
i . _. i7....... -- 
It has been mentioned earlier (section F. 2.1 of this 
chapter) that the immune response to an antigen is 
controlled by the Ir gene. The antigens which evoke 
antibodies whose expression is controlled by the strain 
specific or species specific Ir genes, may not be 
immunogenic in a different strain or species. It is 
therefore necessary to establish that the Ir genes for 
these conserved neutralising epitopes are present in 
humans. Indirect evidence may be obtained if these 
epitopes are shown to be broadly immunogenic by 
demonstrating their response in different laboratory 
animals. Various laboratory animals may be immunised 
under the above mentioned immunisation conditions and 
cross reactivity may be demonstrated in the polyclonal 
antiserum. 
1.2 Studies on Vaccine Development with the Conserved 
Neutralising Epitopes 
Synthetic peptide and anti-idiotypic antibody approaches 
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are currently available for developing a vaccine based 
on isolated antigens. 
1.2.1 Synthetic Peptide Approach 
The synthetic peptide approach is generally based upon B 
cell epitopes and therefore it may lack the segment that 
can react with T-lymphocytes. T-cell stimulation is 
essential for recruitment of T-helper cells or T-cell 
derived growth and differentiation factors. Thus the 
absence of T-epitopes may result in weaker 
immunogenicity of the B-cell epitopes. Neurath, et al., 
(1988) reported that the synthetic peptide for the pre S 
envelope region of Hepatitis B virus was highly 
immunogenic if B- and T-cell epitopes were included. 
However, it required the systhesis of long peptides of 
20-40 residues. 
The necessity of long peptides to include both B 
and T-cell epitopes may not be economical. Further, the 
Mabs made in this study provide infomation about the B- 
cell epitopes only. The information on relevant T-cell 
epitopes is not yet available. Therefore a synthetic 
peptide based approach is not recommended for the 
vaccine development in the immediate future. 
1.2.2 Anti-idiotype Vaccine Approach 
The basis for using anti-idiotype reagents to induce an 
immune response has been the demonstration that some 
anti-idiotypic antibodies (Ab2) can represent an 
internal image of the antigen. Anti-idiotypic antibodies 
have been shown to be capable of inducing a specific 
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immune response without any injection of the 
corresponding antigen (Lambert, 1986). 
The generation of the antibodies reacting with 
antigen after the administration of Ab2 can reflect a 
recognition of Ab2 at different levels (Fig-19). First 
an Ab2 can be seen by at least two sets of B -cells: 
those bearing idiotype positive antibody (Abl) receptors 
and those bearing anti Ab2 receptors (Ab3). This 
recognition can lead to cross linking of receptors and 
to the first step of B-cell activation. Such activated 
cells then would be more sensitive to other events for 
example exposure to antigen and to accessory cell 
binding or T-cell growth and differentiation factor. 
Secondly, an Ab2 which has been recognised either 
by these Abl/Ab3 B-cells or by accessory cells (possibly 
in the form of Abl-Ab2 complexes) can be processed and 
presented, as a peptide, on the cell membrane, in 
association with class II MHC products. It may allow: 1) 
for recognition by putative T-helper cells seeing Ab2 
variable peptide in this context, 2) specific help to 
those presenting B-cells and 3) for the activation and 
differentiation of these Abl or Ab3 producing B-cells 
which present the antigen to T-cells (Lambert, 1986). 
It has also been reported that the anti-idiotype 
can be used to enhance the priming when the antigen is a 
poor immunogen. This makes the anti-idiotypic approach 
more pertinent for developing the vaccine with these 
conserved neutralising epitopes. 
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Appendix-1 
Reagents for cell culture and general virological 
techniques 
A)Media 
A. lGrowth medium 
A. la. For monolayer cells 
BMEM lOX (Flow Lab cat. no. 14-000-54) - 100 ml 
Newborn calf serum - 100 ml 
Glutamine (0.2 M sol. ) - 10 ml 
Penicillin (0.6% of 1662 I. U. /mg) and - 10 ml 
Streptomycin ( 1%) 
Sodium bicarbonate (0.8%) - 25 ml 
Distilled Water to make 11 
Adjust pH to 7.2 to 7.4 with HC1 or NaOH 
A. lb For suspension cells 
MEM lOX (Flow Lab Cat. No. 14-170-54) - 100 ml 
Newborn calf serum - 100 ml 
Glutamine (0.2M sol. ) - 10 mi 
Penicillin (0.6% of 1662 I. U. /mg ) and - 10 ml 
Streptomycin (1% sol. ) 
Sodium bicarbonate (0.8% sol. ) - 25 ml 
Pluronic F-68 (10% sol. ) - 10 ml 
Distilled water to make 11 
Adjust pH to 7.2 to 7.4 with HC1 or NaOH 
(XXIV) 
A. 2 Maintenance medium 
BMEM lOX - 100 ml 
Foetal calf serum - 20 ml 
Tryptose phosphate broth (13% sol. ) - 10 ml 
Magnesium chloride ( 3M sol. ) - 10 ml 
Sodium bicarbonate (0.8% sol. ) - 25 ml 
Penicillin (0.6% of 1662 I. U. /mg) and - 10 ml 
Streptomycin (1% so l. ) 
Distilled water to make 11 
Adjust pH to 7.2 to 7.4 with HC1 or NaOH 
A. 3 Preservation medium 
Growth medium -8 parts 
Serum -1 part 
50% glycerol or DMSO -1 part 
B. Crystal violet staining of the cell sheet 
1) Pour off the medium in a discard jar or remove the 
agar overlay by a sharp flick of the wrist into an 
autoclavable bag 
2) Add Crytal violet stain (0.1% in 20% ethanol) to 
cover the surface. 
3) Leave for atleast 10 minutes 
4) Rinse with water 
Dead cells are removed during the rinsing and cell sheet 
is stained violet 
(XXV) 
C. EDTA solution 
EDTA (0.005% in water) -1 part 
PBS -9 parts 
Versene and trypsin 
1- A) 2% solution of EDTA in 60 ml distilled water and 
add one tablet of PBS 
B) Dissolve 100 mg of phenol red in 3-6 mis of PBS 
2- Add 3 tablets of NaOH to A and then add B to A. make 
upto 100 mis 
3- Filter through Whatman Nol and autoclave 
4- Add 1 ml of veresene as prepared above to 2 mis of 
the trypsin and then added 100 mis PBS. 
(XXVI) 
Appendix-2 
Reagents used for the preparation of the antigen for 
immunisation 
A Agar overlay 
For HRV-2 
Maintenance medium 2X -1 part 
Agar (2%) -1 part 
For other picornaviruses 
Growth medium 2X -1 part 
Agar (2%) -1 part 
B. Staining of the plaques with neutral red 
Neutral Red stain (1%) - 0.8 ml 
Overlay medium - 100 ml 
Add 2 ml of the neutral red containing overlay medium 
to each well of a6 well plate. Incubate the plate in 
dark at 370 C. The live cells are coloured and plaques 
are visible as unstained a reas. 
C. Buffer IV 
Sodium chloride 1M in 0.02M Tris buffer neutralised to 
pH 7.4 with acetic acid 
D. LS buffer 
Sodium chloride - l0mM 
HEPES - 25mM 
pH- 7.5 
(XXVII) 
E. Sucrose solutions 
Stock sol. - 80% W/V sucrose in water 
% conc. stock sol. to 
make 100 ml 
15% 19.9m1 
20% 27.1ml 
25% 34.6m1 
30% 42.4m1 
35% 50.6m1 
40% 59.1ml 
45% 68. Oml 
(XVIII) 
Appendix-3 
Reagents for the hybridoma studies 
Hybridoma medium 
L-15 medium - 500m1 
Foetal calf serum - 100m1 
HAT (50X) - 12m1 
Glutamine (2M sol. ) - 5ml 
Penicillin (0.6% of - 5m1 
16621. U. /mg) and 
Streptomycin (1% sol. ) 
Substrate for ELISA 
TMB buffer 
Sodium acetate - 0.2M 
Citric acid (0.2M) to adjust pH to 6.0 ( approximately 
50 ml of the citric acid is required for 21 sodium 
acetate). 
TMB recipe 
TMB buffer - 20 ml 
TMB in DMSO (42mM) - 200 ul 
H2O -3 u1 
gmsmoFSURMueM 
(XXIX) 
